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The clinical diagnosis of arthritis is characterised by warm, painful and swollen joints 
in one or more areas. The most common chronic inflammatory joint syndrome is rheu-
matoid arthritis, which affects approximately 1% of the population (1). In rheumatoid 
arthritis, the arthritis eventually leads to destruction of the joint. Distinguishing rheu-
matoid arthritis from other types of arthritis can be difficult. In the 1950s, a committee 
of the American Rheumatism Association (ARA) categorised arthritis based on expert 
opinions, epidemiologic surveys and clinical cases. Diagnostic criteria for possible, prob-
able and classical or definite rheumatoid arthritis were proposed (2). In 1987 the criteria 
for rheumatoid arthritis were reassessed (3). These criteria are still used to define distinct 
research populations. Table 1 shows the criteria for probable rheumatoid arthritis from 
Table 1. Criteria for rheumatoid arthritis and probable rheumatoid arthritis
No. Criterion
1 Morning stiffness.
2 Pain on motion or tenderness in at least one joint (observed by a physician).
3 Swelling (soft tissue thickening or fluid, not bony overgrowth alone) in at least one joint (observed by 
a physician).
4 Swelling (observed by a physician) of at least one other joint (any interval free of joint symptoms 
between the two joint involvements may not be more than 3 months).
5 Symmetrical joint swelling (observed by a physician) with simultaneous involvement of the same 
joint on both sides of the body (bilateral involvement of midphalangeal, metacarpophalangeal or 
metatarsophalangeal joints is acceptable without absolute symmetry). Terminal phalangeal joint 
involvement will not satisfy this criterion.
6 Subcutaneous nodules (observed by a physician) over bony prominences, on extensor surfaces or in 
juxta-articular regions.
7 X-ray changes typical of rheumatoid arthritis (which must include at least bony decalcification 
localized to or greatest around the involved joints and not just degenerative changes). Degenerative 
changes do not exclude patients from any group classified as rheumatoid arthritis.
8 Positive agglutination test - demonstration of the “rheumatoid factor” by any method which, in 
two laboratories, has been positive in not over 5% of normal controls - or positive streptococcal 
agglutination test.
9 Poor mucin precipitate from synovial fluid (with shreds and cloudy solution).
10 Characteristic histologic changes in synovial membrane with three or more of the following: marked 
villous hypertrophy; proliferation of superficial synovial cells often with palisading; marked infiltration 
of chronic inflammatory cells (lymphocytes or plasma cells predominating) with tendency to form 
“lymphoid nodules”; deposition of compact fibrin, either on surface or interstitially; foci of cell necrosis.
11 Characteristic histologic changes in nodules showing granulomatous foci with central zones of cell 
necrosis, surrounded by proliferated fixed cells, and peripheral fibrosis and chronic inflammatory cell 
infiltration, predominantly perivascular.
(A) Diagnostic criteria for probable rheumatoid arthritis (2). This diagnosis requires three of the criteria. 










































1958 and for rheumatoid arthritis from 1987. If the arthritis does not fulfil any criteria 
belonging to a disease description by the American College of Rheumatology and other 
diagnoses involving arthritis are ruled out, you are left with an undifferentiated arthritis. 
This undifferentiated arthritis can be an early stage of rheumatoid arthritis which has 
not been recognised yet as such. To study amongst others the epidemiology of arthritis, 
early arthritis clinics were set up throughout the world. In Leiden, an Early Arthritis 
Clinic was started in 1993. From the first 1000 patients who were included 37% was 
classified as having an undifferentiated arthritis (4). After 1 year, the diagnosis of the 
patients who presented with an undifferentiated arthritis was reassessed (5). About 30% 
of these patients had no signs of arthritis after 1 year. However, 28% of the patients were 
recognised within 1 year to have rheumatoid arthritis.
Monitoring arthritis
Rheumatoid arthritis is characterised by progressive destruction of the joints, either 
slowly or rapidly. These destructions eventually lead to disability. To monitor efficacy of 
treatments different methods were developed to evaluate the intensity of a (destructive) 
rheumatoid arthritis. The main methods that are used in the next chapters are described 
in this paragraph.
No. Criterion Definition
1 Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement
2 Arthritis of 3 or more joint areas At least 3 joint areas simultaneously have had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. The 
14 possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, 
and MTP joints
3 Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint
4 Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) 
on both sides of the body (bilateral involvement of PIPs, MCPs, or 
MTPs is acceptable without absolute symmetry)
5 Rheumatoid nodules Subcutaneous nodules, over bony prominences, on extensor 
surfaces, or in juxtaarticular regions, observed by a physician
6 Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the result has been positive in <5% of 
normal control subjects
7 Radiographic changes Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints (osteoarthritis changes alone 
do not qualify)
(B) 1987 Criteria for the classification of acute arthritis of rheumatoid arthritis (3). For classification 
purposes, a patient shall be said to have rheumatoid arthritis if he/she has satisfied at least 4 of these 7 
criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 2 clinical diagnoses 









































The disease activity score (DAS) consists of both objective and subjective items. It was 
developed using a discriminant analysis based on the decision of rheumatologists to 
start or switch an anti-rheumatic drug in combination with parallel blind clinical assess-
ments of research nurses (6;7). The DAS is calculated as follows:
DAS = 0.53938 * sqrt (Ritchie score)
 + 0.06465 * (number of swollen joints)
 + 0.330 * ln (erythrocyte sedimentation rate)
 + 0.00722 * (patient global assessment)
In the Ritchie articular index 53 joints are scored for tenderness. Forty-four joints are scored 
for swelling (8). For most rheumatologists a DAS of more than 2,4 means an active disease 
state that is high enough to intensify medication (9). A DAS of 1,6 is used as a cut off for 
remission (10). To simplify the calculation of the DAS for daily practice, substitutes were de-
veloped. The original DAS with the mentioned 4 variables was reduced to a DAS with three 
variables in which the patient global assessment value was replaced by 0,224 (7). A modified 
DAS that included 28-joint counts instead of 44 (8) and a simplified disease activity index 
were validated as well (11). In studies described in this thesis the original DAS was used.
A more objective method for measuring the destructiveness of rheumatoid arthritis is 
scoring the radiographic joint damage. There are different scoring methods to evaluate 
radiographic joint damage. In the projects described in this thesis the Sharp-van der 
Heijde modification scoring method was used. This method focuses on the small joints 
in the hands, the wrists and the feet. Joint space narrowing is scored in 42 joints, and the 
distribution of erosions is scored in 44 joints, as is depicted in Figure 1 (12).
The health assessment questionnaire (HAQ), arthritis impact measurement scales 
(AIMS), rheumatoid arthritis disease activity index (RADAI) and modifications on them 
are patient centered assessments focussing on the impact of the arthritic disease in daily 
life (13-16). For example, performance of physical activities is graded by the patient, and 
the general well being and disease activity are rated on visual analogue scales (VAS) 
from 1 to 10 by the patient or the physician.
Evidence for early treatment
There is no curative treatment for rheumatoid arthritis. Over the past twenty years, 
the treatment of rheumatoid arthritis has significantly changed with the introduction 
of disease-modifying anti-rheumatic drugs (DMARDs) and later on the introduction 
of biologicals. Before 1994 most patients who were diagnosed with RA started with a 
non-steroid anti-inflammatory drug (NSAID). NSAIDs give symptom reduction, but are 
not thought to interfere with the underlying disease process in contrast to DMARDs. 









































the diagnosis was made had less disease activity and less radiographic joint damage 
or progression of it compared to patients who first started with NSAIDs, and the best 
results were yielded in the first year of treatment (17-19). After 10 years, the beneficial 
effects of immediate treatment with DMARDs was even reflected in a lower need for 
joint surgery (20). Taking this knowledge into account, it was proposed that recognizing 
rheumatoid arthritis in an early phase is crucial to the disease outcome on the long 
term, a so-called window of opportunity (Figure 2). Treatment strategies have only been 
developed for patients in the clinical phase who are recognised to have rheumatoid 
arthritis. The window of opportunity actually lies in recognising individuals who are 
at risk for developing rheumatoid arthritis in the preclinical phase and in recognising 
Figure 1. Scoring of hands and feet according to the Sharp-van der Heijde scoring method
Joints and sites scored for joint space narrowing (left panel), joints and surfaces of the joints scored for 
erosions (middle panel), examples of scoring erosions according to the joint surface involved (right panel) 
with the van der Heijde modification for hands and feet. The small numbers indicate how an erosion is 
scored and the numbers in the boxes give the total score for that joint. Reproduced from Van der Heijde 
DMFM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. 









































patients with an undifferentiated arthritis who actually have rheumatoid arthritis, but 
have no joint destruction yet.
Pathophysiology
Rheumatoid arthritis is classified as an autoimmune disease, in which leucocytes attack 
the joints, leading to inflammation and resulting in destruction of the joint. Different fac-
tors are thought to be involved in the pathophysiology of rheumatoid arthritis. Genetic 
susceptibility and environmental factors can create the conditions in which harmful T 
cell responses are activated that are also able to provide help to B cells with subsequent 
production of antibodies. Past decades different parts of this cascade have been under 
investigation.
Genetic background
The influence of a genetic component for rheumatoid arthritis is emphasised in a three- 
to fourfold higher concordance percentage of disease in monozygotic twins compared 
to dizygotic twins and the total genetic contribution to rheumatoid arthritis is estimated 
to be 50-60% (21-24). A wide variety of candidate genes has been investigated for their 
influence on susceptibility to and severity of rheumatoid arthritis. The most prominent 
genetic risk factor found so far are the human leucocyte antigen (HLA) class II molecules. 
An approach to understanding the molecular genetics of susceptibility to rheumatoid 
arthritis is the shared epitope hypothesis (25). The initiation of an immune response re-
quires T cell activation, and such activation requires the presence of antigen presented 
by HLA class II molecules on antigen presenting cells. At the level of protein structure, 
certain HLA-DRB1 alleles share an amino acid sequence in the beta-sheet of the peptide-
binding groove of the HLA molecule, the shared epitope. It is thought that the shared 
epitope containing HLA-molecules are important for the presentation of arthritogenic 
antigens. The shared epitopes, QRRAA (DR1), QKRAA (DR4) and RRRAA (DR10), are not 
only associated with susceptibility to rheumatoid arthritis, but also with a more pro-
gressive disease course (26;27). The contribution of the presence of the shared epitope 
counts for 30% of the genetic aspects of rheumatoid arthritis (28). However, the puta-
tive peptides that fit in the groove and are directly involved in the cause of rheumatoid 
arthritis have not been discovered so far.
T cells
The involvement of HLA class II molecules and the presence of joint antigen-directed 
T cells suggest a role for CD4+ T cells (29). After arising from bone marrow stem cell 
precursors, progenitor cells migrate to the thymus, where they will be maturated into T 









































molecules. Firstly, those T cells that recognise self-HLA molecules are positively selected. 
Secondly, the negative selection process is said to eliminate the auto-reactive T cells.
Roughly, there are two types of T cells. Cytotoxic T cells, characterised by CD8 expres-
sion, recognise antigens in the context of HLA class I molecules, which are present on 
almost all nucleated cells. HLA class I molecules are loaded with intracellular proteins. If 
the CD8+ T cell is activated, it kills the antigen presenting cell by lysis. During these ac-
tions, pro-inflammatory cytokines like interferon (IFN)-gamma, tumour necrosis factor 
(TNF)-alpha and interleukin-2 (IL-2) are released.
T helper cells express CD4 and recognise antigens in the context of HLA class II mol-
ecules. Only antigen presenting cells like dendritic cells, monocytes, macrophages and 
B cells can process extracellular proteins to present them in HLA class II to CD4+ T cells. 
If the T cell is activated, it in turn activates a B cell that then starts to produce isotype-
switched antibodies. This process is characterised by the release of IL-4 and IL-10.
However, this does not explain why regulatory or suppressor T cells exist and why 
or how autoimmune diseases develop. Different hypotheses about the origin of auto-
immunity have been described varying from genetic defects involving the selection 
processes in the thymus to danger models in which damaged tissue releases danger 
signals that work as a costimulation factor for activating an auto-reactive process (30-
33). The functional existence of regulatory T cells was first demonstrated in nude mice 
in which infusion with CD25+CD4+ T cells after transfer of CD25-CD4+ T cells prevented 
development of autoimmune diseases (34). CD25 is the alpha chain of the IL-2 receptor. 
It is highly expressed on activated T cells in the early phase of activation, often described 
as the CD25 bright cells in flowcytometric analysis, whereas regulatory T cells show an 
























































































(CTLA-4), glucocorticoid induced TNF receptor (GITR) and foxP3 have been used to 
describe regulatory T cells, but are also not specific. The regulatory T cell response is 
characterised by the release of anti-inflammatory cytokines like IL-10 and tumour 
growth factor (TGF)-beta (37;38). Thus, T cell-mediated immunoregulation does likely 
play a role in immunologic self-tolerance but exact characterisation of the regulatory T 
cells remains difficult, especially in a human setting.
Autoantibodies
The presence of autoantibodies is also a reason to consider rheumatoid arthritis an auto-
immune disease. The positive predictive value of the presence of certain antibodies aims 
at another phase of the immune response that may play a role in the pathophysiology of 
rheumatoid arthritis. Rheumatoid factor (RF) is an antibody that is directed to the Fc part 
of immunoglobulins. The presence of IgM-RF is part of the 1987 criteria for rheumatoid 
arthritis. However, RF is also detected in other autoimmune diseases and healthy indi-
viduals. For diagnosing rheumatoid arthritis, the sensitivity of RF ranges from 60 to 70%; 
the specificity from 80 to 90% (39).
Anti-citrullinated protein antibodies (ACPAs) are much more predictive for rheuma-
toid arthritis. In the Leiden EAC, 93% of the patients with ACPAs who presented with 
undifferentiated arthritis were diagnosed with rheumatoid arthritis within 3 years (40). 
Furthermore, patients with ACPA-positive rheumatoid arthritis had more erosive disease 
than patients who had no ACPAs. Citrullination facilitates the degradation process 
in a cell and is a normal physiologic process in the presence of inflammation (41). A 
calcium-ion influx leads to activation of the peptidylarginine deiminase (PAD) enzyme, 
which converts arginine into citrulline. The formation of antibodies against citrullinated 
proteins is not physiological and is mainly found in rheumatoid arthritis (42). ACPAs 
can be present up to 14 years upon diagnosing rheumatoid arthritis (43;44). During the 
last years it has become clear that the genetic and environmental risk factors for ACPA-
positive and ACPA-negative disease differ. Moreover, the histology differs and, as stated 
above, the clinical outcome differs. This has led to the awareness that subclassification of 
rheumatoid arthritis in ACPA-positive and ACPA-negative disease is appropriate (45-47).
Outline of this thesis
The research projects described in this thesis are divided into two themes: part I involves 
mainly epidemiological and clinical aspects of patients with undifferentiated arthritis 
and part II involves immunological aspects of patients with rheumatoid arthritis. 
The aim in part I of this thesis is to describe the epidemiology of undifferentiated ar-
thritis, to gather more evidence for early intervention, and to predict disease outcome. In 
the Leiden EAC 37% of the patients who presented with arthritis were classified as having 









































in several early arthritis registries in other parts of the world is described. Some patients 
with rheumatoid arthritis present with a full blown rheumatoid arthritis while others 
present themselves with clinically an undifferentiated arthritis. To characterise this dif-
ferent onset of disease, the long-term outcome of patients with such a ‘slow onset’ were 
compared to the long-term outcome of patients who present with rheumatoid arthritis. 
The results are described in chapter 3. In rheumatoid arthritis evidence for justification 
of early aggressive treatment is accumulating. Starting treatment for rheumatoid arthri-
tis in patients with undifferentiated arthritis, the window of opportunity, has not been 
performed before. The PROMPT study was the first randomised controlled trial in which 
patients with undifferentiated arthritis were treated with a DMARD, methotrexate. The 
results of the PROMPT-study are presented in chapter 4. In the PROMPT-study, the DAS-
score was used to evaluate the disease activity in patients with undifferentiated arthritis. 
Based on the DAS-score the intensity of the study medication was maintained or raised. 
However, this score system was designed for patients with rheumatoid arthritis. In chap-
ter 5, the DAS in patients with undifferentiated arthritis is discussed, investigated and 
validated. Not all patients who were included in the PROMPT study had a very early stage 
of rheumatoid arthritis. Before a patient is exposed to a treatment with methotrexate or 
another DMARD or even more, a combination of DMARDs, the indication for such a treat-
ment should be carefully evaluated. Actually, you would like to predict which patient with 
undifferentiated arthritis will benefit from an early treatment and who will go spontane-
ously in remission or will never develop the clinical syndrome of rheumatoid arthritis. 
Therefore, a rule to predict disease outcome in patients with recent-onset undifferenti-
ated arthritis was developed and validated in the PROMPT study. This rule is presented in 
chapter 6. ACPAs have a strong predictive value in predicting the probability of having 
a very early stage of rheumatoid arthritis in patients presenting with undifferentiated 
arthritis. Having identified an individual with an indication for treatment with second-
line anti-rheumatic drugs, you are left with a palette of DMARDs and combinations of 
DMARDs. Tailor-made treatments for each stage of disease focused on individual needs 
would be the best. In chapter 7 the response to methotrexate treatment is related to the 
pre-treatment serum levels of ACPA in patients with undifferentiated arthritis. 
In part II, the accent lies on the immunological background of rheumatoid arthritis and 
possibilities for intervention. Biologicals, like anti-TNF-alpha, have had a major impact on 
the outcome of rheumatoid arthritis. However, it is unclear how TNF-alpha influences the 
immune response in patients with rheumatoid arthritis. In chapter 8 the effect of anti-
TNF-alpha on regulating the immune response in patients with rheumatoid arthritis is 
described. In understanding and identifying the underlying immunological changes in 
healthy individuals to processes resulting in rheumatoid arthritis, T-cell responses against 
a human cartilage protein, HC-gp39, and in particular the presence of regulatory T cells 









































change the pro-inflammatory response in patients with rheumatoid arthritis, a phase I co-
hort study was performed by others (48). T cells derived from patients included in this study 
were analysed for their immunological response. However, the results were not conclusive. 
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Chapter 2
Undifferentiated arthritis - Disease course 

















































The prognosis of patients with undifferentiated arthritis (UA) may vary from self-limited 
to severe destructive rheumatoid arthritis (RA). Because early aggressive treatment 
might offer an effective means to slow disease progression in RA, it is important to 
identify UA patients who will develop RA and treat them as early as possible. At the same 
time, inappropriate treatment of patients with a more benign disease course should be 
avoided. Here, an overview is given of the characteristics and numbers of patients with 
UA who evolve into RA.
UA is defined as any arthritis that has the potential for a persistent course, without ful-
filling the classification criteria for specific rheumatic disorders. To compare endpoints in 
the different databases, the 1987 ACR criteria for RA were used.
In the nine databases employing a similar definition for undifferentiated arthritis, 
the proportion of patients with UA that evolved into RA within 1 year varied from 6% 
to 55%. These differences arise in large part from differences in the inclusion criteria 
and in the definitions used for UA and RA. The data from the various cohorts support a 
hypothesis that a considerable proportion of UA patients are actually patients with RA in 
a very early stage. Controlled intervention studies with early antirheumatic treatment in 
these patients are mandatory in order to provide further insight into the natural course 









































Disease course of UA 25
Introduction
Several studies have indicated a beneficial effect of the early treatment of rheumatoid 
arthritis (RA) to achieve a less severe disease course or even to induce remission (1-3). 
The possible extra therapeutic benefit attainable in this early period in the disease has 
been called the “window of opportunity”. Since the presentation pattern of RA varies 
widely, it has been suggested that the treatment should be started as early as possible, 
even before patients fulfil the American College of Rheumatology (ACR) criteria for RA 
(4). Ideally, knowledge of prognostic factors in patients with undifferentiated arthritis 
(UA) will allow the identification of those patients who will develop RA, so that the inap-
propriate treatment of patients who will not develop RA can be avoided. For this it is also 
necessary to know the natural course of UA. The present review will attempt to describe 
the natural course of UA as reported in early arthritis cohorts.
The first problem encountered in the search for the percentage of patients present-
ing with UA who will develop RA is the fact that UA is a non-validated description of a 
phenotype. In clinical practice, all cases of arthritis that cannot be classified in one of the 
accepted categories are referred to as e causa ignota or “undifferentiated”. For inclusion 
in early arthritis cohorts, various definitions and criteria have been used for the early 
phase of arthritis, which makes it difficult to compare the composition of the different 
study groups. ‘Early arthritis’, ‘early RA’, and ‘undifferentiated arthritis’ are terms that are 
currently in use to describe either arthritis that might evolve into RA or that has been 
diagnosed early after onset of arthritis or even early in the disease course of definite 
RA. Therefore, patients with UA are in general seen as those patients with the potential 
for development of persistent inflammatory arthritis, including RA, but in whom a 
recognized clinical pattern does not (yet) exist. In 1958 the American Rheumatism As-
sociation (ARA) identified criteria for ‘probable rheumatoid arthritis’ (5) as a distinction 
from classical RA, but these criteria only define a subgroup of patients generally referred 
to as having UA.
In this review, defining RA according to the classification criteria also has disadvan-
tages from a scientific viewpoint. The ACR criteria for RA were developed to identify 
patients with established RA, and not for diagnostic purposes. In clinical practice, it is of 
great relevance to distinguish patients on prognostic items such as persistent arthritis 
or destructive arthritis. On the other hand, all intervention studies to date have been 
based on fulfilment of the ACR criteria, and evidence that adequate treatment changes 
the course of disease as well as the prognosis is available only in patients who meet the 
ACR criteria. Therefore, notwithstanding the imperfect definitions of the phenotype for 
clinical practice, it is important to assess what proportion of UAcases progress to RA, as 










































Early RA databases and their inclusion criteria are listed in Table 1. The databases marked 
by an asterisk have included and described patients with UA. Only the latter databases 
will be discussed. The other databases include ‘early RA’ patients who fulfilled the 1987 
ACR criteria for established RA. 
In Finland an early arthritis cohort was started in 1975 (6). Adults with one or more swollen 
joints and a symptom duration of less than 6 months were referred to the hospital in 
Heinola. Fortythree percent of the patients from this cohort had non-specific arthritis, de-
fined as probable RA according to the 1958 ARA criteria or arthritis not falling within any 
Table 1. Early RA databases








≥ 1 swollen joints
disease duration ≤ 6 months 
age ≥ 16 years
prospective cohort 
referred by phycisians of several 
health centres and hospitals






age ≥ 16 years
≥ 2 swollen joints
symptom duration ≥ 4 weeks
onset after January 1989
referred from GP and local 
rheumatologists
yearly follow-up for at least 5 yrs
patient visited at home
(10;22)
Leeds (UK) * undifferentiated arthritis of the 
hands
symptom duration < 12 months 







duration ≤ 1 year
age > 15 years
2-year prospective cohort study





inflammatory arthritis with ≥ 2 
clinical criteria and ≥ 1 laboratory 
criterion 
duration of symptoms < 12 weeks
referred by GPs and internists to 
participating rheumatologists 
multi-centre (country-wide)







disease duration ≤ 2 years
half of patients self-referred








certain or probable clinical 
diagnosis of RA 
UA that may develop into RA
duration of symptoms < 6 months
age 18-70 years
≥ 2 inflammatory joints for the past 
6 weeks
no DMARD use prior to inclusion






≥ 2 swollen joints
disease duration < 3 years










































Disease course of UA 27
specific diagnostic group (7). The percentage of UA patients who developed RA was not 
mentioned. After 3 years 58% of the UA patients had no symptoms. Twenty-eight percent 
of the patients in this cohort met the 1987 ACR classification criteria for RA at inclusion.
From the same cohort, 32 patients were described with the diagnosis of non-classified 
monoarthritis, defined as swelling of a peripheral joint not due to trauma, degenerative 




Arthritis Clinic (The 
Netherlands) *
any arthritis confirmed by 
rheumatologist
symptom duration < 2 years
no DMARD use prior to inclusion
referred by GPs







disease duration ≤ 4 yrs
Norwegian part of international 
collaborative research effort





RA diagnosis < 1 year
no DMARD use prior to inclusion
multi-centre
referred from primary care








newly diagnosed RA (ARA’58 
criteria)




definite RA (ARA’58 criteria) and ≥ 2 
criteria (ESR>20mm/hour, ≥ 6 joints 
with active RA, duration morning 
stiffness > 45 minutes)
age 18-80 years
symptom duration < 1 year
randomised, double blind, 
placebo controlled study on 
treatment with sulfasalazine
follow-up at 4, 8, 12, 24 and 48 
weeks
80 (6;26)
Central Finland RA 
database  
(newly) diagnosed RA according to 
physician
all new patients with RA are 





RA (ACR’87 or revised ACR’87 
criteria)
symptom duration < 2 year
no DMARD use prior to inclusion
prospective study on early 
aggressive therapy






symptom duration < 2 year
age 18-65 year,
≥ 3 swollen joints and three 
of: ESR>28, CRP>19, morning 
stiffness.>29min, >5 swollen joints, 
>10 tender joints
multi-centre






disease duration < 2 years
African-American
500 (29)




disease duration < 1 year 
prospective, multi-centre study
referred by GP, rheumatologist, 
arthritis care units










































joint diseases or any other specific joint disease (8). Of those 32 patients, 2 (6%) had 
rheumatoid factor (RF)-positive definite RA after a 3-9 year follow-up. In 29 patients the 
diagnosis remained “non-classified” arthritis during follow-up.
In the Finnish cohort a group of 47 patients with recent onset RF-negative oligoarthri-
tis was also described (9). After 23 years of follow-up, reclassification of the diagnoses 
revealed 1 patient with RA, 7 patients with erosions in the hands or feet, 1 patient with 
systemic lupus erythematosus (SLE), 1 patient with ankylosing spondylitis, 2 patients 
with “post-traumatic arthritis”, 4 patients with osteoarthritis, and 6 patients with reactive 
arthritis. The other 25 patients presumably still did not fulfil the criteria for a rheumatic 
disease.
In the UK the Norfolk Arthritis Registry (NOAR) has been following patients with 
early inflammatory polyarthritis who had been referred by general practitioners (GPs) 
and local rheumatologists since January 1990, as described by Symmons et al. (10). All 
adults with two or more swollen joints, lasting for at least 4 weeks, could be included. 
The proportion of UA patients who developed RA was not mentioned in the published 
data. However, Wiles et al. (11) described a study in which the ACR criteria were applied 
cumulatively, meaning that once a criterion was fulfilled, this criterion was regarded as 
positive in all subsequent assessments. In this study, 55% of the patients with a symptom 
duration of less than 2 years satisfied the criteria for RA at inclusion as described above. 
Sixty-seven percent fulfilled these criteria after one year.
Also from the UK, Quinn et al. (12) recently described a cohort of 97 patients with early 
undifferentiated arthritis of the hands and a disease duration of less than 12 months 
who were followed for 12 months. RA developed in 14% of the 97 UA patients. Thirty-six 
percent had persistent synovitis (defined as the presence of 2 or more of the following: 
joint swelling, joint tenderness or decreased range of motion) after 12 months, whereas 
13% were in clinical remission. Only 54% of the patients could be diagnosed with a 
specific rheumatic disease after a 12-month follow-up.
Initially these patients were included in a cohort of 1877 patients in the Leeds early 
arthritis clinic of whom 56% had an inflammatory arthritis at inclusion; 50% of these 
patients had RA and 23% had UA. Patients with UA were classified as having an inflam-
matory disorder where a specific rheumatic disease could not be diagnosed. It should be 
noted that patients were eligible for inclusion in the study if they had a history sugges-
tive of inflammatory arthritis, but clinically detectable synovitis was not required. This 
resulted in the observation that 47% of patients with UA had no synovitis at the time of 
inclusion.
In Germany Huelsemann et al. (13) described a two-year prospective cohort study of 
patients with “rheumatic symptoms” for less than 1 year’s duration who were investi-
gated in an early arthritis clinic in Duesseldorf. The patients were sent to the tertiary 
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patients who were investigated, 217 were classified as having inflammatory rheumatic 
diseases. Of these 217 patients, 117 (54%) could not be diagnosed definitely and were 
thus considered undifferentiated, and 39 (19%) were diagnosed as having RA. Sixty-
eight percent of the patients with UA presented with oligoarticular joint manifestations, 
while 14% had a monoarticular and 18% had a polyarticular disease (5 or more joints). 
Follow-up data 4 to 38 months after the initial symptoms were available for 28 patients 
with UA. Fifteen (54%) of them had a complete remission, 8 patients had unchanged or 
progressive unclassified disease and 2 (7%) were diagnosed with RA according to the 
ACR 1987 criteria.
The Austrian early arthritis registry (Austrian Early Arthritis Action, EAA) (14) follows 
patients with inflammatory arthritis whose symptoms began less than 12 weeks before 
presentation and who fulfil at least 2 clinical criteria (absence of trauma, joint swelling in 
at least 1 joint, joint pain in at least 1 joint, morning stiffness > 60 minutes) and at least 
1 laboratory criterion (positive RF, ESR > 20 mm/hour, CRP > 5 mg/L, leucocytes > upper 
limit of normal). Approximately 15% of the patients after 1 year still had no established 
diagnosis and were classified as having UA. Sixty-five percent of the patients had RA 
after 1 year, using the ACR 1987 criteria cumulatively as described in the NOAR (15).
In another paper, Machold et al. (16) describe 108 patients who had been followed 
for at least 1 year. At inclusion, 31 patients (29%) had undifferentiated arthritis and 50 
patients (46%) were diagnosed with RA. After 1 year, 17 of the UA patients (55%) were 
diagnosed with RA. The diagnosis of RA was made if patients fulfilled the ACR 1987 crite-
ria, or if clinical examination revealed a polyarthritis of at least 6 weeks duration without 
evidence of other inflammatory rheumatic diseases. In cases in which the diagnosis 
could not be ascertained by the rheumatologist, the disease was classified as UA.
Wolfe et al. (17) followed 532 patients with undifferentiated arthritis at the Wichita 
Arthritis Center who at presentation had a symptom duration of at least 2 years. Synovi-
tis was not required if the patient had other clinically suspected characteristics of RA in 
the history, at physical examination or in laboratory results. 100% were followed up for 
>13 months, 93% for >2 years and 87% for > 3 years. 22% of the patients had no joint 
swelling, and 6% had questionable swelling at the time of inclusion. Fifty-four percent 
of the cases resolved, while 17% evolved into RA.
A French multi-centre cohort study (18) that includes patients with early arthritis with 
a maximum duration of 6 months has recently been started. No data on this ESPOIR 
cohort have been published yet. The study includes RA patients, probable RA patients 
and patients with a clinical diagnosis of UA that may potentially develop into RA and 
with at least two inflammatory joints for the past 6 weeks. UA patients with “no potential 
to develop into RA” are excluded.
In a Dutch study by Jansen et al. (19), a group of patients from the Amsterdam early 









































of less than 3 years was followed in order to identify variables that could predict an 
outcome of progressive disease after 1 year. In this study 27% (n=77) of the patients 
were clinically diagnosed as having UA at inclusion and 72% (n=203) as RA. 42% of the 
UA patients had oligoarthritis and 58% had polyarthritis. After one year 42% of the 
patients with UA were categorized as progressive and 58% as mild, using radiographic 
parameters and the HAQ score as criteria. Thirtyone percent of the progressive UA group 
(n=10) fulfilled the ACR criteria for RA after one year. From the total UA group, 17% were 
classified as having RA at 1 year.
The other Dutch cohort is the Leiden Early Arthritis Clinic, which includes patients 
with any form of arthritis confirmed by a rheumatologist except gout, and a symptom 
duration of 2 years or less (20). Out of 936 patients at inclusion, 346 (37%) were catego-
rized as having UA and 22% were diagnosed with RA. After one year of follow-up 32% of 
the UA patients fulfilled the ACR 1987 criteria for RA. The percentage had increased to 
40% at 3 years of follow-up (21).
Discussion
We have reviewed inception cohorts with monoarthritis and polyarthritis to evaluate 
what proportion of patients with UA progress to RA. In the various cohorts these pro-
portions varied considerably. This may be explained by the differences in referral and 
recruitment procedures, inclusion criteria and, most notably, disease criteria between 
the various cohorts. The reported proportion of patients with UA who progressed to 
RA one year after inclusion range between 6% and 55%. However, in the cohorts that 
required arthritis to be present at inclusion and that defined RAaccording to the ACR 
1987 criteria, the proportions range from 17% to 32%.
The part of the Finnish early RA cohort in which only 6% of the patients with UA pro-
gressed to RA after a follow-up period of 3 to 9 years (8) probably represents a subgroup 
of UA, defined as non-classified monoarthritis and RF negative oligoarthritis, and con-
sequently, a small group of patients is concerned (n = 32). Huelsemann et al. reported 
that 7% of his patients with UA developed RA (13). However, at inclusion patients were 
diagnosed based on clinical expertise and were not classified according to ACR criteria. 
As only 18% of the UA patients at inclusion had a polyarticular disease, it is possible 
that a certain proportion of the patients with polyarthritis at inclusion were prematurely 
diagnosed as having RA. Therefore the proportion of UA patients who progressed to RA 
might have been underestimated. Also, only 24% of the 117 patients with UA at inclu-
sion were followed. This suggests that these patients represent a subgroup of UA that 
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Wolfe et al. reported that 17% of their UA patients progressed to RA after 3 years (17). 
The inclusion of patients without synovitis in this cohort could have led to an under-
estimation of this value however. The same is true for the cohort described by Quinn 
et al. (12). Jansen et al. (19) described a cohort of oligo- or polyarthritis patients, and 
found a 17% progression from UA to RA. In a mixed population of monoand polyarthritis 
patients, Van Gaalen et al. (21) reported that 32% progressed from UA to RA (diagnosis 
according to the ACR 1987 criteria) within one year. An even higher rate of 55% was 
described by Machold et al. (16). However, in that study not only patients who fulfilled 
the ACR criteria were diagnosed as having RA, but also patients with polyarthritis for 
more than 6 weeks without evidence of other inflammatory rheumatic diseases upon in-
vestigation. Therefore, the value of 55% could be an overestimation of RA in comparison 
with other studies that focused only on the ACR criteria for diagnosing RA.
The findings of these cohort studies support the hypothesis that many patients with 
UA are actually in the first stages of RA. Unpublished observations in the Leiden EAC 
cohort indicate that patients whose UA evolved into RA within one year have, on aver-
age, the same prognosis as patients who presented with RA at baseline, as measured by 
the rate of joint destruction, disease activity and functional status. Early treatment may 
moderate the disease progression, possibly to the point that fewer patients develop RA 
as defined by the ACR 1987 criteria. Ideally, patients with UA who will progress to RA 
should be identified at presentation in order to receive early aggressive treatment.
Decisions to treat UA patients will depend on the likelihood that a patient will develop 
RA. When this is high, it is worthwhile to start disease modifying anti-rheumatic drug 
(DMARD) therapy immediately. Our review shows there is a 17-32% pre-test probability 
that a patient with UA actually has RA. The question is what tests are available to obtain 
a substantially higher post-test probability. 
A great deal of research has already been carried out to try to identify predictors that 
could be used for such a test. At present the most promising diagnostic tool appears to 
be a test for anti-cyclic citrullinated peptide (CCP) autoantibodies. Van Gaalen et al. (21) 
reported that in the Leiden EAC 93% of the patients with UA who were anti- CCP posi-
tive fulfilled the ACR 1987 criteria for RA within 3 years. The negative predictive value 
was 75%. Furthermore, anti-CCP antibody testing was of little value in UA patients who 
fulfilled none of the ACR 1987 criteria for RA, but had a significant additional value in 
predicting the progression to RA in UA patients fulfilling one or more of these criteria 
at presentation. As anti-CCP antibodies can be detected several years before the onset 
of disease, Holers and Majka (32) proposed a model in which the development of anti-
CCP antibodies in genetically predisposed individuals initiates the autoimmune process 
in a preclinical phase. The presence of anti-CCP antibodies could therefore be used as 









































Another more intuitive approach rather than an analytical one is to treat all UA pa-
tients with a relatively safe drug regardless of their post-test probability in the event of 
new predictive tests. This would prevent that “false-negative” patients would not receive 
aggressive therapy. It is however not (yet) clear how aggressive such a – at the same 
time safe – therapy could be. It is unclear if such a therapy should be, for example, MTX, 
corticosteroids or NSAIDs.
Current research is focusing on these treatments and on whether patients with UA will 
benefit from early treatment with DMARDs to a similar extent as RA patients. In Leiden a 
doubleblind placebo-controlled randomised trial (Probaat) with 110 patients who fulfill 
the ACR 1958 criteria for probable RA and with a symptom duration of less then 2 years 
is now underway. The aim of the study is to determine whether early treatment can pre-
vent progression into RA or even induce remission. The patients are being treated with 
either placebo or MTX. After one year the medication will be tapered and then stopped.
The study ‘Stop Arthritis Very Early’ (SAVE) is another placebo-controlled study that 
has just started and will try to modify the disease course of UA patients whose com-
plaints began less than 16 weeks earlier, with a single injection of methylprednisolone 
i.m. Subgroup analyses may reveal whether all UA patients need to be treated or if only 
a proportion of these patients will benefit from early treatment.
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The outcome of undifferentiated arthritis (UA) ranges from remission to rheumatoid ar-
thritis (RA) fulfilling the American College of Rheumatology (ACR) classification criteria.
Objectives
To report the outcome of UA after 1-year of follow up and compare the disease course of 
patients who presented with UA, but evolved into RA within 1 year (UA-RA group), with 
that of patients who presented with RA fulfilling the ACR criteria (RA-RA group).
Methods
The diagnosis of 330 patients who presented with UA was recorded at 1-year. The UA-RA 
and RA-RA groups were then followed up for 3 more years. Outcome measurements 
were radiographic progression, disease activity, and functional capacity.
Results
From 330 patients who were diagnosed UA, 91 had evolved into RA at 1-year; 62 patients 
had presented with RA. No significant differences were detected between the UA-RA 
and RA-RA groups in median Sharp/van der Heijde score at baseline, radiographic 
progression rates, disease activity, and functional capacity. However, significantly more 
disease modifying antirheumatic drugs were prescribed in the RA-RA group.
Conclusion
The disease outcome of patients who present with UA that evolves into RA within 1 
year is the same as that of patients who present with RA as measured by radiographic 








































Long term outcome of RA 37
Introduction
In various studies of patients with recent onset arthritis, 6–55% of the patients who 
presented with undifferentiated arthritis (UA) progressed into rheumatoid arthritis 
(RA) according to the American College of Rheumatology (ACR) classification criteria or 
according to the rheumatologist (1). Multivariate analysis of characteristics of these pa-
tients showed that the presence of antibodies to cyclic citrullinated peptide (anti-CCP), 
polyarthritis, symmetric arthritis, and erosions on radiographs predict the development 
of RA. Among these characteristics, anti-CCP has the highest specificity and positive 
predictive value for RA (2). Thus, either by clinical or by serological data, clinicians will 
be confronted with patients with UA who are likely to develop RA. The natural course of 
patients who present with UA and subsequently develop RA is unknown compared with 
patients who present with RA. In patients with RA many studies have demonstrated the 
benefit of the early initiation of disease modifying antirheumatic drugs (DMARDs), re-
sulting in less disease activity and reduction of radiographic joint damage (3-5). Patients 
included in these studies fulfilled the 1987 ACR classification criteria for RA (6). However, 
the ACR classification criteria were not developed for the purpose of early diagnosis as is 
illustrated by the fact that a minority of patients with inflammatory polyarthritis fulfilled 
the ACR criteria at the first visit (7).
Although patients with RA benefit from early aggressive treatment (8), it is unknown 
whether patients with UA whose disease will evolve into RA will also benefit from such 
a treatment strategy. Hypothetically, if at presentation the duration of complaints is 
similar, patients who present with UA might have a disease course that evolves more 
slowly than that of patients who present with RA (figure 1). In the worst situation, the 
“window of opportunity” for early treatment to induce long term disease modification 









































in the patients who presented with UA has been passed once the diagnosis RA is made, 
and long term outcome will be comparable or worse than patients who were diagnosed 
with RA at presentation and treated immediately.
Here, we describe the 1 year diagnosis and outcome of patients who presented with 
UA, and compare the disease course of the patients with UA who had developed RA 
within 1 year after presentation (UA-RA group) with that of patients who presented with 
RA (RA-RA group). Radiographic progression was the major outcome measure; disease 
activity and functional capacity were minor outcome measures.
Patients and methods
Patients
The Leiden Early Arthritis Clinic (EAC) was started in 1993. General practitioners were 
asked to refer patients with suspected arthritis as soon as possible. Patients were 
included in the EAC cohort if a rheumatologist confirmed the suspected arthritis and 
the symptoms of arthritis did not exceed 2 years; for details of this cohort see Van der 
Horst-Bruinsma et al.(9). Patient history, general physical examination, a painful and 
swollen joint count, laboratory tests, questionnaires, and radiographic joint scores were 
performed at inclusion and at the follow up visits. Based on the test results, a diagnosis 
was recorded at the second visit, 2 weeks later, but could be revised during follow up.
Study design
From the EAC database (figure 2) patients diagnosed with UA at the second visit were 
selected and their subsequent diagnosis was recorded at 1 year. UA comprised arthritis 
of unknown cause and “probable RA” according to the 1958 ACR criteria (10). The group 
of patients diagnosed with UA who evolved into RA fulfilling the 1987 ACR criteria within 
1 year (UA-RA group) was followed up for 4 years. Because these patients had the op-
portunity to be treated with DMARDs as soon as the diagnosis was made, the long term 
outcome was compared with that of a group of patients in whom RA was diagnosed at 
the first and/or second visit and who still had RA after 1 year, and who were treated with 
DMARDs as soon as RA was diagnosed (RA RA group).
Outcome measurements
Major outcome measurements were radiographic joint damage and calculated radio-
graphic progression rate. Radiographs of hands and feet were taken at inclusion in the 
EAC and yearly thereafter. Radiographic scoring according to the Sharp/van der Heijde 
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was unaware of the clinical data and the study questions. The intraclass correlation coef-
ficient for the assessor’s scoring was 0.95, as measured in 62 patients.
Minor outcome measurements were disease activity, functional capacity, erythrocyte 
sedimentation rate (ESR) in the 1st hour, and C reactive protein (CRP) concentration. 
Disease activity was calculated by a modified version of the disease activity score (DAS) 
(8):
(0.54×(√Ritchie score)+0.065×(swollen joint score)+0.33×ln ESR+0.224).
Functional capacity was measured by the Health Assessment Questionnaire (HAQ) 
(12).
Statistical analysis
Differences between patient characteristics were tested with the Mann-Whitney U test 
or the χ2 test. For each patient separately, simple linear regression was used to fit the 
course of the radiographic progression in time. Progression rates were calculated for 
varying time intervals, assuming that radiographic damage progresses at a constant rate 
(13;14). The slopes of these regression lines estimate the average increase in Sharp/van 
der Heijde score per year. Differences between slopes of the groups of interest were 
tested with the Mann-Whitney U test.









































To construct the radiographic progression as depicted in figure 3, the geometric mean 
of the Sharp/van der Heijde scores was estimated using a linear mixed model, in which 
account was taken of missing measurements (15). Differences in disease activity and 
functional capacity were compared with a linear mixed model. All tests were two tailed 
and p values ≤ 0.05 were considered significant.
Results
Outcome of UA after 1 year
Between 1993 and 1999, 1064 patients were included in the EAC. At presentation, 330 
patients were diagnosed with UA. Table 1 shows the diagnosis after 1 year of follow up of 
patients who had presented with UA and the numbers of patients who had ended follow 
up and their reasons for doing so. Ninety one patients had developed RA according to 
the 1987 ACR criteria (UA-RA group).
Patient characteristics at baseline
Table 2 shows the baseline characteristics of the UA-RA group, the RA-RA group, and the 
group of patients with UA who did not develop RA within 1 year. The UA-RA group dif-
fered from the RA-RA group in duration of morning stiffness, number of swollen joints, 
Figure 3. Estimated geometric mean Sharp/van der Heijde Score (95% confidence interval) of the UA-RA 
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Table 2. Patient characteristics at baseline of the RA-RA group, the UA-RA group, and patients with UA 







no RA at 1 year
(n=238)
Age (years) 53 (42-72) 0.683 55 (44-65) 46 (35-58)
Female patients 43 (69) 0.492 58 (64) 119 (50)
Duration of symptoms at first 
visit (days)
130 (61-278) 0.611 131 (73-230) 81 (20-164)
Duration of morning stiffness 
(min)
90 (45-150) 0.035 60 (18-120) 15 (0-60)
Number of swollen joints 7 (5-8) <0.001 4 (2-6) 2 (1-3)
Modified DAS score 3.5 (3.1-4.0) 0.012 3.2 (2.7-3.7) 2.3 (1.9-2.8)
Rheumatoid factor positive 44 (71) 0.001 38 (42) 28 (12)
Anti-CCP antibodies 35/59 (59) 0.397 43/83 (52) 16 (8.2)
ESR (mm/1st hour) 38 (20-56) 0.695 31 (19-53) 18 (9-37)
CRP (mg/l) 24 (9-41) 0.414 17 (8-46) 10 (4-26)
HAQ score 1.0 (0.6-1.4) 0.184 0.8 (0.4-1.2) 0.6 (0.1-1.0)
Erosive disease at baseline 
(hands and feet radiographs)
18/60 (30) 1.000 26/88 (30) 20 (13)
Sharp/van der Heijde score 1 (0-4) 0.281 0 (0-3) 0 (0-0)
*p Value of RA-RA group versus UA-RA group.
Results are shown as number (%) or median (interquartile range).
Table 1. Diagnosis after 1 year of follow-up of patients who presented with UA and the numbers of 
patients who had ended EAC follow up at 1 year, and their main reason for doing so.
Diagnosis at 1 year Patients 
No (%)
Patients who ended 
follow-up (n)
Main reason for end of follow-up 
No (%)
Arthritis of unknown cause 134 (40.6) 76 Remission 57 (75%)




Probable RA 39 (11.8) 9 Remission 7 (78%)
Osteo-Arthrosis/Arthritis 11 (3.3) 10 End of treatment 7 (70%)
Psoriatic Arthritis 8 (2.4) 2 Remission 2 (100%)
Reactive Arthritis 6 (1.8) 6 Remission 6 (100%)
Crystal Induced Arthritis 4 (1.2) 3 EAC protocol 3 (100%)
Lyme Arthritis 4 (1.2) 2 Remission 2 (100%)
Paraneoplastic Arthritis 3 (0.9) 2 Remission 1 (50%)
Life-threatening illness 1 (50%)
Systemic Lupus Erythematosus 2 (0.6) 0
Palindromic RA 1 (0.3) 1 Move house 1 (100%)
Spondylarthropathy 1 (0.3) 1 EAC protocol 1 (100%)
Unknown cause 6 (1.8) 6 Remission 4 (67%)









































modified DAS, and percentage of patients who were rheumatoid factor (RF) positive. 
These differences reflect the ACR criteria for RA.
The patients with UA who did not develop RA within 1 year were significantly different 
at baseline from both the UA-RA group and the RA-RA group in all characteristics.
Radiographic joint damage
No significant differences were detected between the UA-RA and RA-RA groups for 
median Sharp/van der Heijde score (table 3, figure 3). At 4 years 75% of all patients in 
both the UA-RA group (77%) and the RA-RA group (73%) had erosive disease compared 
with 30% at baseline.
Disease activity and functional capacity
Figures 4A-D show the mean DAS, HAQ, ESR, and CRP of the two groups. During follow 
up no significant differences were seen.
DMARDs
Table 4 shows the use of DMARDs. At all time points significantly fewer DMARDs were 
prescribed in the UA-RA group than in the RA-RA group. Frequently prescribed DMARDs 
were hydroxychloroquine, sulphasalazine, and methotrexate or a combination of these. 
Table 3. Sharp/van der Heijde scores and radiographic progression rates (increase in score per year) in the 










Sharp/van der Heijde score
Baseline 88 0 (0-3) 60 1 (0-4)
1 year 79 4 (0-13) 56 5 (0-18)
2 years 71 8 (0-17) 48 5 (1-27)
3 years 66 10 (2-20) 45 11 (2-26)
4 years 53 9 (2-30) 41 15 (4-27)
Radiographic progression rate
Slope 0-1 year* 2 (0-8) 2 (0-10)
Slope 0-2 years* 3 (0-8) 1 (0-8)
Slope 0-4 years* 2 (0-7) 2 (0-4)
Slope 1-4 years* 2 (0-8) 1 (-1-3)
Slope 2-4 years* 2 (-1-8) 2 (0-5)
*p>0.05 in the UA-RA group versus the RA-RA group.
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Prednisolone was also prescribed as single drug or combination therapy. Gold, azathio-
prine, and ciclosporin were prescribed in a minority of patients, and biological agents 
were not prescribed at all.
In the UA-RA group, 16/91 patients never received DMARDs during the follow up 
period of 4 years. Of these 16 patients, 11 were RF negative and in 10 patients erosive 
disease was seen during follow up.
Dropouts
Follow up of 3 - 4 years was available for 124 patients. Twenty nine patients were lost to 
follow up (dropouts). In the UA-RA group five patients were in remission, two refused 
follow up, five had died, one discontinued because of a concomitant illness, and in six 
Figure 4. Secondary outcome values of the UA-RA and RA-RA groups from baseline to 4 years. 
(A) Modified Disease Activity Score; (B) Health Assessment Questionnaire score; (C) Erythrocyte 
Sedimentation Rate in mm/1st h; (D) C reactive protein concentration. Mean values (SEM).
Table 4. Number (%) of patients receiving prescribed DMARDs at 3 months, 1, 2, 3 and 4 years in the UA-






3 months 42 (46) 62 (100) <0.001
1 year 62 (68) 58 (94) <0.001
2 years 63 (69) 56 (90) <0.001
3 years 60 (66) 49 (79) 0.04









































patients the cause was unclear. In the RA-RA group four patients were in remission, two 
refused follow up, one had died, one discontinued because of a concomitant illness, 
and in two patients the cause remained unclear. Table 5 compares the baseline char-
acteristics of the dropouts with those of patients with 4 year follow up (completers). 
Only CRP in the UA-RA group was significantly higher in the dropout group than for the 
completers
Discussion
Here, the hypothesis was tested whether patients with UA who developed RA within 
1 year have a different disease course than those who presented to the Leiden EAC 
with RA fulfilling the ACR criteria (6). Of the 330 patients who initially presented with 
UA, 91 (28%) had developed RA within 1 year. Although the patients with UA might 
hypothetically have evolved more slowly towards RA, joint damage, disease activity, and 
functional capacity were the same in both groups over a follow up period of 4 years.
UA is a commonly encountered problem in daily practice. In one third of patients with 
recent onset arthritis it is not possible to come to a definite diagnosis at presentation. 
Overall, 63% of the patients at the Leiden EAC had a self limiting disease course and 28% 
progressed from UA to RA. Other studies show that 6 - 55% of patients with UA will even-
Table 5. Baseline characteristics of dropouts (before or at 3 years of follow-up) versus completers
Patient characteristics









Age (years) 64 (46-75) 55 (44-63) 0.099 57(36-85) 53 (46-69) 0.745
Female patients 57 65 0.598 60 71 0.479
Duration of symptoms at 
first visit (days)
102 (61-209) 144 (78-250) 0.381 159 (63-
275)
126 (59-290) 0.851
Duration of morning 
stiffness (min)
60 (30-180) 60 (15-120) 0.341 75 (41-135) 90 (45-180) 0.875
Number of swollen joints 5 (3-8) 4 (2-5) 0.087 7 (4-8) 7 (5-8) 0.658
Modified DAS score 3.3 (2.8-4.2) 3.1 (2.6-3.6) 0.218 3.5 (2.9-4.7) 3.5 (3.1-4.0) 0.626
RF- positive 26 47 0.127 60 73 0.457
anti-CCP antibodies 42 55 0.435 50 61 0.725
ESR (mm/1st hour) 37 (25-65) 30 (18-50) 0.091 46 (25-61) 35 (19-57) 0.410
CRP (mg/l) 57 (13-74) 11 (7-32) 0.002 19 (9-44) 27 (9-42) 0.984
HAQ score 1.0 (0.12-1.37) 0.75 (0.5-1.12) 0.852 1.31 (0.65-
1.75)
1.0 (0.5-1.37) 0.382
Erosive disease (hands 
and feet radiographs)
33 29 0.695 44 28 0.309
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tually evolve into RA (1). These percentages are dependent on the different inclusion 
criteria, recruitment procedures, and disease criteria. For example, low percentages are 
found in RF negative patients with monarthritis (16), and higher percentages are found 
in inception cohorts where patients with polyarthritis are diagnosed with RA, regardless 
of fulfilment of the ACR criteria (17).
Despite the fact that many studies have tried to describe the natural history of UA, the 
long term outcome of the subgroup of patients with UA who develop RA has never been 
described. As can be expected, the UA-RA and RA-RA groups differed at presentation in 
duration of morning stiffness, number of swollen joints, modified DAS, and percentage 
of RF positive patients, because these variables are directly or indirectly part of the 1987 
ACR classification criteria for RA. The presence of anti-CCP was equal in both groups and 
is similar to previous studies (18). The group of patients with UA who did not develop RA 
within 1 year differed significantly in all patient characteristics at baseline from the other 
two groups. This is a very heterogeneous group considering the diagnosis after 1 year, 
but all these patients were diagnosed with UA at baseline.
Median symptom duration is about the same in both groups. However, given the large 
variation in symptom duration some misclassification of patients might have occurred. 
Theoretically, patients with UA who presented with short symptom duration might have 
belonged to the RA-RA group, and patients with RA with very long symptom duration 
might have had the chance of being included in the UA-RA group. However, analysis of 
subgroups with different intervals of symptom duration did not show an effect on joint 
damage.
In the dropout analysis, only CRP in the UA-RA group was significantly higher in the 
dropout group than for the completers. These data argue against the possibility that 
the UA-RA group equals the RA-RA group because the dropouts in the UA-RA group 
were the patients who presented with a milder disease, and only the patients with more 
aggressive disease completed the follow up.
At all time points, the UA-RA group received fewer DMARDs than the RA-RA group. In 
this observational study, this might reflect a historical development in DMARD prescrip-
tion. It also might be a confounding by indication, as clinicians are inclined to prescribe 
DMARDs to patients who they expect to have a more destructive disease course. Then, 
patients in the RA-RA group might have a more aggressive disease course that is modi-
fied by DMARDs. However, the power to detect an effect of the presence or absence 
of DMARD use on radiographic progression was too low given the small number of 
patients with RA who did not use DMARDs (n=16). In the UA-RA group, 16/91 patients 
did not receive DMARDs during the 4 year follow up. Although 11 of these patients were 
RF negative, 10 had erosive disease. However, with a median radiographic progression 









































with DMARDs. A randomised clinical trial with DMARDs in patients with UA would be the 
most appropriate study design to overcome this issue.
The overall outcome of UA poses challenging treatment goals. Patients with UA who 
will go into remission will need treatment aimed at reducing symptoms, whereas pa-
tients prone to progress to RA will need treatment to improve their long term outcome 
as well. Furthermore, there is a need for new criteria to identify patients with UA that 
will evolve into RA, as the current ACR criteria for RA are not suitable for this purpose. 
This study implies that the long term outcome of patients who present with UA which 
evolves into RA is the same as that of patients who present with RA. New serological 
tests combined with clinical judgment will help to determine which patients with UA 
are most likely to develop RA. Randomised clinical trials in such patients with UA are 
currently under way to test whether this group of patients may benefit from very early 
DMARD treatment.
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To determine whether patients with undifferentiated arthritis (UA; inflammatory, non-
traumatic arthritis that cannot be diagnosed using current classification criteria) benefit 
from treatment with methotrexate (MTX).
Methods
The PRObable rheumatoid arthritis: Methotrexate versus Placebo Treatment (PROMPT) 
study was a double-blind, placebo-controlled, randomized, multicenter trial involving 
110 patients with UA who fulfilled the American College of Rheumatology (ACR) 1958 
criteria for probable RA. Treatment started with MTX (15 mg/week) or placebo tablets, 
and every 3 months the dosage was increased if the Disease Activity Score was >2.4. 
After 12 months, the study medication was tapered and discontinued. Patients were 
followed up for 30 months. When a patient fulfilled the ACR criteria for RA (primary 
end point), the study medication was changed to MTX. Joint damage was scored on 
radiographs of the hands and feet.
Results
In 22 of the 55 patients (40%) in the MTX group, UA progressed to RA compared with 29 
of 55 patients (53%) in the placebo group. However, in the MTX group, patients fulfilled 
the ACR criteria for RA at a later time point than in the placebo group (P = 0.04), and 
fewer patients showed radiographic progression over 18 months (P = 0.046).
Conclusion
This study provides evidence for the efficacy of MTX treatment in postponing the 
diagnosis of RA, as defined by the ACR 1987 criteria, and retarding radiographic joint 
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Introduction
For a number of autoimmune diseases, such as diabetes mellitus, it has been sug-
gested that a critical period exists during which intervention may reverse the disease 
process (1). For rheumatoid arthritis (RA), such a window of opportunity may also exist, 
because laboratory abnormalities, such as antibodies against cyclic citrullinated peptide 
(anti-CCP), can occur years before disease onset (2). In previous studies of patients with 
undifferentiated arthritis (UA), defined as an inflammatory arthritis in which no definitive 
diagnosis can be made (3), it was observed that the presence of anti-CCP, with an odds 
ratio of 38, is an important predictor of the development of RA (4). Of all the patients who 
present with UA, depending on the study population, 6-55% develop RA within 1 year (5).
Current treatment of UA patients mainly consists of nonsteroidal antiinflammatory 
drugs (NSAIDs), and treatment with disease-modifying antirheumatic drugs (DMARDs) is 
not initiated until the disease has progressed to RA (3). Once patients fulfill the American 
College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 
criteria for RA (6), early initiation of DMARD treatment results in less disease activity, 
reduction of radiographic joint damage, and maintenance of function, as compared 
with delayed treatment (7-9). Consequently, it is hypothesized that DMARD treatment 
that is started as early as possible in UA patients may alter disease progression and may 
prevent the development of RA.
Therefore, we designed a double-blind, placebo-controlled, randomized clinical 
trial to compare 2 treatment strategies. The immediate treatment strategy consisted of 
methotrexate (MTX) for a course of 1 year followed by tapering the amount of treatment 
if UA had not evolved into RA (as defined by fulfillment of the ACR classification criteria). 
The control group received conventional treatment with NSAIDs, and MTX therapy was 
initiated only if the patients fulfilled the ACR criteria for RA (the primary end point). 
The primary outcomes of the PRObable RA: Methotrexate versus Placebo Treatment 
(PROMPT) study were diagnosis at the end of the study and progression of radiographic 
joint damage.
Patients and methods
Study setting and design
The PROMPT study was a prospective double-blind, randomized, placebo-controlled, 
multicenter trial involving 110 patients. Randomization was performed by the pharma-
cist. The study was conducted between March 2001 and January 2006 in 4 hospitals in 
Leiden, The Hague, and Delft, The Netherlands. The study was approved by the medical 









































containing either 2.5 mg MTX or placebo. Every 3 months, the medication was increased 
by 2 tablets if the Disease Activity Score (DAS) was >2.4 (10), to a maximum of 12 tablets 
or 30 mg of MTX (Figure 1). The DAS was calculated using a tender joint count (Ritchie 
Articular Index; RAI), the erythrocyte sedimentation rate (ESR), and a visual analog scale 
(VAS) for general health status, according to the following formula:
DAS = 0.54×√(RAI) + 0.065×(swollen joint count) + 0.33×ln(ESR) + 0.0072×(VAS general 
health)
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 Figure 1. Overview of treatment strategy. Patients received open-label methotrexate (MTX) if rheumatoid 
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Trained research nurses calculated the tender and swollen joint scores. To minimize the 
side effects of MTX, all patients, including those in the placebo group, received folic acid 
daily (1 mg) or weekly (5 mg). In both groups, patients were allowed to take NSAIDs, 
but no other immunosuppressive therapies, including steroids, were allowed. In cases of 
side effects that might be related to MTX, the treatment was adjusted.
If a patient reached the primary end point during followup, defined as fulfilling the 
ACR 1987 RA classification criteria, it was considered unethical to continue with study 
medication (possibly placebo), and the treatment was initially continued by building 
up open-label MTX to the same amount as in the study medication scheme. After 12 
months, the study medication was decreased by 2 tablets every 4 weeks until it reached 
a level of 0 in the patients who did not reach the primary end point. At study inclusion 
and at 3, 6, 9, 12, and 18 months thereafter, a tender and swollen joint count, a Health 
Assessment Questionnaire, and a VAS for general health were obtained (11;12). Every 6 
months, radiographs of hands and feet were obtained. At 30 months, the diagnosis was 
recorded.
Participants
Eligible patients attended the rheumatology outpatient clinic of the participating hos-
pitals, had symptoms of arthritis that did not exceed 2 years in duration, were 18 years 
of age or older, and were diagnosed as having UA (i.e., did not fulfill classification criteria 
for any rheumatologic disorder). Given the lack of criteria for UA, patients had to fulfill 
the ACR 1958 criteria for probable RA (13). One patient with psoriasis was also included 
because the small joints of the hands and feet were involved. Exclusion criteria were RA 
(according to the ACR 1987 criteria), impaired kidney or liver function, alcoholism, bone 
marrow insufficiency, pregnancy or the desire to become pregnant within 21 months 
from inclusion in the study, and DMARD use in the past. All patients provided written 
informed consent.
Outcome
The diagnosis at the end of the study and the radiographic progression were prespeci-
fied primary outcomes. After 30 months, a diagnosis of RA, UA, remission, or other was 
recorded. Remission was defined as no clinical symptoms of arthritis according to the 
patient’s rheumatologists and no DMARD use in the preceding year.
Radiographic damage was graded by 2 experienced readers (JvA and HvD) using the 
Sharp/van der Heijde scoring method (SHS), with the radiographs in chronological order 
and patient identity masked (14;15). The interobserver intraclass correlation coefficient 
(ICC) was 0.898. The intraobserver ICCs for both readers were 0.990 and 0.993, as mea-









































secondary outcomes were changes in disease activity represented by the ESR and the 
DAS.
For a post hoc analysis of the outcomes according to anti-CCP status, the presence 
of anti-CCP was measured at the end of the study in baseline serum samples from all 
patients, before decoding the treatment arms.
Statistical analysis
Using historical data from the Leiden Early Arthritis Clinic (EAC), 40% of the patients 
with UA were expected to develop RA within 1 year (4). It was estimated that immediate 
treatment with MTX would result in <20% of the patients with UA developing RA. A 
sample size of 46 patients per treatment group was required in order to attain a power 
of 80% to detect a significant difference between groups with a P value of 0.05. To allow 
for dropouts, 110 patients were included in the study.
Demographic and baseline characteristics, changes in the DAS and ESR, and radio-
graphic progression in the 2 treatment groups were compared using the chi-square test, 
Student’s 2-tailed t-test, or the Mann-Whitney U test. Because MTX reduces radiographic 
joint damage in RA and the SHS method does not allow for healing, radiographic pro-
gression was tested 1-sided (15;17). Differences in the development of RA during the 
study were determined using a Kaplan-Meier curve with a log rank test. The Cox propor-
tional hazards model yielded the hazard ratios and 95% confidence intervals. P values 
less than 0.05 were considered statistically significant.
Results
Characteristics of the study patients
The demographic and clinical characteristics of the patients at baseline are shown in 
Table 1. To allow for assessment of the external validity of this trial, the baseline char-
acteristics of the total group of patients in the PROMPT study were compared with a 
control group of UA patients who were included in the Leiden EAC study between 1993 
and 1999 (3). In the PROMPT study group, the duration of symptoms was longer and the 
proportion of patients who were rheumatoid factor (RF)-positive was higher than in the 
EAC group. The ESR and C-reactive protein (CRP) levels were lower in the PROMPT group 
than in the EAC group.
Diagnosis at the end of the study
Figure 1 shows the randomization and treatment strategy. After 30 months, in 22 of 
55 of the patients in the MTX group (40%) versus 29 of 55 in the placebo group (53%) 
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disease had progressed to RA fulfilled the ACR criteria within 1 year, versus only one-half 
of the RA patients in the MTX group (P = 0.04) (Figure 2A). The other half of the RA 
patients in the MTX group reached the diagnosis during or after tapering of the study 
medication. After 30 months, a similar number of patients achieved remission in both 
treatment groups: 15 in the MTX group and 13 in the placebo group (Table2).
Radiographic progression
The distribution of the radiographic progression over 18 months is shown in Figure 3A. 
In both groups, 51 patients had completed radiographic followup. After 18 months, the 
majority of patients had no radiographic progression at all: 73% in the placebo group 
and 88% in the MTX group. However, 6 patients in the MTX group versus 14 patients in 
the placebo group showed radiographic progression above the SDC (P = 0.046). Indi-
vidual progression measured only in patients with erosions was significantly lower in the 
MTX group versus the placebo group (P = 0.035).
Table 1. Demographic and clinical characteristics at baseline of members of the PROMPT study and of the 







Age, years 51 (42-60) 51 (42-56) 48 (36-61)
Female, no. (%) 35 (64) 38 (69) 177 (54)†
Duration of symptoms at first visit, days 312 (195-507) 263 (169-432) 92 (31-186) †
Duration of morning stiffness, minutes 30 (10-60) 30 (10-60) 30 (0-60)
No. of swollen joints 3 (2-5) 2 (2-4) 2 (1-4) †
3-variable DAS 2.7 (2.1-3.1) 2.4 (2.0-3.0) 2.5 (2.0-3.1)
4-variable DAS 2.7 (2.2-2.7) 2.5 (2.0-3.0)
RF positive, no. (%) 20 (36) 19 (35) 66 (21) †
Anti-CCP positive, no. (%) 12 (22) 15 (27) 55 (20)
ESR, mm/hour 12 (5-24) 11 (5-25) 22 (10-40) †
CRP, mg/liter 5 (3-11) 5 (3-9) 11 (5-31) †
HAQ score 0.75 (0.38-1.13) 0.75 (0.25-1.13) 0.62 (0.25-1.12)
Patients with erosive disease, no. (%) 2 (4) 3 (6) 37 (16) †
Sharp/van der Heijde score 0.5 (0-2.5) 1 (0-3.0) 0 (0-1.0) †
* Except where indicated otherwise, values are the median (interquartile range). PROMPT = PRObable 
rheumatoid arthritis: Methotrexate versus Placebo Treatment; UA = undifferentiated arthritis; EAC = Early 
Arthritis Clinic; MTX = methotrexate; DAS = Disease Activity Score; RF = rheumatoid factor; anti-CCP = 
anti-citrullinated peptide antibody; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; HAQ 
= Health Assessment Questionnaire.










































In the anti-CCP-positive subgroup treated with placebo, UA in 14 of the 15 patients 
(93%) progressed to RA and did so at an earlier time point than that in 8 of the 12 pa-
tients (67%) in the MTX group (P < 0.001) (Table 2 and Figure 2B). In contrast, in the 







Figure 2. Kaplan-Meier survival analysis for the diagnosis of rheumatoid arthritis (RA). The methotrexate 
(MTX) group is indicated by the broken line, the placebo group is indicated by the solid line, and drop-
outs are indicated by circles. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) indicate the risk 
of developing RA during the study in the placebo group versus the MTX group. (A) Total group (n=110) 
(HR 1.7 [95% CI 0.99-3.01], P=0.04). (B) Members of the subgroup positive for antibodies against cyclic 
citrullinated peptide (anti-CCP) (n=27) (HR 4.9 [95% CI 1.88-12.79], P<0·001). (C) Members of the subgroup 
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2C). Similar effects on radiographic progression were observed (Figures 3B and C). In 
the anti-CCP-negative group, no MTX effect could be detected, whereas in the anti-CCP-
positive group, the progression was slowed down significantly (P = 0.03).
Subgroup analysis for the presence of RF showed considerable overlap with the pres-
ence of anti-CCP: 26 of 39 RF-positive patients (67%) were anti-CCP positive, whereas 60 
of 61 RF-negative patients (98%) were anti-CCP negative. In the placebo group, UA in 13 of 
the 19 RF-positive patients (68%) progressed to RA and did so at an earlier time point than 
did 11 of the 20 RF-positive patients (55%) in the MTX group (P = 0.036). In contrast, in the 
RF-negative subgroup, no differences in outcome at 30 months were seen (P = 0.403). With 
regard to radiographic progression, RF-positive patients in the placebo group showed a 
trend for more radiographic progression than those in the MTX group (data not shown).
Subgroup analysis of the development of RA over time for autoantibody-positive 
(anti-CCP-positive or RF-positive) patients weakened the significance as compared with 
analysis of the anti-CCP-positive patients alone (P = 0.024). Of the 27 anti-CCP-positive 
patients, only 1 was RF negative. This patient received placebo and was diagnosed as 
having RA 6 months after study inclusion. The outcome of the 26 patients who were 
anti-CCP-positive and RF-positive is shown in Table 2.
Cross-sectional followup
At the time of submission of this article, further followup data were not available for all 
patients due to different followup periods. However, we can report on 5 of 27 patients 
in the anti-CCP-positive subgroup (18%) who did not develop RA after 30 months 
(Table 2). The 3 patients who were in remission at 30 months (1 in the placebo group 
and 2 in the MTX group) were still in remission without DMARD treatment 4 years after 
study inclusion. However, the 2 patients with persistent UA (both from the MTX group) 
restarted MTX treatment after 30 months, 1 because of recurrent symptoms and, ulti-
Table 2. Diagnosis at 30 months, by subgroup*
Group (n)
RA UA UA in 
remission
Other Lost to 
follow up
Total
 MTX (55) 22 10 15 3 (2 osteoarthritis, 1 autoimmune hepatitis) 5
 Placebo (55) 29 4 13 4 (3 osteoarthritis, 1 diabetic arthropathy) 5
Anti-CCP-positive
 MTX (12) 8 2 2 0 0
 Placebo (15) 14 0 1 0 0
Anti-CCP-negative
 MTX (43) 14 8 13 3 (2 osteoarthritis, 1 autoimmune hepatitis) 5
 Placebo (40) 15 4 12 4 (3 osteoarthritis, 1 diabetic arthropathy) 5










































mately, arthritis shortly after withdrawal of study medication and 1 because of recurrent 
arthritis after a 6-month remission period. The patients continued to receive MTX at the 
time of submission of this article. As a result, although only 1 fulfilled the ACR criteria 
for RA, it can be argued that they both have RA, given the recurrent arthritis symptoms 
that require DMARDs. Taking these data into account, 10 of 12 anti-CCP-positive patients 
(83%) in the MTX group eventually developed RA and 2 of 12 patients (17%) achieved 















Figure 3. Occurrence of radiographic progression. The presence or absence of radiographic progression 
(Sharp/van der Heijde score) at 18 months in 102 patients who completed radiographic followup was 
calculated. Each symbol represents 1 patient. Horizontal lines represent the smallest detectable difference 
(indicating radiographic progression). A, Total group (n = 102). B, Patients positive for antibodies against 
cyclic citrullinated peptide (anti-CCP) (n = 27). C, Patients negative for anti-CCP (n = 75). For methotrexate 
(MTX)-treated versus placebo-treated patients, P = 0.15 in the total group, P = 0.03 in the anti-CCP-positive 








































Efficacy of MTX in UA 59
Disease activity
After 3 months, the mean decrease in DAS (from 2.7 to 2.3) and ESR (from 17 mm/hour 
to 13 mm/hour) values in the MTX group differed significantly from the mean change in 
DAS (from 2.5 to 2.5) and ESR (from 15 mm/hour to 16 mm/hour) in the placebo group 
(P = 0.01 and P = 0.02, respectively). However, subgroup analysis showed that in the 
anti-CCP-positive patients, the mean DAS decreased (from 2.8 to 1.9) in the MTX group 
and increased in the placebo group (from 2.6 to 3.1) (P < 0.001). However, in the anti-
CCP-negative patients, the mean DAS decreased irrespective of treatment group (from 
2.7 to 2.4 versus from 2.5 to 2.3 in the MTX and placebo groups, respectively; P = 0.62).
After 12 months, study medication was decreased regardless of the DAS. In the MTX 
group, 8 of 40 patients who still received study medication had a DAS >2.4 at 12 months 
and started phasing out the study medication; the UA in 2 of these 8 patients later pro-
gressed to RA. Of the 32 patients with a DAS ≤2.4, the UA in 9 of them progressed to RA. 
Of the anti-CCP-positive patients in the MTX group, only 1 of the 10 who still received 
study medication at 12 months had a DAS >2.4 and later developed RA. Of the 9 patients 
with a DAS ≤2.4, 5 developed RA, 2 had UA without fulfilling the ACR criteria for RA at 30 
months, and 2 went into remission.
Toxicity
Adverse events were recorded during the first 18 months, the intervention period of 
the study. Of the patients who were taking study medication, 26 of 55 patients (47%) in 
the MTX group and 18 of 55 patients (33%) in the placebo group experienced ≥1 (seri-
ous) adverse event (P = 0.173). While taking the study medication, a total of 44 adverse 
events and 5 serious adverse events occurred in the MTX group versus a total of 25 
adverse events and 4 serious adverse events in the placebo group (Table 3). 
When patients fulfilled the ACR 1987 RA classification criteria during followup, they 
were switched to open-label MTX. If MTX produced undesirable adverse events or was 
ineffective, other DMARDs were prescribed. The 20 patients who developed RA in the 
former MTX group in the first 18 months were subsequently treated with MTX (19 pa-
tients), sulfasalazine (1 patient), hydroxychloroquine (3 patients), and/or leflunomide (1 
patient). Adverse events (12 adverse events and 3 serious adverse events) were reported 
in 7 of 20 patients while they were treated with these DMARDs. In the former placebo 
group, the 29 patients who developed RA in the first 18 months were treated with MTX 
(29 patients), sulfasalazine (2 patients), hydroxychloroquine (5 patients), leflunomide (1 
patient), infliximab (2 patients), etanercept (1 patient), and/or adalimumab (2 patients). 
Adverse events (39 adverse events and 3 serious adverse events) were reported in 18 of 









































Table 3. Adverse events and serious adverse events during the use of the study medication and during 
the use of DMARDs after RA diagnosis, by treatment group*
During use of study 
medication








  Gastrointestinal 11 6 1 12
  Dermal / mucosal 9 7 2 5
  Neurologic 3 5 5 4
  Cardiologic 3 - - 2
  Pulmonary 3 1 3 1
  Haematologic 1 1 - -
  Ophtalmologic 3 - 1 2
  Elevated serum liver enzyme levels 6 1 - 4
  Other
            Tiredness 1 1 - 2
            Giant cell tumor 1 - - -
            Rhinitis 1 - - -
            Not feeling well 2 - - 1
            Fracture - 1 - -
            Hair loss - 1 - 3
            Synovectomy - 1 - 1
            Arthroplastic surgery - - - 1
            Weight gain and oedema - - - 1
  Total 44 25 12 39
Serious adverse events
  Necessitating discontinuation of study medication
             Gastrointestinal 1 1 NA NA
             Erythema annulare centrifugum 1 - NA NA
             General unwellness - 1 NA NA
             Dyspnea, insomnia, weight gain - 1 NA NA
  Necessitating hospital admission
             Pancreatitis 1 - - -
             Knee replacement surgery 1 - - -
             Erosive arthritis 1 - 2 3
             Meningitis - 1 - -
             Venous thrombosis - - 1 -
  Total 5 4 3 3
* Values are the number of events. DMARDs = disease-modifying antirheumatic drugs; RA = rheumatoid 
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Discussion
This study indicates that MTX treatment of patients with UA can postpone progression 
to RA, as defined by fulfillment of the ACR 1987 criteria, and can retard radiographic joint 
damage. However, the results do not suggest that a 1-year course of MTX treatment can 
prevent the development of RA from UA. Although these findings must be confirmed 
in future trials, the PROMPT study provided the first evidence of the efficacy of MTX 
treatment in UA patients.
Data from the current study showed that initiation of MTX treatment in UA patients 
in the stage before they fulfilled the ACR criteria for RA resulted in postponement of the 
diagnosis of RA. During the first year, the incidence of RA was lower in the MTX group 
than in the placebo group, but after 12 months, the opposite was seen. Furthermore, 
the results suggest that MTX did not induce more remission, but prolonged the period 
of persistent UA. Interestingly, the benefit of this effect seemed to be the retardation 
of radiographic progression. The majority (62%) of the 29 RA patients in the placebo 
group had already fulfilled the ACR criteria and started taking open-label MTX within 6 
months. Nevertheless, the results still show a more favorable outcome in the group that 
immediately received MTX after study inclusion.
This is the first double-blind, randomized, placebo-controlled trial that addresses early 
DMARD treatment in patients with UA before they fulfill the ACR criteria for established 
RA. Although these criteria are currently under debate for use in clinical practice, for 
research purposes they are regarded as the standard for objectively describing the RA 
phenotype and have been widely used as inclusion criteria for trials. Moreover, results 
from many randomized controlled trials have shown that in patients who fulfill the 
ACR criteria for RA, DMARDs improve the outcome (18;19). Thus, for ethical reasons, a 
placebo-controlled trial in UA patients could not be extended once the patients fulfilled 
the criteria. Therefore, the primary outcome of the study, the diagnosis of RA as defined 
by fulfillment of the ACR 1987 classification criteria, seems a reasonable end point.
Patients with UA included in this study are not completely representative of the av-
erage UA patient. This was illustrated by comparing the data from the patients in the 
PROMPT study with controls from the Leiden EAC. Longer symptom duration and lower 
ESR and CRP levels were seen in the patients in the PROMPT study. This indicates that 
the UA patients were no longer in the earliest and most active disease state by the time 
they were included in the current study. The best explanation for this observation seems 
to be that physicians at the 4 centers were reluctant to expose patients with UA to a 
1-year course of MTX treatment, given the high spontaneous remission rate and the 
risk of unnecessary toxicity (3;20). Also, the use of the ACR 1958 criteria for RA as inclu-









































patients already had longer disease duration, a 1-year course of MTX treatment was still 
able to provide beneficial effects on disease and joint damage progression.
The existence of a therapeutic window of opportunity in UA patients, defined as a 
period of time in which the disease process can be reversed, might not be demonstrated 
in this study. However, it is possible that with a different design and a different medica-
tion scheme, such a therapeutic window can be addressed. First, the incidence of RA 
increased during tapering of the study medication in the MTX group. This raises the 
question of what would have happened if MTX had not been tapered. Second, MTX 
as monotherapy could not have been sufficient, since in the MTX group, half of the RA 
patients still developed RA while taking study medication, and 6 patients still showed 
progression of joint damage. Trials in RA patients have shown that treatment with com-
bination therapy and/or biologic agents is more effective in preventing radiographic 
joint damage (18;19;21). Finally, dosages of study medication were altered according to 
the DAS because rheumatologists are generally satisfied and do not intensify therapy 
when the DAS is <2.4 in RA patients (22;23). It is possible that treatment in UA patients 
should aim at remission or a lower cutoff value of the DAS.
In this study, 53% of the patients in the placebo group developed RA and 24% 
achieved spontaneous remission, demonstrating that MTX treatment is overtreat-
ment in a considerable proportion of UA patients. Because it is undesirable to start a 
potentially harmful drug in UA patients who will remit spontaneously, there is a need 
to identify those UA patients who will most likely develop RA and who will benefit the 
most from DMARD treatment. In previous studies and in a recently published prediction 
model that calculates the UA patients’ risk of developing RA based on clinical variables, 
the presence of anti-CCP emerged as one of the strongest predictors of RA (2;4;24). 
Moreover, applying the model to our study, theoretically initiating treatment in patients 
with a prediction score ≥8 and withholding treatment in patients with a prediction score 
≤6, only 6% of the patients would have been inaccurately withheld from treatment, and 
no patients would have been inaccurately treated.
In the current study, subgroup analysis revealed that the beneficial outcomes were 
most pronounced in patients with anti-CCP. In striking contrast, in the anti-CCP-negative 
subgroup, the effect of MTX on the development of RA, the radiographic progression, 
and even on the signs and symptoms, was not demonstrable. The same observations 
were made for patients who were or were not RF-positive, although this could reflect 
the overlap with anti-CCP. Although the current groups are small, this post hoc analysis 
suggests that only anti-CCP-positive UA patients, who have the highest risk of develop-
ing RA, benefit from early MTX treatment. It also supports the growing evidence that 
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We conclude that treatment with MTX benefits patients with UA by reducing signs and 
symptoms, by postponing the progression to RA as defined by the ACR 1987 criteria, and 
by retarding radiographic joint damage. Furthermore, with the guidance of a prediction 
model and the antibody status, it seems feasible to identify a subset of UA patients who 
are most in need and who will benefit the most from initiation of MTX therapy, thereby 
avoiding unnecessary toxic treatment. Although these findings have to be confirmed, 
and the optimal duration and intensity of treatment still have to be determined, the 
PROMPT study provides evidence for the efficacy of MTX treatment in UA patients.
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To study whether the disease activity score (DAS) is a valid measure of disease activity in 
undifferentiated arthritis (UA). 
Methods
Data from a double-blind placebo-controlled, randomized trial of MTX and placebo 
involving 110 patients with UA were used. Data included baseline and 3, 6, 9, and 12 
months, and diagnosis at 18 months. Validity of the DAS was analyzed using factor anal-
ysis, correlations with disease activity variables, correlations with changes in disability 
and joint damage, differences in DAS between diagnoses, and detecting the difference 
between placebo and MTX.
Results
Three disease activity factors were retrieved from the disease activity variables: patient 
reported outcomes, tender and swollen joints, and acute phase reactants. The DAS 
had its highest correlations (r>0.77) with tender joint counts, followed by swollen joint 
counts (r>0.63) and patient reported outcomes (r>0.30), but correlated less with CRP 
(r=0.32). DAS over time was related to HAQ response with an OR (95%CI) of 4.1 (2.1-8.0), 
but not with change in joint damage. At 18 months, the mean DAS for RA patients was 
2.6, for UA it was 2.2, and 1.9 for patients in remission (p=0.001). The DAS discriminated 
better than all single variables between MTX and placebo, with a Guyatt’s effect size of 
0.89.
Conclusion
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Introduction
In Rheumatoid Arthritis (RA), the disease process develops before the diagnosis can be 
made according to the current diagnostic criteria for RA (1,2). Indeed, depending on the 
study population, 6-55% of patients with undifferentiated arthritis (UA) may develop 
RA within 1 year (3). UA is defined as an inflammatory arthritis in which no definitive 
diagnosis can (yet) be made. UA may be successfully treated before it develops into 
erosive arthritis, such as RA (4). Until now, there is no valid measure of disease activity 
in UA available. The Disease Activity Score (DAS) is a valid measure of RA disease activity 
(5). The DAS may also be useful and valid in UA clinical trials, but the DAS has not been 
formally tested in that setting. 
The DAS was developed in RA patients, using data from the first 3 years after diagnosis 
according to the ACR criteria (5). Although the variables included and the weights ap-
plied in the DAS were derived from early RA patients, later validation proved that the 
DAS is also valid in patients with longer disease duration (6). UA covers a spectrum of 
disease before the ACR classification criteria are fulfilled, and not all patients with UA 
will eventually develop RA. Moreover, in UA generally less joints are involved, and the 
pattern of involvement may differ from RA. Therefore, extended joint counts may be 
more appropriate than reduced joint counts in UA. 
The objective was to study whether the DAS is a valid measure of disease activity in 
early undifferentiated arthritis, using the data from a randomised placebo-controlled 
trial. The modified DAS (DAS28), which includes reduced joint counts, was also studied. 
The alternative DAS28 modifications: Clinical Disease Activity Index (CDAI) or Simple 
Disease Activity Index (SDAI) could not be calculated due to missing components.
Patients and methods
Trial data
Use was made of data from the “PRObable rheumatoid arthritis: Methotrexate versus 
Placebo Treatment” (PROMPT) trial that is described in more detail elsewhere (4). In sum-
mary, this study was a double-blind placebo-controlled, multi-centre, randomized trial 
involving 110 patients with early undifferentiated arthritis (UA). Treatment started with 
MTX (15 mg/week) or placebo tablets, and every 3 months the dose was increased if the 
DAS was >2.4. After 12 months, the study medication was tapered and discontinued in 
patients not fulfilling the ACR criteria for RA. When a patient fulfilled the ACR criteria 
for RA (primary endpoint), the study medication was changed to MTX. The diagnosis 
at the end of the study and the progression of joint damage were prespecified primary 










































Eligible patients attended the rheumatology out-clinic of the participating hospitals 
and had symptoms of arthritis for not longer than 2 years, were at least 18 years of age, 
and were diagnosed as having UA according to the American College of Rheumatology 
(ACR) 1958 criteria for probable RA (7).
At baseline and 3, 6, 9, and 12 months, ESR and CRP, the 68 tender joint count, Ritchie Ar-
ticular Index, 66 swollen joint count, disability measurement (HAQ), and visual analogue 
scales (0-100) for assessing pain, global disease activity, severity of morning stiffness, 
fatigue, and general health were obtained. Every 6 months, radiographs of the hands and 
feet were obtained, and scored according to the Sharp/van der Heijde scoring method. 
At 18 months, the diagnosis was recorded by the patients’ rheumatologist as RA, UA or 
remission. Remission was defined as no clinical symptoms of arthritis and no DMARD use 
the preceding year.
The disease activity score was calculated according to the original formula:
DAS=0.54x√RAI + 0.065xSJC+0.33xlnESR+0.0072xGH,
where RAI is the Ritchie Articular Index, SJC is a 44 swollen joint count, ESR is the 
Erythrocyte Sedimentation Rate, and GH is a patient assessed visual analogue scale 
of General Health (0-100 mm.) (5). The RAI contains 53 joints and joint units that are 
rated for tenderness on a scale from 0 (no tenderness), 1 (pain on pressure), 2 (pain 
and winced), 3 (winced and withdrew). (8) For the 44 SJC, joints included in the RAI are 
scored for swelling on a 0-1 scale, excluding TMJ joints, neck, hips, subtarsal and tarsal 
joints. Levels of DAS<2.4 are equated with “low” disease activity, and levels of DAS>3.7 
are equated with “high” disease activity (9). Similarly, the DAS28 was calculated using the 
formula based on the 28-swollen and 28-tender joint count. (6).
Statistical analysis
Cumulative frequency plots of the 68 tender joint count (TJC68), the 53 joint count of 
the RAI without grading (TJC53), the 28 tender joint count (TJC28), and the 66, 44 and 
28 swollen joint counts (SJC66, SJC44, SJC28) were produced to analyze the degree 
of misclassification when using reduced joint counts. Differences between SJC66 and 
SJC44, SJC44 and SJC28 at baseline and at 12 months were tested using the signed rank 
test; similarly for TJC68 and TJC53, TJC53 and TJC28.
Analysis of the validity of the DAS was performed in 5 steps. For these analyses, data 
were used from baseline and 3, 6, 9, and 12 months, and the final diagnosis obtained at 
18 months. For comparison, the DAS28 was analyzed in the same way.
1) Factor analysis. The DAS had been devised to draw information from three underly-
ing factors of disease activity in RA: physical examination, laboratory values, and patient 








































Validity of DAS in UA 71
in UA, factor analysis with varimax rotation was used with a minimum eigen value >1 to 
obtain factors using baseline data. 
2) Concurrent validity. To inform how strong changes in the DAS within a patient are 
correlated with changes in other variables supposed to assess disease activity, within-
subject correlations were calculated using linear regression with correction for repeated 
observations, using the 5 visits of the first 12 months (10). 
3) Construct validity. It was studied whether the DAS was related to changes in dis-
ability and to progression of joint damage over the first 12 months. Ordinal logistic re-
gression was used to relate the time-averaged DAS (0-12 months) to the HAQ response 
at 12 months. The minimal clinical important difference of 0.22 in HAQ score was used 
to classify patients as ‘worsened’, ‘unchanged’, or ‘improved’ (11). The proportional odds 
assumption was checked by dichotomising the HAQ response into ‘worsened’ versus 
‘unchanged or improved’, and ‘worsened or unchanged’ versus ‘improved’ and applying 
two separate logistic regression models. It was checked graphically whether the logits 
of the dichotomised HAQ responses were linearly related to the time-averaged DAS (12). 
The Hosmer-Lemeshov test was used to indicate goodness of fit of both logistic regres-
sion models (p>0.05), and a Chi-Square score test was used to test the proportional odds 
assumption in the ordinal logistic regression model (p>0.05) (12). Time-averaged DAS, 
time-averaged CRP and the change in modified Sharp score over 0-12 months were ana-
lysed using logistic regression with progression > 3 points (yes/no) in modified Sharp 
score as dependent variable and also using linear regression with change in modified 
Sharp score as dependent variable.
4) Criterion validity. It was studied whether the mean DAS over the 5 visits in the first 
12 months was different for patients who had erosive arthritis, undifferentiated arthritis, 
or were in remission at visit 6 (18 months), using ANOVA and using ordinal logistic 
regression. The underlying assumption is that disease activity, and mean DAS, is high-
est in patients developing erosive arthritis and lowest in patients going into remission. 
The proportional odds assumptions for the ordinal logistic regression were tested in a 
similar way as described above for HAQ responses.
5) Responsiveness. Responsiveness, or sensitivity to change, was calculated over the 
visits at baseline and 12 months, using the Standardised Response Mean (SRM, mean 
change / standard deviation of change), and Guyatt’s responsiveness statistic (mean 
change active treated group / standard deviation placebo group). Moreover, the t-value as a measure 










































The values of the disease activity parameters at baseline of the study are shown in Table 
1. The majority of the patients were female, the average age was about 50, 25% (27/110) 
were positive for anti-CCP antibodies, and 39% (39/110) were rheumatoid Factor 
positive. According to the distributions of the disease activity parameters in table 1, the 
majority of patients were in moderate-to-low states of disease activity. There were 36% 
(20/55) and 45% (25/55) patients with a DAS<2.4 at baseline. There were no statistically 
significant differences between the trial arms at baseline in any of the parameters. The 
DAS and the DAS28 had a Gaussian distribution (not shown).
Table 1. Disease activity parameters at baseline.
MTX (n=55) Placebo (n=55)
Gender (female), n (%) 35 (64%) 38 (69%)
Age (year), mean (SD) 53 (14) 50 (14)
Symptom duration at first visit (days), median (IQR) 312 (195-507) 263 (169-432)
RF positive, n (%) 20 (36%) 19 (35%)
Anti-CCP positive, n (%) 12 (22%) 15 (27%)
ESR (mm/h), median (IQR) 12 (5-24) 11 (5-25)
CRP (mg/L), median (IQR) 5 (3-11) 5 (3-9)
SJC28, median (IQR) 2 (1-5) 2 (1-3)
SJC44, median (IQR) 3 (2-5) 2 (2-4)
SJC66, median (IQR) 3 (2-5) 3 (2-5)
TJC28, median (IQR) 6 (2-9) 4 (2-7)
TJC53, median (IQR) 11 (4-16) 7 (4-14)
RAI (0-78), median (IQR) 7 (3-10) 5 (2-8)
TJC68, median (IQR) 11 (4-17) 7 (4-14)
Pain (VAS), median (IQR) 44 (18-61) 48 (28-54)
Disease activity (VAS) , median (IQR) 49 (15-60) 52 (29-64)
Morning stiffness severity (VAS), median (IQR) 45 (20-61) 47 (23-62)
Fatigue (VAS), median (IQR) 55 (22-76) 46 (9-72)
General health (VAS), median (IQR) 40 (19-52) 36 (16-55)
HAQ (0-3), median (IQR) 0.75 (0.38-1.13) 0.75 (0.25-1.13)
DAS, mean (SD) 2.72 (0.78) 2.52 (0.76)
DAS28, mean (SD) 3.94 (1.04) 3.72 (1.06)
Values are count (percentage) or median (interquartile range) or mean (SD). RF=rheumatoid factor, 
Anti-CCP=anti-cyclic citrullinated peptide antibody, ESR=erythrocyte sedimentation rate, CRP=C-reactive 
protein, SJC=swollen joint count, RAI=Ritchie articular index, TJC=tender joint count, VAS=visual analogue 
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Cumulative frequency plots
In figure 1, a cumulative frequency plot of the 28, 44, and 66 swollen joint counts is 
shown at baseline (A). Every individual patient is represented in the curves as a single 
symbol, patients being ranked by the number of joints involved. The different kind of 
symbols denote the different joint counts, the patients do not necessarily have the same 
rank in the three curves. All differences between reduced and extended joint counts 
were statistically significant (p≤0.002), for the tender joint counts (B) as well as for the 
swollen joint counts (A) at baseline, and at 12 months (not shown). 
Figure 1. Cumulative frequency plots of joint counts at baseline: average differences (A and B) and 
individual differences (C and D).
SJC=Swollen Joint Count; TJC=Tender Joint Count. Every individual patient is represented in the plots as 
a single symbol, patients being ranked by the number of joints involved. In panel A and B, the patients 
do not necessarily have the same rank in the three curves. The position of the median scores is where the 
cumulative frequency is 50%. In panel C and D, again every individual patient is represented in the plots 
as a single symbol, patients being ranked by their scores on the extended joint count. Only the median of 
the extended joint count is at a frequency of 50%.









































It can be seen in figure 1 A that the 66 SJC (squares) detects most swollen joints, with 
the 44 SJC (triangles) being close to it. The 28 SJC (filled dots) scores are somewhat lower 
than the other scores and the 28 SJC thus slightly underestimates the number of swollen 
joints. The number of patients with no swollen joints according to the 28 SJC and one 
or more swollen joints according to the extended joint counts does not exceed 10% 
at baseline, and at 12 months (not shown). Figure 1 B similarly shows the cumulative 
frequency plots of the 28, 53, and 68 tender joint counts at baseline. It can be seen 
that the number of tender joints involved is larger than the number of swollen joints. 
In figure 1 B, the scores of the tender joint counts follow the same trend, but the 28 TJC 
is the lowest. Misclassification (no tender joints according to the 28 TJC but at least 1 
tender joint according to the extended joint counts occurred in 6% at baseline (1 B) and 
11% at 12 months.
In figure 1 C and D, cumulative frequency plots are shown of the 28 and 44 SJC (C) 
and the 28 and 53 TJC (D). Now the patients are ordered by their scores on the extended 
joint count only. It can be seen in figure C that patients with no or few swollen joints 
according to the 28 SJC may have more than 1 swollen joint according to the 44 SJC. The 
same is seen for the 28 and 53 TJC in figure D.
Table 2. Exploratory factor analysis at baseline.
Factor
1 2 3
ESR (mm/h) -0.05 0.02 0.88
CRP (mg/L) -0.02 -0.09 0.88
SJC44 -0.15 0.60 -0.03
TJC53 0.18 0.93 -0.06
RAI (0-78) 0.28 0.85 -0.03
Pain (VAS) 0.86 0.06 0.10
Disease activity (VAS) 0.82 -0.08 0.08
Morning stiffness (VAS) 0.65 0.29 -0.14
Fatigue (VAS) 0.72 0.29 -0.12
General health (VAS) 0.85 -0.01 -0.13
HAQ (0-3) 0.53 0.57 0.06
Variance explained 46% 32% 22%
Three factors were derived using exploratory factor analysis with varimax rotation and a mineigen value 
>1 to obtain factors using baseline data. The factors may be named 1) ‘patient reported outcomes’, 2) ‘joint 
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Factor analysis
By factor analysis, three factors were retrieved from the disease activity parameters at 
baseline (Table 2). The first factor consisted of all the items on patient reported out-
comes, the second factor consisted of the examinations of tender and swollen joints, the 
third factor included the acute phase reactants ESR and CRP. The HAQ loaded on both 
the first and second factors. The ordering of factors in factor analysis and the amount of 
variance explained also reflect the number of items included. 
Concurrent validity
In table 3, the within-subject correlations of the DAS with other  disease activity variables 
are shown, using the visits of the first 12 months. The DAS had its highest correlations 
with the RAI and the tender joint counts, it correlated well with the swollen joint counts 
and most of the patient assessments and correlated less with CRP. Correlations of the 
DAS28 generally were similar.
Construct validity
It was studied whether the time averaged DAS over 12 months was associated with 
a change in HAQ over the same period of time, irrespective of treatment allocation 
(Figure 2). HAQ scores were available of 102 patients. Over 12 months, there were 16 
Table 3. Within-subject correlations with DAS and DAS28 over visits 1-5.
DAS DAS28
r (95%CI) r (95%CI)
ESR (mm/h) 0.47 (0.31-0.61) 0.50 (0.34-0.63)
CRP (mg/L) 0.32 (0.14-0.48) 0.36 (0.19-0.52)
SJC28 0.62 (0.49-0.72) 0.63 (0.50-0.73)
SJC44 0.63 (0.50-0.73) 0.52 (0.37-0.65)
SJC66 0.62 (0.49-0.72) 0.50 (0.35-0.63)
TJC28 0.62 (0.49-0.72) 0.69 (0.58-0.78)
TJC53 0.71 (0.60-0.79) 0.63 (0.51-0.73)
RAI (0-78) 0.77 (0.68-0.84) 0.60 (0.47-0.71)
TJC68 0.64 (0.51-0.74) 0.57 (0.43-0.69)
Pain (VAS) 0.43 (0.26-0.57) 0.49 (0.33-0.62)
Disease activity (VAS) 0.43 (0.27-0.57) 0.48 (0.32-0.61)
Morning stiffness (VAS) 0.39 (0.22-0.54) 0.42 (0.25-0.56)
Fatigue (VAS) 0.30 (0.12-0.46) 0.35 (0.17-0.50)
General health (VAS) 0.46 (0.30-0.60) 0.54 (0.39-0.66)
HAQ (0-3) 0.35 (0.17-0.50) 0.35 (0.21-0.53)
The within-subject correlations inform about in how far a change in DAS (or DAS28) is paralelled by a 









































patients with a worsening in HAQ over 0.22 points, 40 patients with an improvement 
over 0.22, and 46 patients with smaller changes in either direction who were regarded 
as ‘unchanged’ (Figure 2). In ordinal logistic regression, the time averaged DAS was 
significantly associated with a minimal clinical important change (>0.22) in HAQ, with 
an OR (95%CI) of 4.1 (2.1-8.0), corrected for baseline HAQ, anti-CCP, age and gender 
as confounders. The assumptions for ordinal logistic regression, as outlined in the 
methods, were met. Further, it was studied whether time averaged disease activity and 
joint damage progression were correlated. However, there was no relation between 
time averaged CRP or time averaged DAS and change in Sharp score, irrespective of RF 
positivity, anti-CCP positivity, treatment, or final disease outcome (results not shown). 
Criterion validity
The level of disease activity is supposedly different for patients who develop RA, have 
undifferentiated arthritis, or reach remission. The mean (SD) DAS for patients with RA 
(n=49) was 2.6 (0.90), for patients with undifferentiated arthritis (n=21) it was 2.2 (0.72), 
for patients reaching remission (n=29) the DAS was 1.9 (0.64); p=0.001 for the differ-
ences between diagnostic groups. The OR (95%CI) for the differences between diagnos-
tic groups in ordinal logistic regression was 2.5 (1.5-4.2) per time-averaged DAS point. 
A similar difference was observed for the DAS28. The assumptions for ordinal logistic 
regression were met for both analyses. 
The mean (SD) DAS28 for patients with RA was 3.7 (1.09), for patients with undiffer-
entiated arthritis it was 3.2 (1.91), for patients reaching remission the average DAS28 
over time was 2.8 (0.79); p=0.0007 for the differences between diagnostic groups. At 
Figure 2. Response in HAQ and DAS scores averaged over time.
Box plots of the patient-averaged DAS over month 0-12, by HAQ response at month 12. HAQ response 
was defined as worsening (change in HAQ score > -0.22), no change (change in HAQ score between -0.22 
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18 months, 13 patients fulfilled the ARA criteria of remission. At that time, there were 
32 patients with a DAS<1.6, and 13/32 (40%) fulfilled the ARA criteria for remission. The 
number of patients with a DAS28<2.6 was 37, with 13/37 (35%) fulfilling the ARA criteria.
Responsiveness
The changes in disease activity parameters from baseline to 12 months are shown in 
Table 4. Disease activity improved in both treatment arms, but generally changes were 
larger in the MTX group. When adopting p=0.05 as critical value for determining sta-
tistical significance, the critical value of t with this sample size is 2.0. In table 4 it can 
be seen that in the MTX group the DAS had a higher responsiveness (SRM) than the 
single parameters. The tender joint counts and the DAS and DAS28 showed the best 
performance in discriminating MTX from placebo according to Guyatt’s responsiveness 
statistic and the t-value, with increasing discrimination with increasing number of joints 
assessed. The other variables did not exceed the critical t-value value of 2.0.
Table 4. Responsiveness of disease activity parameters.
MTX (n=55) Placebo (n=55)
Mean (SD) SRM Mean (SD) SRM Guyatt’s ES t-value
DAS -0.8 (0.8) 1.02 -0.4 (0.9) 0.40 0.89 2.40
DAS28 -1.1 (1.1) 1.05 -0.6 (1.3) 0.47 0.85 2.15
ESR (mm/h) -5.6 (11.8) 0.47 -1.8 (15.2) 0.12 0.37 1.40
CRP (mg/L) -3.6 (15.0) 0.24 -0.7 (17.0) 0.04 0.21 0.87
SJC28 -1.7 (2.6) 0.62 -1.2 (2.9) 0.42 0.57 0.77
SJC44 -1.9 (3.6) 0.53 -1.0 (4.7) 0.20 0.55 1.17
SJC66 -2.3 (4.5) 0.52 -1.4 (4.7) 0.29 0.55 1.08
TJC28 -2.7 (3.9) 0.68 -0.5 (5.2) 0.10 0.52 2.44
TJC53 -3.8 (6.4) 0.59 -0.31 (6.8) 0.04 0.57 2.71
RAI (0-78) -3.3 (5.0) 0.65 -0.7 (4.4) 0.16 0.74 2.77
TJC68 -4.8 (7.8) 0.62 0.17 (9.0) 0.02 0.54 3.04
Pain (VAS) -11 (25) 0.45 -15 (28) 0.52 0.41 0.59
Disease activity (VAS) -10 (24) 0.41 -17 (28) 0.59 0.34 1.39
Morning stiffness (VAS) -13 (25) 0.53 -15 (28) 0.54 0.46 0.49
Fatigue (VAS) -7 (25) 0.27 -7 (30) 0.24 0.22 0.10
General health (VAS) -9 (21) 0.44 -6 (31) 0.20 0.29 0.54
HAQ (0-3) -0.19 (0.45) 0.42 -0.13 (0.47) 0.29 0.40 0.59
Shown are changes over 0-12 months in mean (SD). SRM=standardised response mean. For other 










































In this post-hoc analysis of the data from the PROMPT study of MTX versus placebo in 
patients with early UA, it was studied whether the DAS is a valid measure of disease 
activity in early UA. According to the results of this study, the DAS indeed appears to be 
a reasonably valid measure of disease activity for use in UA clinical trials. However, the 
validity of the DAS to measure arthritic disease activity in UA should also be tested in 
other UA samples in different settings. 
In absence of an unambiguous “gold standard” measure, validation took five steps: 
factor analysis, concurrent validity, construct validity, criterion validity and respon-
siveness.  The primary interest of this study in UA was in the DAS, because it includes 
extended joint counts. The DAS28 with its reduced (28) joint counts was included to be 
able to see whether or not there were large differences between the two measures in 
their performance. 
According to the comparison of reduced with extended joint counts in cumulative 
frequency plots, it appeared that up to 10% of patients were misclassified as having no 
swollen or tender joints by the 28 joint count. In contrast, these patients had 1 to 10 
joints involved according to the extended joint counts. The largest difference between 
28 and extended joint counts is that the former does not include the feet joints. Feet 
joints may typically be involved in early RA (13). As the DAS includes extended joint 
counts, the DAS may be preferred over the DAS28 in clinical trials in early RA or UA. It 
could be shown in the frequency plots that the reduced joints are underestimating the 
involvement of the number of joints. However, the lesser performance of the reduced 
joint counts was not substantiated in the correlation of the DAS28 with other variables 
and its responsiveness.
By the factor analysis, similar factors of disease activity were found in this study as 
previously in RA (5). The three factors were patient reported outcomes, tender joints and 
swollen joints, and acute phase reactants. Indeed, as can be seen in the DAS formula, the 
DAS taps information from each of these constructs. Results of factor analysis depend 
on the variables that are put in. The fact that a large proportion of the disease activity 
parameters was patient-assessed, that naturally are closely correlated, will have contrib-
uted to retrieval of patient reported outcomes as the first factor.
In this study, the DAS correlated moderate-to-good with all other disease activity 
parameters, including patient assessments, except for the acute phase reactants. The 
contribution of the GH item to the DAS is relatively low (maximally 0.72 if GH is scored 
100), which may be criticized as neglecting the patient perspective. However, despite 
the weighting, the DAS is reasonably well associated with the other frequently used 
patient assessments. The low within-subject correlations of the DAS with ESR and CRP 
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the normal range so changes in the acute phase reactants were not highly related to 
changes in DAS or DAS28. On the other hand it is known that the DAS28 is sensitive for 
changes in the low (even normal) range of ESR (14). The DAS over time was indeed re-
lated to a change in HAQ, as expected in advance. However, DAS over time and CRP over 
time were both not associated with the progression of joint damage in this study. This 
could not be explained, not even approximately, by differences in RF positivity, anti-CCP 
positivity, treatment, or final disease outcome. However, the small number of patients 
experiencing joint damage progression made it difficult to analyse these relations.
It was supposed in advance that the course of disease activity would be different 
for patients who turned out to have RA, who still had UA, or who were in remission at 
the end of the study. Indeed the mean DAS levels were clearly different for these three 
diagnostic groups. The DAS and the DAS28 both did not perform well in predicting the 
ARA criteria for clinical remission: all patients with ARA clinical remission had a DAS<1.6 
and a DAS28<2.6, but only 40% of patients with a DAS<1.6 and 35% of patients with a 
DAS28<2.6 fulfilled the ARA remission criteria.
The original PROMPT trial was powered for the primary outcome, which was the 
diagnosis reached at 18 months (4). When analyzing the responsiveness of the several 
disease activity parameters included as secondary outcomes, the DAS discriminated 
well between MTX and placebo. Neither of the other parameters, except the tender joint 
counts, reached statistical significance. Like in RA clinical trials, the pooling of informa-
tion in the DAS therefore may be advantageous for trials in UA.
An advantage of the DAS for assessment of disease activity is that it includes extended 
joint counts. Whilst the 28 joint counts were introduced to facilitate a quick performance 
of joint counts, their use may lead to an underestimation of disease activity if only few 
joints are involved that are not among the 28 counted, such as the feet. This may play 
a role in UA as well as in early RA. In UA, disease activity is generally low, and by using 
extended joint counts including the feet an underestimation of the number of joints 
involved may be prevented. For that reason, for clinical trials of early interventions in UA 
or RA that aim at clinical remission the DAS may be preferred over the DAS28 (13). On 
the other hand, in this validation study in UA, the DAS28 performed closely to the DAS 
regarding all parameters of validity and responsiveness. It was the assessment of clinical 
remission that was impeded by the use of reduced joint counts.
In summary, it can be concluded that the DAS, which is a valid measure of RA disease 
activity, appears to be a reasonably valid measure of disease activity for use in UA clinical 
trials. Similar factors of disease activity were found in this study as previously in RA; the 
DAS correlated moderate-to-good with all other disease activity parameters including 
patient-assessments; the DAS over time was related to changes in HAQ; the DAS was 
different for patients with RA, UA and patients in remission; and the DAS discriminated 









































relatively small (N=110) for validation purposes and therefore, studying the validity of 
the DAS in UA in other samples is most welcome. The DAS may be used as primary or 
secondary outcome measure for clinical trials in early UA. Instead of the DAS, the DAS28 
may also be used, but the use of reduced joint counts underestimates the involvement 
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Chapter 6
A prediction rule for disease outcome 
in patients with recent-onset 
undifferentiated arthritis. How to guide 
individual treatment decisions
A.H.M. van der Helm-van Mil 
S.le Cessie 















































In patients with undifferentiated arthritis (UA), methotrexate is effective for inhibiting 
symptoms, structural damage, and progression to rheumatoid arthritis (RA). How-
ever, 40-50% of patients with UA experience spontaneous remission. Thus, adequate 
decision-making regarding treatment of patients with early UA requires identification of 
those patients in whom RA will develop.
Methods
A prediction rule was developed using data from the Leiden Early Arthritis Clinic, an 
inception cohort of patients with recent-onset arthritis (n = 1,700). The patients who 
presented with UA were selected (n = 570), and progression to RA or another diagnosis 
in this group was monitored for 1 year of followup. The clinical characteristics with 
independent predictive value for the development of RA were selected using logistic 
regression analysis. The diagnostic performance of the prediction rule was evaluated us-
ing the area under the curve (AUC). Cross-validation controlled for overfitting of the data 
(internal validation). An independent cohort of patients with UA was used for external 
validation.
Results
The prediction rule consisted of 9 clinical variables: sex, age, localization of symptoms, 
morning stiffness, the tender joint count, the swollen joint count, the C-reactive protein 
level, rheumatoid factor positivity, and the presence of anti-cyclic citrullinated peptide 
antibodies. Each prediction score varied from 0 to 14 and corresponded to the percent 
chance of RA developing. For several cutoff values, the positive and negative predictive 
values were determined. The AUC values for the prediction rule, the prediction model 
after cross-validation, and the external validation cohort were 0.89, 0.87, and 0.97, 
respectively.
Conclusion
In patients who present with UA, the risk of developing RA can be predicted, thereby 
allowing individualized decisions regarding the initiation of treatment with disease-
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Introduction
Making individualized decisions regarding treatment is one of the most important chal-
lenges in medicine. To this end, several studies have associated clinical variables or gene 
expression profiles with disease outcome, thereby providing help for clinicians making 
treatment decisions in several diseases, e.g., breast cancer, Hodgkin’s disease, and lym-
phoma (1-4). For the past decennium, treatment of rheumatoid arthritis (RA) has been 
characterized by early, aggressive treatment with disease-modifying antirheumatic 
drugs (DMARDs), because this treatment strategy prevents joint damage and functional 
disability (5-7).
In rheumatology practices, the majority of patients who present with recent-onset 
arthritis have undifferentiated arthritis (UA), which is a form of arthritis that does not 
fulfill the classification criteria for a more definitive diagnosis. Based on results from sev-
eral inception cohort studies, it is known that ~40-50% of patients with UA experience 
spontaneous remission, whereas RA develops in one-third of patients with UA (8-10). 
Recent evidence indicates that treatment with methotrexate in patients with early UA 
hampers progression to RA and progression of joint damage (11), underscoring the 
need for guidance when starting treatment with a clinically beneficial but potentially 
harmful drug in UA. Ideally, only the patients with UA in whom RA develops would be 
treated with DMARDs, excluding those in whom UA remits spontaneously.
At present, although several risk factors for the development of RA have been identi-
fied (8;12), a model that predicts the disease course specifically in patients with recent-
onset UA is lacking. In the present study, we aimed to develop a model that predicts 
progression from UA to RA, using clinical variables that are easily assessed in clinical 
practice. The derived prediction rule was internally validated, controlling for overfitting 




The prediction rule was derived using the Leiden Early Arthritis Clinic (EAC) cohort. 
This inception cohort comprises more than 1,900 patients with recent-onset arthritis, 
of whom ~1,700 have completed at least 1 year of followup. The EAC cohort began in 
1993 at the Department of Rheumatology of the Leiden University Medical Center, the 
only referral center for rheumatology in a health care region of ~400,000 inhabitants in 









































when arthritis was suspected; patients were included if a physical examination revealed 
arthritis.
At the first visit, the rheumatologist completed a questionnaire regarding the present-
ing symptoms, as reported by the patient: type, localization and distribution of initial 
joint symptoms, symptom duration, and course of the initial symptoms. The patient’s 
smoking history and family history were assessed. Patients rated morning stiffness on a 
visual analog scale (VAS; range 0-100 mm). For the present study, the severity of morn-
ing stiffness was used instead of the duration of morning stiffness, because the former 
variable has been proven to be a better discriminator (14;15). The Health Assessment 
Questionnaire (16) was used to provide an index of disability. A 44-joint count for tender 
and swollen joints was performed, scoring each joint on a 0-1-point scale (17). Compres-
sion pain in the metacarpophalangeal and metatarsophalangeal joints was recorded.
Baseline blood samples were obtained for determination of the erythrocyte sedimen-
tation rate (ESR), the C-reactive protein (CRP) level, the presence of IgM rheumatoid 
factor (RF), as determined by enzyme-linked immunosorbent assay (ELISA), and the 
presence of antibodies to cyclic citrullinated peptide 2 (anti-CCP), as determined by 
ELISA (Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands). The cutoff 
level for anti-CCP positivity was 25 arbitrary units. Radiographs of the hands and feet 
were obtained and scored according to the Sharp/van der Heijde method (18). Patients 
provided informed consent, and the local ethics committee approved the protocol.
Assessment of disease status after 1 year
Two weeks after being included in the study, when results of laboratory investigations 
and radiography were known, 570 patients were determined to have a form of arthritis 
that could not be classified according to American College of Rheumatology (ACR; 
formerly, the American Rheumatism Association) criteria (19) and were documented 
as having UA. After 1 year of followup, the disease status of all patients with UA was 
examined to determine whether RA or another specific type of arthritis had developed, 
based on fulfillment of the ACR criteria. Inherent in the design of an inception cohort, 
the duration of followup differed within the study population, and at the moment of 
analysis (July 2005), the majority of patients with UA (94%) had been followed up for 
more than 1 year (mean ± SD followup 8 ± 3 years).
External validation cohort
Patients included in the placebo arm of the Probaat (PROMPT) trial, a double-blind, 
placebo-controlled, randomized trial in which patients with recent-onset UA were 
treated with either methotrexate or placebo, were used for validation (n = 55) (11). 
Exclusion of the patients with UA who were also included in the EAC cohort resulted in 
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patient, the progression score at baseline was calculated, and the development of RA 
after 1 year of followup was assessed (11).
Statistical analysis
Patients with UA in whom RA developed were compared with those in whom RA did 
not develop, using the chi-square test for nominal variables and Student’s t-test for 
continuous variables. Symptom duration was categorized. Subsequently, all clinical 
variables were entered as possible explanatory variables in a logistic regression analysis, 
with disease outcome (RA or non-RA) at 1 year of followup as the dependent variable. 
Using a backward selection procedure, the most significant independent variables were 
identified, using a P value greater than 0.10 as the removal criterion.
In the logistic regression model, the predicted probability of RA was related to the 
covariates via the following prognostic index: B1 × x1 + B2 × x2 + B3 × x3 ...Bk × xk. The 
regression coefficient (B) of the covariate indicates an estimate of the relative magnitude 
of the prognostic power of a specific variable. Using the prognostic index, we calculated 
the predicted probability of RA developing for every patient. For continuous variables 
(age, VAS score, tender and swollen joint counts, CRP level), the effect was studied both 
as a continuous variable and as a categorized variable. Categories were created using 
clinically applicable cutoff levels and percentiles. Categories were pooled if correspond-
ing regression coefficients were similar. Data were missing for some patients, as follows: 
morning stiffness score on a 100-mm VAS (n = 160 patients), anti-CCP antibody level 
(n = 64 patients), disease duration (n = 22 patients), tender joint count (n = 5 patients), 
swollen joint count (n = 4 patients), CRP level (n = 1 patient), and presence of RF (n = 1 
patient). To prevent exclusion of these patients from the logistic regression analysis, the 
median values for these variables were imputed.
To obtain a simplified prediction rule, the regression coefficients of the predictive 
variables were rounded to the nearest number ending in .5 or .0, resulting in a weighted 
score; subsequently, the values for the independent predictive variables were summed. 
The calculated prediction scores were compared with the observed percentage of 
patients who experienced progression to RA. The positive and negative predictive 
values were determined for several cutoff values of the prediction scores. To evaluate 
the diagnostic performance of the rule, a receiver operating characteristic (ROC) curve 
was constructed. The area under the ROC curve (AUC) values provided a measure of the 
overall discriminative ability of a model.
For internal validation, cross-validation was performed to control for overfitting (20). 
Cross-validation mimics the prediction situation and for each observation yields a pre-
diction score based on the other (n - 1) observations (20). To validate the model, a ROC 
curve was made using the cross-validated predictions as well as the external validation 









































Table 1. Baseline characteristics of patients with UA, according to progression to RA*
Characteristic
No progression to RA  
(n = 393)
Progression to RA  
(n = 177)
P
Age, mean ± SD 48.6 ± 17.0 56.3 ± 15.3 <0.001
Female sex 208 (53) 121 (68) 0.001
Positive family history of RA 81 (21) 54 (31) 0.01
Course of starting symptoms
      acute for <24 hours
      subacute for > 24 hours
      gradual









Symptom duration at inclusion
      < 6 weeks
      6 weeks to 3 months
      3 to 6 months









Localization of affected joints
      small joints
      large joints







Localization of affected joints
      symmetric 147 (37) 118 (67) <0.001
Localization of affected joints
      upper extremities
      lower extremities







Morning stiffness, mean ± SD score on a 100-
mm VAS
35.5 ± 30.0 53.3 ± 30.1 <0.001
Compression pain in MCP joints 159 (40) 116 (66) <0.001
Compression pain in MTP joints 134 (34) 103 (58) <0.001
Number of tender joints, median (IQR) 5 (2-11) 11 (7-22) <0.001
Number of swollen joints, median (IQR) 2 (1-4) 4 (2-7) <0.001
C-reactive protein level, median (IQR) mg/liter 8 (3-21) 14 (7-43) <0.001
ESR, median (IQR) mm/hour 17 (8-38) 32 (19-53) <0.001
Rheumatoid factor positivity 56 (14) 84 (47) <0.001
Anti-CCP positivity 38 (11) 83 (51) <0.001
HAQ score, mean ± SD 0.7 ± 0.6 1.0 ± 0.7 <0.001
Smoking 187 (48) 84 (47) 1.0
Erosive disease 29 (7) 29 (16) 0.001
* Except where indicated otherwise, values are the number (%). UA = undifferentiated arthritis; RA = 
rheumatoid arthritis; VAS = visual analog scale; MCP = metacarpophalangeal; MTP = metatarsophalangeal; 
IQR = interquartile range; ESR = erythrocyte sedimentation rate; anti-CCP = anti-cyclic citrullinated 
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Results
Disease outcome
During the first year of followup, RA developed in 177 of the 570 patients with UA, other 
rheumatologic disease developed in 94 patients, and 150 patients achieved clinical 
remission, defined as discharge from the outpatient clinic because of the absence of ar-
thritis while not receiving DMARD treatment. For further analysis, patients with another 
rheumatologic diagnosis or UA and those who achieved remission were assembled as 
the non-RA group (n = 393).
Table 2. Independent predictive variables for development of RA based on results of multivariate 
regression analysis*
Variable B OR 95%CI P Points†
Sex 0.8 2.1 1.3-3.6 0.003 1
Age 0.02 1.02 1.01-1.04 0.011 0.02/year
Localization small joints hand/feet 0.6 1.8 1.1-3.1 0.024 0.5
Symmetric localization 0.5 1.6 1.0-2.8 0.075 0.5
Localization in upper extremities











Morning stiffness score on 100-mm VAS
                 0-25
                 26-50
                 51-90





















Number of tender joints
                 0-3
                 4-10
















Number of swollen joints
                 0-3
                 4-10

















                0-4
                5-50
















RF positivity 0.8 2.3 1.2-4.2 0.009 1
Anti-CCP positivity 2.1 8.1 4.2-15.8 <0.001 2
* B values are regression coefficients. RA = rheumatoid arthritis; OR = odds ratio; 95% CI = 95% confidence 
interval; VAS = visual analog scale; CRP = C-reactive protein; RF = rheumatoid factor; anti-CCP = anti-cyclic 
citrullinated peptide. 










































The characteristics of patients with UA in whom RA developed and those in whom RA 
did not develop are compared in Table 1. In the univariate analyses, all variables except 
smoking were significantly associated with progression to RA.
Multivariate analyses and derivation of the prediction rule
In the logistic regression analysis, the independent predictive variables for development 
of RA were age, sex, localization of joint symptoms (small/large joints, symmetric/asym-
metric, upper/lower extremities), morning stiffness, tender and swollen joint counts, 
CRP level, and the presence of RF or anti-CCP antibodies (Table 2).
Because age was more predictive as a continuous variable than as a categorized vari-
able, age was not categorized. The other variables were categorized. For the resulting 
model, the fraction of explained variation (Nagelkerke’s R2) was 0.57; when using a 
predicted probability of 0.5 as the cutoff value, the outcomes for 83% of patients were 
predicted correctly. The coefficients for the simplified prediction score are listed in Table 
2. Figure 1 presents a form that can be used to easily calculate the prediction score. The 
 1 
1. What is the age in years?  Multiply with 0.02  
2. What is the sex? 
    In case female:   1 point 
3. How is the distribution of involved joints? 
    In case small joints hands/feet:  0.5 point 
    In case symmetric:   0.5 point 
    In case upper extremities  1 point 
    In case upper and lower extremities: 1.5 points 
4. What is the score for morning stiffness on a 100-mm VAS? 
    In case 26-90 mm:   1 point 
    In case >90 mm:   2 points 
5. What is the number of tender joints? 
    In case 4-10:    0.5 point 
    In case 11 or higher:   1 point 
6. What is the number of swollen joints? 
    In case 4-10:    0.5 point 
In case 11 or more:   1 point 
7. What is the C-reactive protein level? 
In case 5-50 mg/liter:   0.5 point 
In case 51 mg/liter or higher:  1.5 points 
8. Is the patient rheumatoid factor positive? 
    If yes:     1 point 
9. Are the anti-CCP antibodies positive? 




Figure 1. Form used to calculate a patient’s prediction score. The range of possible scores is 0-14, with 
higher scores indicating a greater risk of developing rheumatoid arthritis. VAS = visual analog scale; anti-
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range of the prediction scores is 0-14, with a higher score indicating a greater risk of 
developing RA.
A prediction score was calculated for every patient with UA. Figure 2 shows the pre-
dicted risk of RA as a function of the prediction score (obtained from a logistic regression 
model with score as the independent variable). Table 3 shows the observed percentage 
of patients who experienced progression to RA in relation to the calculated prediction 
score. None of the patients with UA who had a prediction score ≤3 progressed to RA dur-
ing the 1-year followup period, and all of the patients with UA who had a score ≥11 did 
experience progression to RA. Among the patients with scores of 4-10 who experienced 
progression to RA, the frequency of such progression increased with rising scores. 
Table 4 shows the percentage of patients in whom RA developed, according to several 
cutoff values of the prediction score. For example, when the scores 5.0 and 9.0 were cho-
sen as cutoff values, 97% of patients with UA who had a score ≤5.0 did not develop RA, 
and a score ≥9.0 was associated with progression to RA in 84% of patients. When cutoff 
values of 6.0 and 8.0 were used, 91% of patients with UA who had a score ≤6.0 did not 
develop RA (negative predictive value 91%, 95% confidence interval [95% CI] 88-94%), 
and a score ≥8.0 corresponded to progression to RA in 84% of patients (positive predic-
tive value 84%, 95% CI 75-91%). Using these cutoff values, 145 patients with UA (25%) 
had a score between 6.0 and 8.0, indicating that no adequate prediction could be made 
for these patients. Twenty-five patients with UA did not fulfill the 1987 ACR criteria for RA 
after 1 year of followup, but RA developed later in the disease course. These patients had 
a median prediction score of 5.7 (interquartile range [IQR] 4.8-6.2); this value is between 
 









































the scores for the patients with UA in whom RA developed and those in whom RA did 
not develop during the first year of followup (median score 7.7 [IQR 6.6-8.8] and median 
score 4.6 [IQR 3.3-5.9], respectively).
Discriminative ability
The discriminative ability of the logistic regression model and the prediction rule were 
evaluated with a ROC curve (Figure 3). Both the logistic regression model and the pre-
Table 3. Prediction scores and progression or nonprogression to RA*




0 1 (100) 0 (0)
1 8 (100) 0 (0)
2 42 (100) 0 (0)
3 58 (100) 0 (0)
4 78 (93) 6 (7)
5 73 (85) 13 (15)
6 63 (74) 22 (26)
7 37 (49) 38 (51)
8 16 (33) 33 (67)
9 6 (14) 36 (86)
10 5 (23) 17 (77)
11 0 (0) 8 (100)
12 0 (0) 1 (100)
13 0 (0) 1 (100)
14 0 (0) 0 (0)
* Values are the number (%) of patients with a given score. Scores were rounded to the nearest number 
ending in .5 or .0 (i.e., scores ≤0.5 are in the category 0, scores >0.5 and ≤1.5 are in the category 1, etc.). RA 
= rheumatoid arthritis.
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* Values are the number (%) of patients with a given score. Scores were rounded to the nearest number 
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diction rule had a mean ± SD AUC value of 0.89 ± 0.014. The finding that the AUC values 
for the logistic regression model and the prediction rule were equal indicates that the 
derivation of the prediction rule from the logistic regression model had not introduced 
a loss of discriminative ability.
Internal validation
Cross-validation was used to control for overfitting. This procedure yielded a value for 
the predicted probability of RA for every patient, based on results of model-fitting on 
the other patients (20). The AUC value of the cross-validated predictions nearly equaled 
the mean ± SD AUC value of the prediction score (0.87 ± 0.015) (Figure 3), indicating that 
overfitting was not a major problem.
External validation
In the validation cohort, 47% of patients with UA had experienced progression to RA 
after 1 year of followup. The prediction scores for the patients with UA in whom RA did 
develop and those in whom RA did not develop are presented in Figure 4. Among pa-
tients with UA who experienced progression to RA, the median prediction score was 8.0 
(IQR 6.1-9.1); among patients in whom RA did not develop, the median prediction score 
was 4.6 (IQR 3.5-5.5). Ninety-four percent of the patients with a prediction score ≤6.0 
had not experienced progression to RA, and the development of RA was observed in 
83% of patients with a score >6. All patients with a score ≥8.0 had progressed to RA, and 
78% of patients with a score <8 did not develop RA. In the validation cohort, 17% of the 
 
Figure 3. Receiver operating characteristic curve for the logistic regression model, the prediction rule, and 
the cross-validated prediction model. The area under the curve values for the logistic regression model, 









































patients with UA had a prediction score between 6 and 8; RA had not developed in two-
thirds of these patients and had developed in one-third of them. If treatment decisions 
were based on the prediction rule using cutoff levels of ≥8 for initiating treatment and 
≤6 for withholding treatment, treatment would have been withheld inaccurately from 
only 6% of the patients, and no patient would have received treatment inaccurately. The 
mean ± SD AUC value for the validation cohort was 0.97 ± 0.024.
Discussion
The currently developed rule predicts the development of RA in patients with UA, using 
9 clinical variables that are commonly assessed during the first visit: sex, age, localization 
of joint symptoms, morning stiffness, tender and swollen joint counts, the CRP level, and 
the presence of RF and anti-CCP antibodies. The resulting prediction score corresponds 
to a chance for progression to RA. The positive and negative predictive values of the 
prediction score depend on the chosen cutoff values. The discriminative ability was 
excellent, with an AUC value of 0.89 and with a value of 0.87 after internal validation cor-
recting for overfitting. Subsequent validation in a small independent cohort revealed an 
AUC value of 0.97. Because the prediction rule is accurate and can be easily determined 
in daily clinical practice, the present model is an important step forward in achieving 




Figure 4. Prediction scores for patients with undifferentiated arthritis in whom rheumatoid arthritis (RA) 
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Because current evidence regarding treatment of RA is based on results of large trials 
involving patients fulfilling the ACR 1987 revised criteria for RA (19), fulfillment of these 
criteria was used as the outcome for the current study. Alternative outcome measure-
ments such as disease persistence or remission can be considered, but no generally 
accepted definitions of these disease states are available, and no trials of patients with 
these disease states are available to provide guidance when making treatment deci-
sions. Nevertheless, the use of fulfillment of the ACR criteria as outcome may lead to 
circularity, because use of the items included in the ACR criteria is expected to result in 
the identification of predictive variables. However, several studies have shown that the 
ACR criteria themselves have low discriminative value in patients with UA (12;21-25), 
and only some of the variables used for the present prediction rule are among the ACR 
criteria. In the end, it will most likely not make a large difference whether the outcome of 
a prediction rule is the diagnosis RA or disease persistence, because the ACR criteria are 
formulated based on patients with longstanding/persistent RA (mean disease duration 
8 years), and the reported remission rate in these patients is low (10-15%) (26;27).
Misclassification may have occurred when patients who presented with UA were 
treated with any drug that hampered the progression to RA. In such cases, patients who 
normally would have progressed to RA would be classified as non-RA. Exclusion of such 
misclassified patients, who supposedly would have high prediction scores because they 
were prone to the development of RA, will result in an increased discriminative ability of 
the current prediction rule.
The presence of erosions on radiographs of the hands and/or feet is reported to 
have high specificity (but low sensitivity) for discriminating between self-limiting and 
persistent disease (25). Although in univariate analysis, the presence of erosions was 
significantly increased in UA patients in whom RA developed compared with patients 
in whom RA did not develop (16% versus 7%), multivariate regression analysis revealed 
that the presence of erosions was not an independent prognostic variable. The presence 
of erosions appeared to be associated with a higher median age (64 years in patients 
with erosive disease versus 49 years in those with nonerosive disease), a higher median 
number of swollen joints (5 joints in patients with erosive disease versus 2 joints in those 
with nonerosive disease), and the presence of RF (46% of patients with erosive disease 
versus 23% of those with nonerosive disease). Because the presence of erosions was not 
identified as a variable with an independent predictive value, data on erosions were not 
included in the prediction rule.
A model for predicting self-limiting, persisting, or erosive arthritis exists (25). For the 
development of that model, all consecutive patients with arthritis who were referred 
were incorporated, including patients in whom a definite diagnosis was made during 
the first weeks. Decisions regarding the initiation of DMARDs are seldom problematic in 









































with recent-onset UA (28), because the disease outcome in patients with UA is variable. 
For the present study, we selected patients with UA from a total of 1,700 consecutive 
patients and developed a prediction rule specifically for UA.
The positive and negative predictive values of the prediction score depend on the 
chosen cutoff level. When the upper and lower cutoff values were 8.0 and 6.0, the cor-
responding positive predictive value and negative predictive value were 84% and 91%, 
respectively. In the original cohort, 25% of patients had a prediction score between 
6.0 and 8.0; in these patients, the chance of RA developing or not developing was 
equal. Apparently, the clinical characteristics of patients with intermediate scores are 
insufficient to predict disease outcome. It is possible that genotype data are helpful in 
these patients. Patients were also typed for HLA-DRB1 shared epitope (SE) alleles and 
PTPN22. In the multivariate analysis, the presence of SE alleles was not identified as 
an independent predictive variable; this might be attributable to the fact that the SE 
alleles are associated with the presence of anti-CCP antibodies (29), which are already 
included in the prediction rule. Also, the presence of the PTPN22 T allele did not result 
in a better ability to predict progression from UA to RA. This is understandable, because 
the PTPN22 T allele confers risk of both UA and RA (30). In the validation cohort, 17% of 
patients had a prediction score between 6.0 and 8.0; for treatment decisions in these 
patients the observed risk of progression to RA can be weighted against the individual 
risk profile for treatment toxicity.
The prediction score discriminated even better in the validation cohort than in the ini-
tial cohort: 100% of patients with a score ≥8.0 had progressed to RA, and 94% of patients 
with a score ≤6.0 did not develop RA. This indicates that if treatment decisions were 
based on the prediction rule using the cutoff levels of ≥8 for initiating treatment and 
≤6 for withholding treatment, treatment would be inaccurately withheld in only 6% of 
patients, and no patient would receive treatment inaccurately. Although the validation 
cohort is relatively small and the current prediction rule should be evaluated in other 
early arthritis cohorts, we believe that the current model allows physicians and patients 
to make an evidence-based choice regarding whether or not to initiate DMARDs in the 
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To direct individual treatment decisions in recent-onset rheumatoid arthritis (RA), 
predictors of treatment response to methotrexate (MTX) need to be identified. Disease 
activity at baseline, gender and genetic polymorphisms have already been found to be 
associated with the effect of MTX treatment, but the predictive value of autoimmune 
antibody status remains less clear(1;2). It has been shown, however, that both the pres-
ence and level of anti-cyclic citrullinated peptide antibodies (ACPA) are strongly associ-
ated with a worse disease course (3). Therefore, we investigated the potential predictive 
effect of levels of ACPA in ACPA-positive patients for the response to MTX treatment. 
As observations from our cohort and others indicate that ACPA levels decrease during 
treatment, we studied two selected populations of disease-modifying antirheumatic 
drug (DMARD)-naïve, ACPA-positive patients with recent-onset arthritis, for whom 
pretreatment ACPA levels were available (4;5).
All ACPA-positive patients with undifferentiated arthritis (UA) who were included in 
the PROMPT study (PRObable RA: Methotrexate versus Placebo Treatment) (MTX group 
n = 12, placebo group n = 15) were enrolled (5). MTX treatment was started with 15 mg/
week and every 3 months the dosage was increased according to the Disease Activ-
ity Score (DAS44) to a maximum of 30 mg/week. Responders were defined as patients 
whose UA did not progress to RA (according to the American College of Rheumatology 
criteria) during the use of MTX (n = 6/12). MTX responders had lower levels of pretreat-
ment IgG ACPA than non-responders (median (interquartile range) 428 (214–643) AU/
Figure 1. (A) Pretreatment anti-cyclic citrullinated peptide antibodies (ACPA) levels in methotrexate (MTX) 
responders versus non-responders within ACPA-positive patients with recent-onset, undifferentiated 
arthritis from the PROMPT study (n = 12, p = 0.024). (B) Percentage of responders to MTX in ACPA-positive 
patients with recent-onset rheumatoid arthritis from the BeSt study with low, intermediate and high 









































ml vs 1594 (781–4495) AU/ml, respectively) (p = 0.024, Mann–Whitney test, figure 1A. 
Further univariate analysis did not show any significant differences in baseline clinical 
measures of disease activity, or in rheumatoid factor levels, between responders and 
non-responders. In addition, the risk of progression to RA, as analysed by survival analy-
sis, was lower in patients with low or intermediate pretreatment ACPA levels than in 
patients with high levels (stratified by tertiles) (p<0.001, log-rank test, figure 2).
Similar associations were found in a second cohort of ACPA-positive patients with 
recent-onset RA, who were treated with initial MTX monotherapy (15–25 mg) aiming at 
a DAS44 ≤2.4 in the BeSt study and from whom pretreatment serum samples were avail-
able (n = 26/131) (6). Responders were defined as patients achieving a DAS44 ≤2.4 after 
6 months. The percentage of responders decreased from 63% and 56% in patients with 
low and intermediate levels, respectively, to 11% in patients with high levels (stratified 
by tertiles) (p = 0.062, χ2 test, figure 1B). In a multivariate logistic regression analysis, low 
and intermediate ACPA levels predicted responsiveness, independently of baseline DAS, 
gender and age (odds ratio = 37, 95% confidence interval 0.8 to 1692, p = 0.064).
Despite the limited number of patients, these data from two distinct cohorts suggest 
that low and intermediate pretreatment levels of ACPA are associated with a more 
favourable response to MTX treatment in recent-onset, ACPA-positive arthritis, whereas 
high levels are associated with an insufficient response. Although these findings have to 
be confirmed in larger studies, quantitative evaluation of ACPA levels might be an addi-
tional tool to determine which patients will benefit most from MTX treatment. Therefore, 
we propose that pretreatment ACPA levels should be used in future prediction analyses.
Figure 2. Kaplan–Meier survival curves for the progression of undifferentiated arthritis to rheumatoid 
arthritis (RA) in anti-cyclic citrullinated peptide antibody (ACPA)-positive patients with undifferentiated 
arthritis. Placebo group (broken line, n = 15); methotrexate group (solid lines, n = 12; categorised into 
patients with low (light line), intermediate (semi-dark line) and high (dark line) pretreatment ACPA levels 
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Previous studies have shown that the suppressive capacity of CD4+,CD25++ T cells is 
compromised in patients with rheumatoid arthritis (RA) and restored by anti-tumor 
necrosis factor α(anti-TNFα) therapy. Given the lack of specific cell surface markers for 
human Treg cells, this study aimed to define surface markers for identifying and enrich-
ing Treg cells with enhanced regulatory ability within the CD4+,CD25++ T cell compart-
ment and to provide additional understanding of the effects of anti-TNFα antibodies in 
humans.
Methods
The expression of membrane-bound TNFα in human peripheral blood CD4+ T cells was 
analyzed by flow cytometry in healthy individuals and RA patients before and after anti-
TNFα treatment. Membrane-bound TNFα-positive and TNFα-negative CD4+,CD25++ T 
cells were purified by fluorescence-activated cell sorting, and their suppressive capacity 
was assessed in vitro by a standard suppression assay.
Results
A substantial number of CD4+,CD25++ T cells expressed membrane-bound TNFα. 
Membrane-bound TNFα-positive CD4+,CD25++ T cells displayed reduced antiinflam-
matory cytokine production and less potent suppressor capacity, since 4 times more 
cells were required to achieve 50% inhibition compared with their membrane-bound 
TNFα-negative counterparts. Treatment of RA patients with TNFα-specific antibodies led 
to a reduction in the number of membrane-bound TNFα-positive CD4+,CD25++ T cells 
from peripheral blood.
Conclusion
Our data indicate that the absence of membrane-bound TNFα on CD4+,CD25++ T cells 
can be used to characterize and enrich for Treg cells with maximal suppressor potency. 
Enrichment of membrane-bound TNFα-negative CD4+,CD25+ cells in the CD4+,CD25++ 
T cell compartment may contribute to restoring the compromised suppressive ability of 
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Introduction
CD4+,CD25+ Treg cells are generated in the thymus and periphery and represent a 
crucial regulator of peripheral self-tolerance (1;2). They are hyporesponsive to T cell 
receptor (TCR) stimulation in vitro (3;4); however, once activated, they can suppress the 
proliferation and cytokine production of effector T cells, antibody production of B cells, 
and the function of monocyte/macrophages (3-6). Hence, CD4+,CD25+ Treg cells have 
been successfully used to prevent/treat immunologic diseases in a variety of animal 
models, such as collagen-induced arthritis (CIA) (7-9).
Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic 
synovial inflammation resulting in cartilage and bone damage, eventually leading to 
joint destruction. Several different cell types and their mediators are thought to be 
involved in this tissue-destructive inflammation, including T cells, B cells, and proinflam-
matory cytokines such as tumor necrosis factor α(TNFα). The chronic inflammatory 
process suggests that immune regulation in RA patients is disturbed. Indeed, numerous 
reports have outlined disturbances in CD4+,CD25+ T cell functions in patients with RA 
as well as other autoimmune diseases (10-15), suggesting an imbalance between Treg 
cell and effector T cell activities. However, functional CD4+,CD25+ Treg cells have also 
been reported in RA patients (16;17), which could be a consequence of the complex 
phenotype of these cells in humans and the lack of specific cell surface markers to define 
and isolate Treg cells.
Although CD25 appears to identify a relatively homogeneous population of Treg cells 
in naive mice, the presence of significant amounts of activated conventional CD25+ 
T cells in humans makes it difficult to distinguish "genuine" Treg cells from activated 
conventional T cells in the CD4+,CD25+ T cell compartment. Indeed, several studies 
have suggested that only the CD4+ T cell subset expressing the highest levels of CD25 
(termed CD25high or CD25++) is mostly forkhead box P3-positive (FoxP3+) and has in 
vitro suppressive activity (18). Nonetheless, activated "conventional" T cells may still be 
present in the CD4+,CD25++ T cell subset, because FoxP3, the most commonly used 
marker for Treg cells (19), is also transiently expressed in activated nonsuppressive T cells 
(20-22). For this reason, the CD4+,CD25++ T cell population that homogeneously ex-
presses FoxP3 might not consist entirely of Treg cells but could also contain conventional 
activated CD4+,CD25++ T cells, especially in situations in which chronic T cell activation 
is thought to occur. The possible "contamination" of Treg cells with "conventional" 
CD4+,CD25++ T cells might also contribute to the compromised suppressive activity of 
CD4+,CD25++ T cell populations in autoimmune diseases such as RA (10-15), in which 
chronic T cell activation has been implicated. Likewise, other surface markers, such 
as CTLA-4 and glucocorticoid-induced TNF receptor, which have been reported to be 









































in humans. Therefore, they cannot be used as such to identify Treg cells, especially not in 
conditions with chronic T cell activation. Hence, further characterization and therapeutic 
use of Treg cells would be greatly facilitated by the identification of surface markers that 
could be used to define and isolate Treg cells with high suppressive activity.
TNFα is a pleiotropic cytokine that is bioactive both as a transmembrane protein and as 
a homotrimeric secreted molecule (25). Membrane-bound TNFα is expressed on normal 
human peripheral blood T cells after activation (26). As part of a range of proteins that 
are expressed on the cell surface after T cell activation, membrane-bound TNFα on CD4+ 
T cells can modulate the activation of macrophages and costimulate B cells, thereby 
enhancing their antibody production (27-29). Because it is conceivable that these lat-
ter features are mediated by conventional effector T cells rather than by Treg cells, and 
given that T cells also up-regulate CD25 upon activation, we reasoned that membrane-
bound TNFα-expressing CD4+,CD25++ T cells are enriched for activated conventional 
T cells rather than for naturally occurring Treg cells. In that case, membrane-bound 
TNFα-positive CD4+,CD25++ T cells would differ in phenotype and/or functional activity 
compared with their membrane-bound TNFα-negative counterparts.
In the present study, we show that the expression of membrane-bound TNFα on 
CD4+,CD25++ T cells is correlated with disease activity in RA patients. Although 
membrane-bound TNFα-positive and TNFα-negative CD4+,CD25++ T cells express com-
parable levels of FoxP3 and are both hyporesponsive to TCR stimulation, membrane-
bound TNFα-negative CD4+,CD25++ T cells produce more of the antiinflammatory 
cytokine interleukin-10 (IL-10) and suppress the proliferation and cytokine production 
of responder T cells in a more profound manner compared with their membrane-bound 
TNFα-positive counterparts. Furthermore, treatment with anti-TNFα antibodies results 
in a reduced frequency of membrane-bound TNFα-positive T cells in the CD4+,CD25++ 
T cell compartment in RA patients, suggesting that selective depletion of the less sup-
pressive membrane-bound TNFα-positive CD4+,CD25++ T cells by anti-TNFα antibodies 




Fresh peripheral blood was obtained from healthy adult donors with no history of auto-
immune diseases. Fresh peripheral blood from RA patients was obtained from patients 
attending the outpatient clinic of the Leiden University Medical Center. All RA patients 
fulfilled the 1987 revised classification criteria of the American College of Rheumatol-
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RA patients are summarized in Table 1. Buffy coats were obtained from the Sanquin 
Bloodbank (Sanquin, Amsterdam, The Netherlands). Informed consent was provided in 
accordance with procedures approved by the local human ethics committee.
Antibodies
Fluorescein isothiocyanate (FITC)-conjugated anti-CD25 (2A3), phycoerythrin (PE)-con-
jugated anti-CD25 (M-A251), anti-CD127 (hIL-7R-M21), anti-CD45RO (UCHL1), allophy-
cocyanin (APC)-conjugated anti-CD4 (SK3), anti-CD25 (M-A251), and peridin chlorophyll 
protein-Cy5.5-conjugated anti-CD4 (SK3) were all from BD Biosciences (San Jose, CA). 
PE/FITC-coupled anti-FoxP3 (PCH101; eBioscience, San Diego, CA) was used as indicated. 
Anti-TNFα monoclonal antibody (infliximab) was labeled with FITC (Calbiochem, La Jolla, 
CA) and used to detect the expression of membrane-bound TNFα on cells.
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood or 
buffy coats by centrifugation over Ficoll-Hypaque gradients. CD4+ T cells were enriched 
from PBMCs by negative selection with the CD4+ T cell isolation kit (Miltenyi Biotec, 
Bergisch Gladbach, Germany). CD4+ T cells were then stained with APC-conjugated 
anti-CD4, PE-conjugated anti-CD25, and FITC-conjugated anti-TNFα for 30 minutes at 
4°C. After washing, CD4+,CD25- responder T cells, membrane-bound TNFα-positive cells, 
and membrane-bound TNFα-negative cells within the CD4+,CD25++ T cell population 
were isolated by sorting with an Aria flow sorting machine (BD Biosciences). The sorted 
cells were gated first on small lymphocytes by forward and side scatter, then for CD4+ 
and CD25++ (top 2-5% of CD4+ T cells) expression, and then for membrane-bound TNFα 
expression. CD4-depleted PBMCs irradiated with 4,500 rads were used as feeders.
Table 1. Characteristics of and disease parameters for the RA patients*
Age, years 55.2 ± 14.5
RA duration, years 5.55 ± 2.79
DAS† 1.60 ± 0.88
ESR, mm/hour† 17.6 ± 15.6
No. of women/no. of men 22/18
No. RF positive/no. RF negative‡ 22/5
No. anti-CCP-positive/no. anti-CCP negative‡ 18/9
* Except where indicated otherwise, values are the mean ± SEM. RA = rheumatoid arthritis. 
† Data on the Disease Activity Score (DAS) and erythrocyte sedimentation rate (ESR) were available for 23 
patients when membrane-bound tumor necrosis factor α(TNFα) expression was analyzed.
‡ Data on rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) status were available for 










































Single-cell suspensions were prepared, and surface molecules were stained for 30 
minutes at 4°C with optimal dilutions of each antibody. After fixation and permeabiliza-
tion, cells were incubated with anti-FoxP3 antibody. Expression of cell surface and in-
tracellular markers was assessed using flow cytometry (FACSCalibur; Becton Dickinson, 
Mountain View, CA) after gating on live cells determined by scatter characteristics. Data 
were analyzed by CellQuest Pro software (Becton Dickinson).
Proliferation and suppression of T cells
Cells were plated at 1 × 104 cells/well in 96-well plates with 1 µg/ml phytohemaggluti-
nin (PHA) and feeders (5 × 104 cells/well) in the presence or absence of 50 units/ml IL-2. 
Cells were pulsed with 3H-thymidine (0.5 µCi/well) on day 4, and proliferation was as-
sessed 18 hours later using a liquid scintillation counter. To test for suppressive capacity, 
CD4+,CD25- responder T cells were stimulated as described above without the addition 
of exogenous IL-2. Autologous membrane-bound TNFα-positive CD4+,CD25++ T cells 
or membrane-bound TNFα-negative CD4+,CD25++ T cells were added, and suppression 
was assessed by determining 3H-thymidine incorporation as well as by measuring the 
amounts of TNFα and interferon-γ (IFNγ) in culture supernatants.
Cytokine detection
To determine the concentration of cytokines, BD CBA Flex Sets (for IL-10 and TNFα) (BD 
Biosciences) or a capture enzyme-linked immunosorbent assay (for IFNγ) was used to 
analyze culture supernatants after 96 hours, following the protocol provided by the 
manufacturer. The beads were analyzed on an LSRII system using BD FCAP Array soft-
ware (BD Biosciences).
Statistical analysis
The Mann-Whitney U test was used to compare Treg cell-mediated suppression results 
and cell frequencies in healthy controls and RA patients. Paired t-tests were used to 
compare measurements in RA patients before and after anti-TNFα treatment. Spear-
man’s correlations were used to compare cell frequencies with subject age. All statistical 
analyses were performed using GraphPad Prism 4.00 software (GraphPad Software, San 
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Results
Preferential expression of membrane-bound TNFα on CD4+,CD25++ T cells in 
vivo
Recent findings have indicated that the suppressive function of CD4+,CD25++ T cells is 
compromised in patients with active RA (10;11). However, the suppressive capability of 
the CD4+,CD25++ T cell population is reversed after anti-TNFα therapy (10-12;30). Given 
the prominent role of TNFα in inflammation and in inflammatory autoimmune diseases 
such as RA (32-34), and given the effector functions of membrane-bound TNFα on acti-
vated CD4+ T cells (i.e., macrophage activation and increment of antibody production) 
(27-29), it is conceivable that the membrane-bound TNFα-expressing CD4+,CD25++ T 
cell population is enriched for "conventional" activated T cells.
We therefore hypothesized that this T cell population possesses inferior suppressive 
abilities compared with the non-membrane-bound TNFα-expressing CD4+,CD25++ 
T cell population. Furthermore, we speculated that membrane-bound TNFα-positive 
CD4+,CD25++ T cells are preferentially depleted following anti-TNFα therapy, which in 
turn could contribute, at least partially, to the reappearance of the suppressive function 
of isolated CD4+,CD25++ T cell populations from RA patients after anti-TNFα therapy 
(10-12;30). Hence, we wished to examine the phenotype and function of membrane-
bound TNFα-expressing cells in more detail to determine whether these characteristics 
could be used to distinguish T cells with different suppressive potency within the 
CD4+,CD25++ T cell compartment. To this end, we first characterized membrane-bound 
TNFα expression on freshly isolated human CD4+ T cells.
PBMCs from RA patients were purified, and membrane-bound TNFα expression was 
detected by flow cytometry. Similar proportions of CD4+,CD25- (mean 13.9% [range 
3.43-30.8) and CD4+, CD25intermediate (mean 13.3% [range 3.68-28.1]) T cells stained posi-
tive for membrane-bound TNFα. However, within the CD4+,CD25++ T cell compartment, 
a significantly higher percentage of membrane-bound TNFα-positive T cells (mean 
26.6% [range 7.49-49.2]) was observed (Figures 1A and B). Similar results were obtained 
with cells isolated from healthy individuals (n = 19) (data not shown). Furthermore, a 
consistent increase in the percentage of membrane-bound TNFα-positive T cells was 
observed within the FoxP3+,CD4+ T cell population compared with their FoxP3-,CD4+ 
counterparts (data not shown). These results could not be explained by binding 
of the antibody to TNFα captured by surface TNF receptors (TNFRs), because most 
TNFRII+,CD4+,CD25++ cells are membrane-bound TNFα negative, and, more important, 
in line with previous reports (35), similar membrane-bound TNFα expression was ob-
served after preincubation of the cells with high concentrations of soluble TNFα (10 and 
50 ng/ml) (data not shown). Together, these data indicate that human CD4+,CD25++ T 









































Correlation of membrane-bound TNFα expression with disease activity in RA 
patients
We next wished to study whether the expression of membrane-bound TNFα on 
CD4+,CD25++ T cells differs between healthy controls and RA patients. To this end, we 



























































































































































Figure 1. Correlation of membrane-bound tumor necrosis factor α(mTNFα) expression with disease 
activity in patients with rheumatoid arthritis (RA). Peripheral blood mononuclear cells were isolated from 
RA patients and stained with anti-CD4, anti-CD25, and anti-TNFα (infliximab). CD25 and membrane-
bound TNFα expression was monitored by flow cytometry. All patients analyzed were naive for TNFα 
antagonists. A, Representative histograms (right panel) showing membrane-bound TNFα staining 
(black line) and isotype staining (shaded area) within each cell population. The gates for CD4+,CD25- 
(bottom box), CD4+,CD25intermediate (CD4+,CD25int; middle box), and CD4+,CD25++ (top box) T cells are 
demonstrated in the left panel. Numbers within boxes in the right panel indicate the percentage of 
positive cells within each gate. B, Bar graph of the percentage of membrane-bound TNFα-expressing cells 
in different T cell populations. Results are expressed as the mean and SEM from 40 different individuals. 
**= P < 0.001. C, Comparison of CD4+,CD25++ or membrane-bound TNFα-expressing CD4+,CD25++ T 
cells between 26 RA patients (mean ± SEM age 46.7 ± 10.9 years) and 19 age-matched healthy controls 
(Cont) (mean ± SEM age 44.3 ± 13.8 years). Horizontal lines indicate median values for each group. *= P 
< 0.05. D, Frequency of membrane-bound TNFα-expressing cells within CD4+ and CD4+,CD25++ T cell 
compartments, plotted against the Disease Activity Scores (DAS) for 23 patients. Linear regression (solid 
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age-matched healthy controls. Although the number of CD4+,CD25++ T cells decreased 
significantly in these RA patients, there was no significant difference in the frequency of 
membrane-bound TNFα-expressing CD4+,CD25++ T cells (Figure 1C).
The Disease Activity Score (DAS) (36) was available for 23 of the 40 RA patients studied 
at the same time that membrane-bound TNFα expression was analyzed (Table 1). Given 
the role of TNFα in the pathogenesis of RA (32-34) and the expression and function of 
membrane-bound TNFα on activated CD4+ T cells (25-29), we wished to address the 
question of whether there is any association between disease activity and the expres-
sion of membrane-bound TNFα. As shown in Figure 1D, the analysis revealed that the 
percentages of membrane-bound TNFα-positive T cells within the CD4+ (r = 0.62, P < 
0.01) or CD4+,CD25++ (r = 0.42, P < 0.05) T cell populations were correlated with disease 
activity in these RA patients. Given that membrane-bound TNFα expression was also 
associated with the erythrocyte sedimentation rate in RA patients (data not shown), 
these data indicated that the expression of membrane-bound TNFα is associated with 
the inflammatory immune response in RA patients. No association of its expression with 
disease duration was observed (data not shown).
Expression of other markers on membrane-bound TNFα-positive and TNFα-
negative CD4+,CD25++ T cells
Given the association of membrane-bound TNFα-expressing CD4+,CD25++ T cells 
with disease activity (Figure 1D) and the possibly compromised suppressive activity of 
CD4+,CD25++ T cells in patients with active RA, as previously reported (10;11), we wished 
to characterize these membrane-bound TNFα-expressing CD4+,CD25++ T cells in more 
detail. Since FoxP3 is the most commonly used marker for human CD4+,CD25+ Treg 
cells thus far (19), and because surface CD127 expression is inversely associated with 
the presence of FoxP3 and the suppressive function of freshly isolated human CD4+ T 
cells from healthy donors (37), we first determined how surface membrane-bound TNFα 
expression correlates with FoxP3 and CD127 expression. Therefore, PBMCs were stained 
for CD4, CD25, and membrane-bound TNFα, together with either FoxP3 or CD127.
As shown in Figure 2, no significant difference in intracellular FoxP3 expression 
was observed between membrane-bound TNFα-positive and membrane-bound 
TNFα-negative CD4+,CD25++ T cells, either in the percentage of positive cells or in 
the expression levels within each cell compartment. Likewise, a similar percentage of 
CD127-/low cells was observed within the membrane-bound TNFα-negative CD4+,CD25++ 
and membrane-bound TNFα-positive CD4+,CD25++ T cell subsets. Because the expres-
sion of CD45RO, the memory marker for human T cells, has been used to discriminate 
different CD4+,CD25+ Treg cell populations (38), we analyzed the expression of this 
marker on membrane-bound TNFα-positive and TNFα-negative CD4+,CD25++ T cells 









































high expression of CD45RO, whereas a significant proportion of their membrane-
bound TNFα-negative counterparts had lower levels of CD45RO expression (Figure 2). 
Similar results were obtained when membrane-bound TNFα-positive or TNFα-negative 
CD4+,CD25+ T cells were analyzed (data not shown). Together, these data indicate that 
membrane-bound TNFα expression on CD4+,CD25++ T cells correlates with levels of 
CD45RO expression, despite similar FoxP3 and CD127 expression.
Association of membrane-bound TNFα with decreased production of 
antiinflammatory cytokines in CD4+,CD25++ T cells
Human CD4+,CD25++ Treg cells are hyporesponsive and produce relatively high levels 
of the antiinflammatory cytokine IL-10 but low levels of proinflammatory cytokines 
such as TNFα and IFNγ (39). To analyze whether membrane-bound TNFα expression on 
CD4+,CD25++ T cells discriminates cells with differential cytokine production profiles, 
we purified membrane-bound TNFα-positive CD4+,CD25++ and membrane-bound 
TNFα-negative CD4+,CD25++ T cells from buffy coats using fluorescence-activated cell 
 
 
Figure 2. Expression of other markers on membrane-bound tumor necrosis factor α(mTNFα)-positive and 
mTNFα-negative CD4+,CD25++ T cells. Peripheral blood mononuclear cells were stained with anti-CD4, 
anti-CD25, and anti-TNFα, together with anti-CD127, anti-CD45RO, or anti-forkhead box P3 (anti-
FoxP3) (intracellular for FoxP3). A, Gating for histograms was performed on the basis of CD4, CD25, and 
membrane-bound TNFα expression, as indicated in the upper panel. Membrane-bound TNFα-negative 
CD4+,CD25++ (region 2 [R2]) and membrane-bound TNFα-positive CD4+,CD25++ (R3) T cell subsets were 
gated by first restricting to CD4+,CD25++ T cells (R1). Percentages of FoxP3+, CD127-/low, and CD45RO-/low 
cells within each gate are shown in the lower panel. CD4+,CD25- T cells (R4) were included as a control. B, 
Bar graph shows the percentages of FoxP3+, CD127-/low, and CD45RO-/low cells within each gate as shown 








































Membrane-bound TNFα discriminates Treg cell activity 115
sorting (FACS), and we subsequently stimulated them with PHA and autologous feeders 
in the presence or absence of exogenous IL-2.
With respect to proliferation and production of the proinflammatory cytokines TNFα 




Figure 3. Association of membrane-bound tumor necrosis factor α(mTNFα) with decreased production 
of antiinflammatory cytokines in CD4+,CD25++ T cells. Fluorescence-activated cell-sorted CD4+,CD25- 
responder T cells (Resp), membrane-bound TNFα-negative CD4+,CD25++ T cells (mTNF-), and 
membrane-bound TNFα-positive CD4+,CD25++ T cells (mTNF+) (1 × 104 cells/well) were activated with 
phytohemagglutinin (1 µg/ml) and feeders (5 × 104 cells/well) in the absence or presence of 50 units/ml 
exogenous interleukin-2 (IL-2). The sorting gates for membrane-bound TNFα-negative and membrane-
bound TNFα-positive CD4+,CD25++ T cells are depicted in the upper panel of Figure 2A. A, Cell 
proliferation was determined by 3H-thymidine uptake 5 days later. B and C, Culture supernatants were 
collected after 96 hours, and the amounts of TNFα, interferon-γ (IFNγ), and IL-10 produced (B) or the ratios 
of IL-10:TNFα and IL-10:IFNγ (C) were determined. Results are expressed as the mean and SEM from 3 or 4 









































CD4+,CD25++ T cells were hyporesponsive compared with autologous CD4+,CD25- re-
sponder T cells (Figures 3A and B). Nonetheless, when membrane-bound TNFα-positive 
and TNFα-negative CD4+,CD25++ cells were compared side by side, membrane-bound 
TNFα-positive CD4+,CD25++ T cells produced more TNFα and IFNγ (Figure 3B) and 
displayed a higher rate of proliferation (Figure 3A). In contrast, both CD4+,CD25++ T 
cell populations produced more IL-10 upon stimulation compared with CD4+,CD25- T 
cells (Figure 3B). Intriguingly, however, membrane-bound TNFα-negative CD4+,CD25++ 
T cells produced twice the amount of IL-10 in comparison with their membrane-bound 
TNFα-positive counterparts after stimulation in the presence of IL-2 (Figure 3B). The 
mean ± SEM IL-10 level produced by membrane-bound TNFα-negative CD4+,CD25++ 
T cells was 121.99 ± 14.27 pg/ml compared with 51.64 ± 7.68 pg/ml produced by their 
membrane-bound TNFα-positive counterparts after 4 days of stimulation in the pres-
ence of IL-2 (P < 0.05; n = 4) (data not shown). 
These results indicate a difference in functional capacity between these two 
CD4+,CD25++ T cell subsets, which is also illustrated by the ratio of IL-10 to TNFα or 
IFNγ (Figure 3C). Together, these data point to the possibility that membrane-bound 
TNFα-negative CD4+,CD25++ T cells display a greater suppressive potency compared 
with their membrane-bound TNFα-expressing counterparts.
Membrane-bound TNFα on CD4+,CD25++ T cells distinguishes a population 
with enhanced suppressor activity
To address whether differential membrane-bound TNFα expression is indeed as-
sociated with differential suppressive activity, fluorescence-activated cell-sorted 
membrane-bound TNFα-positive CD4+,CD25++ and membrane-bound TNFα-negative 
CD4+,CD25++ T cells were placed in a standard in vitro suppression assay using 
CD4+,CD25- T cells as responder T cells. As shown in Figure 4A, membrane-bound 
TNFα-negative CD4+,CD25++ T cells suppressed proliferation more robustly than did 
membrane-bound TNFα-positive CD4+,CD25++ T cells. Approximately 4-fold fewer 
membrane-bound TNFα-negative CD4+,CD25++ cells than membrane-bound TNFα-
positive CD4+,CD25++ cells were required to achieve 50% suppression (Figure 4B).
To further confirm the differential suppressive capability between membrane-bound 
TNFα-positive and TNFα-negative CD4+,CD25++ cells, we next analyzed the amounts 
of TNFα and IFNγ in the coculture supernatants. Consistent with the results described 
above, the addition of membrane-bound TNFα- negative CD4+,CD25++ T cells at a 1:1 
ratio resulted in a stronger reduction of TNFα and IFNγ production than the addition of 
membrane-bound TNFα-positive CD4+,CD25++ T cells (Figure 4C). This difference could 
not be attributed to the higher cytokine production by membrane-bound TNFα-positive 
CD4+,CD25++ T cells, since they secreted relatively small amounts of TNFα and IFNγ 
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membrane-bound TNFα-negative CD4+,CD25++ T cells possess an enhanced suppres-
sive activity.
Decreased numbers of membrane-bound TNFα-positive T cells in RA patients 
after anti-TNFα treatment
Previous studies have shown that anti-TNFα therapy could reverse the compromised 
function of isolated CD4+,CD25++ T cells in RA patients (10-12;30). Given our observa-
tions that membrane-bound TNFα-positive CD4+,CD25++ T cells bear a less potent sup-
pressor activity (Figure 4) and are associated with disease activity in RA patients (Figure 
1D), we wished to know whether the expression of membrane-bound TNFα on T cells 
was decreased in RA patients after TNFα-blocking therapy (adalimumab; n = 7).
All these patients responded well to anti-TNFα treatment, as evidenced by a reduction 




Figure 4. Membrane-bound tumor necrosis factor α(mTNFα) on CD4+,CD25++ T cells distinguishes a 
population with enhanced suppressor activity. Fluorescence-activated cell-sorted CD4+,CD25- responder 
T cells (Resp) (1 × 104 cells/well) were activated with phytohemagglutinin (1 µg/ml) and feeders (5 × 104 
cells/well) in the absence or presence of membrane-bound TNFα-negative CD4+,CD25++ suppressor 
T cells (Supp) or membrane-bound TNFα-positive CD4+,CD25++ suppressor T cells (mTNF- or mTNF+, 
respectively) at a 4:1, 2:1, or 1:1 (Resp:Supp) ratio. In all experiments, CD4+,CD25- responder T cells were 
also added at a 1:1 ratio as a control (i.e., 2 × 104 responder T cells per well), which always yielded greater 
proliferation and cytokine production (data not shown). A, Proliferation after 5 days was determined by 
3H-thymidine incorporation. B, The average percent inhibition of proliferation is shown. The dashed line 
indicates 50% inhibition. C, Culture supernatants were collected after 96 hours, and the amounts of TNFα 
and interferon-γ (IFNγ) were analyzed in cultures of responders only (Resp) or responders plus suppressors 
(Resp +) at a 1:1 ratio. Results are expressed as the mean and SEM from 3 or 4 cultures and represent (A 









































after treatment (P < 0.0001) (data not shown). There was no difference in the absolute 
number and the frequency of CD3+ T cells, CD4+ T cells, and CD4+,CD25++ T cells in 
peripheral blood (Figures 5A and B and data not shown) before and 3 months after 
adalimumab treatment. However, a significantly decreased expression of membrane-
bound TNFα on CD4+,CD25++ T cells (Figures 5A and B) as well as on total CD3+ or CD4+ 
T cells (data not shown) was observed in all patients. This could not be explained by the 
presence of adalimumab on membrane-bound TNFα-positive T cells in vivo that would 
influence the detection of membrane-bound TNFα expression ex vivo by infliximab, 
since the same expression levels of membrane-bound TNFα were observed on cells 




Figure 5. Decreased expression of membrane-bound tumor necrosis factor α(mTNFα) in patients with 
rheumatoid arthritis (RA) after anti-TNFα treatment. Seven patients with active RA (Disease Activity Score 
in 28 joints >5) were evaluated for CD25 and membrane-bound TNFα expression both before and 3 
months after anti-TNFα therapy (40 mg adalimumab subcutaneously every other week in combination 
with stable doses of methotrexate [7.5-25 mg/week orally]). A, Representative histograms showing CD25 
staining on CD4+ T cells or membrane-bound TNFα expression on CD4+,CD25++ T cells in RA patients 
before (Bef ) and 3 months after (Aft) adalimumab treatment. Numbers indicate the percentage of 
CD25++ expression on CD4+ T cells (left panel) or membrane-bound TNFα expression on CD44+,CD25++ 
T cells (right panel). B, Summary of the percentage of CD25++ T cells within CD4+ T cells or of the 
frequency of CD4+,CD25++ T cells coexpressing membrane-bound TNFα in RA patients before and 3 
months after TNFα-blocking therapy. Each dot represents 1 patient (n = 7). C, Histogram showing lack 
of effect of adalimumab on the detection of membrane-bound TNFα by fluorescein isothiocyanate 
(FITC)-labeled infliximab. Cells were incubated with phosphate buffered saline (PBS-Inflix; shaded area), 
adalimumab (Ada-Inflix; thick black line), or infliximab (Inflix-Inflix; thin black line) at 4°C for 30 minutes. 
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Discussion
Immunosuppressive CD4+,CD25++ Treg cells are of great interest for immunotherapy 
to prevent transplant rejection and for the treatment of autoimmune diseases. Success-
ful treatment of mice with CIA, an animal model for human RA, by adoptive transfer of 
CD4+,CD25+ Treg cells has been reported (9). However, unlike the situation in mice, in 
which expression of CD25 identifies a relatively homogeneous population of Treg cells, 
the identification and manipulation of Treg cells in humans is hampered due to the pres-
ence of large amounts of activated conventional T cells within the CD4+,CD25+ T cell 
compartment. Although the highest expression of CD25 (termed CD25high or CD25++) 
on CD4+ T cells is now widely used to identify, isolate, and characterize naturally occur-
ring Treg cells in humans, the reported defective suppressive function of the isolated 
CD4+,CD25++ T cell population from patients with autoimmune diseases, such as RA, 
might still be attributed, at least in part, to the heterogeneous composition of this T cell 
population (10-15). Therefore, one of the main obstacles to therapeutic applications of 
Treg cells is to define and isolate cells displaying high inhibitory activity.
TNFα is a pleiotropic cytokine critical for inflammation, maintenance of secondary 
lymphoid organ structure, and host defense against various pathogens as well as for 
the pathogenesis of RA (32-34;41;42). Moreover, membrane-bound TNFα expressed on 
the surface by CD4+ T cells activates macrophages, costimulates B cell activation, and 
increases antibody production (27-29). Therefore, we speculated that membrane-bound 
TNFα-expressing CD4+,CD25++ T cells are enriched for activated conventional T cells 
and/or T cells with inferior suppressive function, since Treg cells inhibit the function of 
monocyte/macrophages, reduce antibody production of B cells, and produce very small 
amounts of TNFα, even in the presence of IL-2 (5;6;21). Our results reveal a significant 
expression of membrane-bound TNFα within the CD4+,CD25++ T cell population both 
in RA patients and in healthy individuals (Figure 1 and data not shown). Although 
membrane-bound TNFα-positive CD4+,CD25++ T cells display suppressive activity, this 
activity is much less potent than that of their membrane-bound TNFα-negative coun-
terparts (Figure 4). Therefore, we conclude that membrane-bound TNFα expression is 
a marker that is inversely associated with the suppressive capacity of CD4+,CD25++ T 
cells.
It has been shown that the surface expression of CD127 is inversely correlated with 
the expression of FoxP3 and the suppressive function of fresh human CD4+ T cells 
(37). However, our data indicate that these 2 markers are not differentially expressed 
by CD4+,CD25++ T cells that do and those that do not express membrane-bound 
TNFα(Figure 2). Although FoxP3 was thought to program the development and function 
of murine CD4+,CD25+ Treg cells (19), FoxP3 is not a Treg cell-specific marker in humans, 









































CD4+,CD127-/low cells in human PBMCs are FoxP3+, since CD127 is down-regulated in 
recently activated effector T cells (22;37). Therefore, our data suggest that the expres-
sion levels of FoxP3 or CD127 do not correlate with the suppressive activity within the 
CD4+,CD25++ T cell compartment, whereas the absence of membrane- bound TNFα 
on CD4+,CD25++ T cells can be used to characterize and enrich Treg cells with maximal 
suppressor potency.
Recent reports have suggested that in vivo a portion of the human CD4+,CD25++ T 
cell population is generated from rapidly dividing, highly differentiated memory CD4+ T 
cells (44;45). Since the memory T cell marker CD45RO is highly expressed on membrane-
bound TNFα-positive CD4+,CD25++ T cells (Figure 2), and membrane-bound TNFα 
expression on these cells correlates with disease activity (Figure 1D), it is tempting to 
speculate that these FoxP3+, anergic membrane-bound TNFα-positive CD4+,CD25++ 
T cells are "adaptive" Treg cells derived from memory T cells in the periphery. Such cells 
could emerge as a negative feedback to dampen immune responses, as proposed previ-
ously (44-47). Our results showing that a subset of CD4+,CD25++ T cells display a less 
potent suppressive capacity and bear additional activation markers, such as CD45RO, 
would support this notion. The reason why such cells also express membrane-bound 
TNFα could relate to their former function as effector cells, during which they secreted 
TNFα. The expression of membrane-bound TNFα would, in that context, be a residual 
property of these cells. This could also explain the correlation between their presence 
and disease activity, since it is conceivable that greater disease activity would lead to 
more exhausted effector T cells that express membrane-bound TNFα.
Treatment of RA patients with TNFα blockers results in significant clinical benefit, 
which most likely involves the inhibition of the TNFα-induced inflammatory cytokine 
cascades (34). Moreover, recent studies have suggested that anti-TNFα antibodies could 
also reverse the "compromised" suppressive function of isolated CD4+,CD25++ T cells 
in RA patients (10-12;30). This restoration is thought to involve the neutralization of 
circulating soluble TNFα that inhibits Treg cell function via TNFRII and/or the induction 
of a distinct CD62L-,CD25++ Treg cell population via transforming growth factor βin RA 
patients (11;12). Considering the fact that adalimumab could deplete membrane-bound 
TNFα-expressing cells via inducing apoptosis, antibody-dependent cellular cytotoxicity, 
and/or complement-dependent cytotoxicity both in vitro and in vivo (48-50), our results 
provide an additional explanation for the reversal of Treg cell activity of the isolated 
CD4+,CD25++ T cell population after anti-TNFα antibody therapy, since they indicate 
that these antibodies deplete the less suppressive membrane-bound TNFα-positive 
CD4+,CD25++ T cells from the CD4+,CD25++ T cell population in RA patients (Figures 
4 and 5).
In conclusion, we have demonstrated that membrane-bound TNFα is expressed on a 
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expression is correlated with disease activity in RA patients. Moreover, the absence of 
surface membrane-bound TNFα expression can be used to identify and isolate a subset 
of CD4+,CD25++ T cells with potent suppressive capability. Furthermore, our results 
indicate that, in addition to blocking soluble circulating TNFα and/or inducing a new 
Treg cell population (11;12), selective depletion of the less effective membrane-bound 
TNFα-positive suppressors from the CD4+,CD25++ T cell compartment in RA patients 
may be another explanation for the recovery of Treg cell function by anti-TNFα therapy.
Acknowledgements
This work was funded by European Community FP6 Funding Project; Grant Number: 
018661 Autocure, Netherlands Organization for Health Research and Development; 
Grant Number: 920-03-259 and VIDI innovation grant from the Netherlands Organiza-
tion for Scientific Research.
We thank all patients and healthy individuals who donated blood samples. We thank 
A. E. M. Jongma and A. J. M. Schuerwegh for collecting clinical samples and G. M. de Roo 










































 1.  Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, et al. Thymus and autoimmu-
nity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the 
thymus in maintaining immunologic self-tolerance. J Immunol 1999;162:5317–26.
 2.  Apostolou I, von Boehmer H. In vivo instruction of suppressorcommitment in naive T cells. J Exp 
Med 2004;199:1401–8.
 3.  Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional 
characterization of human CD4+CD25+ T cells with regulatory properties isolated from periph-
eral blood. J Exp Med 2001;193:1285–94.
 4.  Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characteriza-
tion of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 2001;193: 
1303–10.
 5.  Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by 
CD4+CD25+ regulatory T cells. J Immunol 2005;175:4180–3.
 6.  Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, et al. Modulation 
of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol 
2005;66:222–30.
 7.  Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4+CD25+ immunoregulatory T cells: 
new therapeutics for graft-versus-host disease. J Exp Med 2002;196:401–6.
 8.  Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regula-
tory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455–65.
 9.  Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, et al. 
Effective treatment of collageninduced arthritis by adoptive transfer of CD25+ regulatory T cells. 
Arthritis Rheum 2005;52:2212–21.
 10.  Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised func-
tion of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 
2004;200:277–85.
 11.  Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodu-
lates the function of human CD4+ CD25hi T-regulatory cells. Blood 2006;108:253–61.
 12.  Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell popu-
lation in patients with rheumatoid arthritis via TGFβ. J Exp Med 2007;204:33–9.
 13.  Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and 
the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 
2005;54:1407–9.
 14.  Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of 
human CD4+CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 
2004;199:1285–91.
 15.  Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ 
regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971–9.
 16.  Van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4+CD25+ regulatory T cells in 
rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral 
blood and synovial fluid. Arthritis Rheum 2004;50: 2775–85.
 17.  Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C. Isolation and functional 
characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheu-








































Membrane-bound TNFα discriminates Treg cell activity 123
 18.  Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human 
peripheral blood. J Immunol 2001;167:1245–53.
 19.  Ziegler SF. FOXP3: of mice and men [review]. Annu Rev Immunol 2006;24:209–26.
 20.  Gavin MA, Torgerson TR, Houston E, Deroos P, Ho WY, Stray-Pedersen, et al. Single-cell analysis of 
normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell develop-
ment. Proc Natl Acad Sci U S A 2006;103:6659–64.
 21.  Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in 
human activated nonregulatory CD4+ T cells. Eur J Immunol 2007;37:129–38.
 22.  Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation-induced FOXP3 
in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 
2007;19:345–54.
 23.  Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-
tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T 
lymphocyte-associated antigen 4. J Exp Med 2000;192:303–10.
 24.  McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al. CD4+CD25+ im-
munoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-
induced TNF receptor. Immunity 2002;16:311–23.
 25.  Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cy-
totoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53: 
45–53.
 26.  Kinkhabwala M, Sehajpal P, Skolnik E, Smith D, Sharma VK, Vlassara H, et al. A novel addition to the 
T cell repertory: cell surface expression of tumor necrosis factor/cachectin by activated normal 
human T cells. J Exp Med 1990;171:941–6.
 27.  Sypek JP, Wyler DJ. Antileishmanial defense in macrophages triggered by tumor necrosis factor 
expressed on CD4+ T lymphocyte plasma membrane. J Exp Med 1991;174:755–9.
 28.  Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor α on 
activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp 
Med 1993;177:1575–85.
 29.  Del Prete G, De Carli M, D’Elios MM, Fleckenstein IM, Fickenscher H, Fleckenstein B, et al. Polyclonal 
B cell activation induced by herpesvirus saimiri-transformed human CD4+ T cell clones: role for 
membrane TNF- α /TNF- α receptors and CD2/CD58 interactions. J Immunol 1994;153:4872–9.
 30.  Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado-Sanchez B, Cuevas-Orta E, Moreno-
Valdes R, et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. 
Clin Exp Immunol 2005;141:372–80.
 31.  Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheu-
matism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis 
Rheum 1988;31:315–24.
 32.  Vassalli P. The pathophysiology of tumor necrosis factors [review]. Annu Rev Immunol 
1992;10:411–52. 33. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis 
factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and 
inflammatory bowel disease [review]. Immunol Rev 1999;169:175–94.
 34.  Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, et al. TNF-blocking 









































 35.  Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. 
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients 
with Crohn’s disease. Gastroenterology 2003;124:1774–85.
 36.  Van der Heijde DM, van ’t Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. 
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development 
of a disease activity score. Ann Rheum Dis 1990;49:916–20.
 37.  Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates 
with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203: 1701–11.
 38.  Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, et al. Naive regulatory T cells: a novel 
subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006;108: 3371–8.
 39.  Levings MK, Sangregorio R, Roncarolo MG. Human CD25+CD4+ T regulatory cells suppress naive 
and memory T-cell proliferation and can be expanded in vitro without loss of function. J Exp Med 
2001;193:1295–302.
 40.  Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified dis-
ease activity scores that include twenty-eight–joint counts: development and validation in a pro-
spective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
 41.  Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in 
TNF α -deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, 
follicular dendritic cell networks and germinal centers, and in the maturation of the humoral 
immune response. J Exp Med 1996; 184:1397–411.
 42.  Cope A, Ettinger R, McDevitt H. The role of TNF α and related cytokines in the development and 
function of the autoreactive T-cell repertoire. Res Immunol 1997;148:307–12.
 43.  Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007;37:21–3.
 44.  Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE, et al. Human 
CD4+CD25hiFoxp3+ regulatory T cells are derived by rapid turnover of memory populations in 
vivo [published erratum appears in J Clin Invest 2006;116:2829–30]. J Clin Invest 2006;116:2423–
33.
 45.  Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory 
and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 2007;7:231–7.
 46.  Taams LS, Wauben MH. Anergic T cells as active regulators of the immune response. Hum Im-
munol 2000;61:633–9.
 47.  Haas J, Fritzsching B, Trubswetter P, Korporal M, Milkova L, Fritz B, et al. Prevalence of newly gener-
ated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg 
dysfunction in multiple sclerosis. J Immunol 2007;179: 1322–30.
 48.  Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by 
adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 
2006;12:22–8.
 49.  Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, et al. Adalimumab induces 
apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment 
Pharmacol Ther 2005;21:251–8.
 50.  Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of 
certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. 
Inflamm Bowel Dis 2007;13:1323–32.
Chapter 9
Functional regulatory immune responses 
against human cartilage glycoprotein-39 
in health vs. proinflammatory 
responses in rheumatoid arthritis
J.H.M. van Bilsen 
H. van Dongen 
L.R.Lard 





R.R.P. de Vries 
R.E.M. Toes










































The class of immune response against autoantigens could profoundly influence the 
onset and/or outcome of autoimmune diseases. Until now, there is only limited in-
formation on the antigen-specific balance between proinflammatory and regulatory 
responses in humans. Here we analyzed the natural immune response against a candi-
date autoantigen in rheumatoid arthritis, human cartilage glycoprotein-39 (HC gp-39). 
Peripheral blood mononuclear cells from healthy individuals reacted against HC gp-39 
with the production of IL-10 but not IFN-γ. Ex vivo assays indicated that the naturally 
occurring HC gp-39-specific immune response in bulk is powerful enough to suppress 
antigen-specific recall responses, demonstrating that rather than being unresponsive, 
the HC gp-39-directed immune response in healthy individuals shows a strong bias 
toward a regulatory phenotype. Moreover, CD4+ T cell lines directed against HC gp-
39 expressed CD25, glucocorticoid-induced tumor necrosis factor receptor, and Foxp3 
molecules and were capable of suppressing antigen-specific T cell responses. Cell–cell 
contact was required for this suppression. As opposed to healthy individuals, the HC 
gp-39-directed immune response in 50% of patients with rheumatoid arthritis exhibits 
polarization toward a proinflammatory T helper 1 phenotype and is significantly less 
powerful in suppressing antigen-specific recall responses. Together these findings in-
dicate that the presence of HC gp-39-specific immune responses in healthy individuals 
may have an inhibitory effect on inflammatory responses in areas where HC gp-39 is 
present. Furthermore, these data indicate that the class of HC gp-39-directed immune 
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease with a variable disease 
outcome, which is characterized by an inflammatory process of unknown origin in 
multiple joints. Although the pathogenesis of RA is multifactorial, RA susceptibility and/
or severity is strongly associated with the presence of isotype-switched autoantibodies 
and certain HLA class II alleles. These observations clearly point to a role for T cells in 
the pathological processes underlying RA. Therefore, much interest has focused on the 
phenotype of the T cell response that is present in the inflamed joints of RA patients. In 
general, these T cells display a typical T helper (Th)1-like phenotype (1). These T cells, 
either directly or indirectly, contribute to the proinflammatory cascades and inflamma-
tory environment that is observed within the joints of RA patients (2). In contrast, other 
mechanisms are likely to be involved in the protection against autoimmunity such as 
the production of antiinflammatory cytokines such as IL-10 and TGF-β. In this respect, a 
population of naturally occurring T cells, T regulatory (Treg) cells, have regained much 
interest in the last decade. These cells display antiinflammatory and antiproliferative 
functions. In several animal model systems, it has been shown that Treg cells play a criti-
cal role in the generation and maintenance of tolerance and generally inhibit immune 
responses that are potentially deleterious to the host (3). Several T cell subsets have 
been described that mediate these protective immunoregulatory effects, of which the 
most extensively studied T cell subset is characterized by the expression of CD4 and 
CD25 in both mice and humans (4–6).
Investigations into the role of Treg cells have been difficult because no specific marker 
for Treg cells has been identified so far. The expression of CD25, cytotoxic T lymphocyte 
antigen-4, the tumor necrosis factor (TNF) family molecule glucocorticoid-induced TNF 
receptor (GITR), and Foxp3 have been used to identify Treg cells but, in general, Treg 
cells are characterized on the basis of a functional definition through their ability to 
down-regulate other immune responses (7, 8).
In vitro studies indicate that T cell receptor triggering by, for example, anti-CD3 is 
required for Treg cell function (3, 9), indicating that antigen recognition most likely 
represents the natural trigger initiating Treg cell activity. However, there is only limited 
evidence for autoantigen-specific regulatory T cell populations in humans. Nonetheless, 
knowledge on the autoantigens capable of inducing regulatory circuits in humans is 
important because this knowledge can be used for the design of rationally defined vac-
cines that prevent and/or inhibit autoimmune diseases. Studying the question whether 
a certain antigen can induce regulatory circuits in humans has been proven difficult 
because of various technical aspects related to low precursor frequencies and the in-
herent difficulty of expanding cells with a regulatory phenotype in vitro. Moreover, the 









































is selected for further studies, high purity to avoid immune activation by contaminants, 
such as lipopolysaccharide, within the antigen preparation is essential.
Here, we have studied the natural immune responses against human cartilage glyco-
protein-39 (HC gp-39), a candidate autoantigen in RA. HC gp-39 is a major constituent 
of human cartilage and is overexpressed in synovial specimens and cartilage from RA 
patients (10). It has been shown that HC gp-39 is efficiently processed and presented 
in the context of MHC class II molecules by dendritic cells (DCs) and macrophages (11, 
12). HC gp-39 can also serve as a target for T cells, because HC gp-39-specific MHC class-
II-restricted T cell responses can readily be induced in HLA-DR4-transgenic mice (13). 
Moreover, proliferative responses have been described in RA patients, indicating that 
HC gp-39-directed T cells are present also in humans (13–15). Interestingly, intranasal 
treatment with HC gp-39 suppressed murine collagen-induced arthritis (16). These 
observations indicate that HC gp-39 can activate/boost regulatory circuits that interfere 
with arthritis in case the antigen is presented in an environment that is adapted to 
induce tolerogenic responses to innocuous antigens. Moreover, they indicate that HC 
gp-39-directed T cells can escape thymic deletion and that HC gp-39-specific T cells are 
present in the natural T cell repertoire. Together, these observations identify HC gp-39 
as an interesting human autoantigen and have led us to hypothesize that HC gp-39 is 
driving regulatory responses in humans. Therefore, the aim of this work was to deter-
mine whether HC gp-39 could stimulate regulatory or suppressive immune responses 
in healthy individuals and whether the bias of HC gp-39-directed immunity is altered in 
RA patients.
Materials and methods
Blood Samples and HLA-DR Typing
After informed consent, citrated or heparinized venous blood was collected from 
healthy blood bank donors and RA patients classified as having definite RA according to 
the 1987 American College of Rheumatology criteria for RA (17). The characteristics of 
the RA patients are summarized in Table 1. Peripheral blood mononuclear cells (PBMCs) 
were isolated and used directly or were cryopreserved in liquid nitrogen. HLA-DR typ-
ing was performed on genomic DNA by using the sequence specific oligonucleotide 
(PCR-SSO) as described in refs. 18 and 19. In this study, DRB1*04-positive donors were 
selected for further analysis.
Antigens
Clinical-grade human recombinant HC gp-39 (Org 39141; 10 μg/ml final conc.) was 
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mix consisted of a mixture of tetanus toxoid (T.tox) (0.75 limit of flocculation unit/ml 
final conc.; National Institute of Public Health and the Environment, Bilthoven, The 
Netherlands), purified protein derivative (PPD) from Mycobacterium tuberculosis (5 μg/
ml final conc.; Statens Serum Institute Copenhagen), and Candida albicans (0.005%, HAL 
Allergenen Lab, Haarlem, The Netherlands).
Keyhole limpet hemocyanin (KLH; 10 μg/ml final conc.) was obtained from Pierce Bio-
technology. Phytohaemagglutinin (PHA HA16; 2 μg/ml final conc.) was obtained from 
Remel (Lenexa, KS). Clinical-grade human insulin (Actrapid; 10 μg/ml final conc.) was 
obtained from Novo Nordisk, Bagsvaerd, Denmark. The preferentially expressed antigen 
of melanoma (PRAME)-derived peptide PRA142–151 (SLYSFPEPEA; 5 ng/ml final conc.) was 
synthesized by solid-phase strategies on an automated multiple peptide synthesizer 
(Abimed AMS 422, Langenfeld, Germany) and subsequently stored at –20°C until usage.
Cytokine Elispot Analysis
PBMCs were stimulated with antigen in culture medium supplemented with 10% FCS 
for 4 days in 24-well plates. Thereafter, the cells were seeded in 4 replicate wells at a 
density of 105 cells per well (IFN-γ) or 1.5 × 105 cells per well (IL-10) of a MultiScreen 96-
well plate (Millipore), coated with IFN-γ or IL-10 catching antibody (MABTECH, Natcha, 
Sweden). After overnight incubation at 37°C, the plates were developed according to 
the manufacturer’s procedures. The number of visible spots was counted in a BioReader 
3000 (BioSys, Karben, Germany). To examine the nature of the responder cells, PBMCs 
were cultured as described above or depleted of CD3+ T cells (>97% pure). The CD3-
negative fraction was seeded at a density of 5 × 104 cells per well. For statistical analysis 
of differences between cocultures in the inhibition assays, Student’s t test was used. 
Table 1. Characteristics of RA patients
No of patients tested 43
Age, years 53.7 ± 13.9 (24.0-78.5)*
Male/female 15/28
HLA-DR4 43/43
Disease duration, years 6.8 ± 1.8 (3.3-9.7)*
Erosive disease 34/43 (81%)
RF positive 33/43 (76.7%)
DMARD treatment 40/43 (93%)
More than one DMARD in use 11/43 (25.6)
More than one DMARD used in the past 30/43 (69.8%)
Methotrexate treatment 23/43 (53.5%)
Prednisolone treatment 3/47 (7.0%)
RF, rheumatoid factor-IgM (RF postitive if ≥5 units; DMARD, disease modifying antirheumatic drug.









































Differences in IFN-γ production between healthy donors and RA patients were analyzed 
by the Mann–Whitney U test.
Detection of Antigen-Specific IL-10-Secreting Cells
Fresh PBMCs were stimulated with antigen in culture medium supplemented with 10% 
autologous or AB-serum for 4 days in 24-well plates. Thereafter, the cells were labeled 
with anti-IL-10 antibody (Miltenyi Biotec, Amsterdam) and subsequently seeded over-
night in six-well plates. Next, the IL-10 secreting cells were stained according to the 
manufacturer’s procedures and analyzed on a FACSCalibur (Becton Dickinson). Isotype-
matched mouse IgG1-phycoerythrin-conjugated control mAb (clone X40) was obtained 
from Becton Dickinson.
Generation of T Cell Lines
PBMCs were stimulated in vitro (2 × 106 per ml) with PPD (5 μg/ml), T.tox. (0.75 limit of 
flocculation unit/ml) or HC gp-39 (10 μg/ml). After 4–5 days, cells were expanded for 
11–13 days in culture medium supplemented with 10% FCS and recombinant human 
IL-2 (rhIL-2; 25 units/ml; Chiron) alone [T cell line raised against PPD from Mycobacterium 
tuberculosis (TPPD)/T cell line raised against T.tox. (TT.tox)] or rhIL-2 combined with rhIL-15 
(10 units/ml; TEBU BIO Peprotech, Heerhugowaard, The Netherlands) for the T cell line 
raised against HC gp-39 (THCgp-39).
Proliferation Assays
Proliferation of T cell lines was measured in 96-well plates in 4–6 replicate cultures. To 
analyze putative toxic properties of HC gp-39, 2.5 × 103 cells from TPPD or TT.tox were incu-
bated per well together with PPD or T.tox and 5 × 103 irradiated (3,000 rad) autologous 
PBMCs as antigen-presenting cells (APCs) with or without HC gp-39. No inhibition of 
proliferation was detected in TPPD or TT.tox, indicating that HC gp-39 was nontoxic. For 
the inhibition assays, each well contained 104 TPPD cells, 10
4 autologous THCgp-39 cells, 2 × 
104 irradiated autologous PBMCs as APCs, and antigen. Control antigen clinical grade 
insulin (Actrapid) was heat pretreated to disrupt 3D structures and prevent putative 
cell interactions. After 4 days of culturing, proliferation was determined by overnight 
incorporation of [3H]thymidine. For statistical analysis the two-tailed Student’s t test for 
unpaired samples was used.
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE)-Labeled Cell Division 
Analysis
TPPD or TT.tox were labeled with 0.5 μM CFSE (Molecular Probes). The CFSE-labeled cells (5 × 
105) were incubated with 106 irradiated PBMCs as APCs, antigen, and with or without 5 × 
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was analyzed on a FACSCalibur. To quantify the absolute number of divided CFSE-labeled 
cells and to correct for apoptotic or dead CFSE-labeled cells, the number of analyzed 
cells was standardized by the addition of 15 × 103 Flow-Count fluorospheres per sample 
(Beckman Coulter). Acquisition was stopped when 3 × 103 beads were counted.
In the transwell experiments, THCgp-39 (5 × 10
5) or control cell line TT.tox were cultured in 
the inner wells (24-well plate) in medium containing 5 × 105 irradiated PBMCs as APCs 
with or without HC gp-39 protein. Equal numbers of CFSE-labeled TPPD cells and APCs 
were added into the outer wells in the same medium with or without PPD. After 4 days 
of culture, the CFSE content of the TPPD was analyzed on a FACSCalibur.
Recall Suppression Assays
PBMCs were incubated with or without HC gp-39 in a 24-well plate. After 3–5 h, the 
cultures were supplemented with a recall-response antigen mix (see above). After 4 
days of culturing, the overnight IFN-γ excretion of the culture was analyzed by elispot 
(see above). Differences in the HC gp-39-induced changes in IFN-γ excretion between 
healthy donors and RA patients were analyzed by the Mann–Whitney U test.
Cytotoxic T Lymphocyte (CTL) Inhibition Assays
An HLA-A2-restricted CTL clone directed against a tumor-associated antigen PRAME-
derived peptide was a kind gift from J. Kessler (Leiden University Medical Center). The 
isolation, maintenance, and properties of the CTL clone are described in ref. 20. During 
stimulation with the PRAME peptide, this CTL clone produces high amounts of IFN-γ. For 
inhibition assays, PBMCs from an HLA-A2-positive donor known to secrete IL-10 after 
incubation with HC gp-39 were incubated with or without HC gp-39 protein. After 48 h, 
the PRAME peptide together with 30,000 A2-restricted PRAME-specific CTLs was added. 
The overnight IFN-γ excretion of the coculture was analyzed by elispot (see above).
Results
HC gp-39-Specific Immune Reactivity Is Characterized by IL-10 Production
Because various observations indicate the presence of HC gp-39-directed T cells in the 
human T cell repertoire, combined with the finding that presentation of HC gp-39 in 
a noninflammatory/tolerogenic environment can induce regulatory circuits (16), we 
wished to evaluate the natural HC gp-39-directed immune response in healthy individu-
als. As elispot analyses allow the detection of low precursor frequencies with preserva-
tion of the class of immune responsiveness (e.g., as measured by IFN-γ or IL-10 produc-
tion), we used elispot analyses after a short, 4-day culture of PBMCs with antigens. Our 









































Figure. 1. HC gp-39-specific immune reactivity in healthy donors. (A) PBMCs from healthy donors (n = 
31) react against HC gp-39 by production of IL-10 but not IFN-α (Left). Responses induced by ‘‘control’’ 
recall antigens are dominated by IFN-γ production (Right). (B) HC gp-39-induced IL-10 responses are 
mediated by T cells. Shown in an analysis of PBMCs from three different donors for IL-10 responses to 
HC gp-39, in which HC gp-39 was cultured with unmanipulated PBMCs or PBMCs immunomagnetically 
depleted of CD3+ T cells before elispot analysis. Background responses (medium alone) were subtracted 
fromHCgp-39 responses. (C) CD4+ T cells respond to HC gp-39 with the production of IL-10. Unstimulated 
CD4+ T cells (Left) produce background amounts of IL-10 (0.2%), whereas IL-10 was produced by 0.4–0.5% 
of HC gp-39-stimulated CD4+ T cells (Right). As a control, HC gp-39-stimulated CD4+ T cells (Center) were 
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gp-39 with the production of IL-10 without the concomitant production of IFN-γ (Figure 
1A Left). This response is specific for HC gp-39 because responses toward a mix of typical 
Th1-associated recall antigens are dominated by IFN-γ production (Figure 1A Right). 
Importantly, HC gp-39 was not toxic to the cells, because relatively high doses of HC gp-
39 did not suppress the proliferative capacity of defined T cell lines (data not shown). No 
IL-10 responses could be detected anymore after depletion of CD3+ cells from the PBMC 
cultures stimulated with HC gp-39 (Figure 1B). In contrast, IL-10 responses remained in 
CD3-depleted cultures stimulated with phytohemag-glutinin. Together, these findings 
indicate that T cells or CD3+ natural killer cells are responsible for the IL-10 production 
after stimulation of PBMCs with HC gp-39. To further validate the source of IL-10 produc-
tion after HC gp-39-stimulation, we investigated whether CD4+ cells produce IL-10 in 
response to HC gp-39 by flow cytometry. Although we were not able to detect IL-10 
production toward HC gp-39 in most donors by this technique (presumably as a result 
of a lower sensitivity of this assay compared with elispot analyses), we reproducibly de-
tected CD4+ IL-10+ cells in a donor harboring a high frequency of cells reacting against 
HC gp-39. As shown in Figure 1C, IL-10 was produced by 0.4–0.5% of CD4+ cells (Right), 
whereas unstimulated PBMCs produced only background amounts of IL-10 (0.2%) (Left). 
Together, these results indicate that the natural immune response against HC gp-39 in 
healthy donors is hallmarked by the production of IL-10 mediated by HC gp-39-directed 
T cells.
Phenotypic and Immunological Characterization of CD4+ T Cell Lines Against 
HC gp-39
The observation that CD3+ T cells produce IL-10 and not IFN-γ on exposure to HC gp-39 
prompted us to investigate whether HC gp-39-responsive T cells represent T cells with 
immunoregulatory properties. For this purpose, we generated T cell lines against HC 
gp-39 (THCgp-39). THCgp-39 were expanded by HC gp-39-specific stimulation in the presence 
of IL-2 and IL-15 (21, 22) and subsequently analyzed for the presence of various markers 
that are associated with CD4+ Treg cells. Phenotypic analyses of the generated THCgp-39 
showed that THCgp-39 were CD4+ expressing high levels of CD25 and glucocorticoid-
induced tumor necrosis factor receptor that produced increased levels of IL-10, tumor 
necrosis factor α, and IFN-γ on stimulation with HC gp-39 (data not shown). Moreover, 
real-time PCR revealed that the THCgp-39 also expressed relatively high levels of Foxp3, 
a transcription factor highly expressed in CD4+ CD25+ Treg cells (23, 24). Control Th1 
cell lines against PPD and T.tox. that were derived from the same donors displayed 
similar markers, although the level of expression was often considerably lower (data not 
shown). These results indicate that the phenotype of the T cell lines against HC gp-39 










































Nonetheless, more definitive evidence of CD4+ Treg cells resides in the demonstration 
that these cell lines can inhibit proliferation of conventional CD4+ T cells in functional as-
says. Therefore, we set out to determine the regulatory capacities of HC gp-39-directed T 
cells in suppression assays. To this end, THCgp-39 cells were titrated into cultures consisting 
Figure 2. CD4+T cell lines raised against HC gp-39 (THCgp-39) are suppressive. (A and B) THCgp-39 suppresses 
proliferation of autologous T cell lines specific for recall antigens, TT.tox (A) and TPPD (B). Background 
responses (unstimulated TT.tox and TPPD) were subtracted from stimulated TT.tox and TPPD. **, P < 0.01. (C) 
THCgp-39 can inhibit cell division of autologous CFSE-labeled TT.tox. TT.tox (Far Left) was incubated with T.tox-
pulsed APCs alone (Center Left) or together with THCgp-39 (Center Right) or TPPD (Far Right). The absolute 
number of dividing cells is indicated in each histogram. Similar results were obtained in four donors. (D) 
THCgp-39 can inhibit proliferation of autologous TT.tox and TPPD. T cell lines directed against T.tox, PPD, and HC 
gp-39 were generated from three different donors (Left, Center, and Right). Although some suppression 
of TT.tox proliferation was sometimes observed after addition of TPPD (center bar in Center), a pronounced 
suppressive activity is displayed by THCgp-39. These data are representative of nine donors analyzed. 
Similar data were obtained whenTPPD was used as a readout, adding TT.tox and THCgp-39 as suppressors (data 
not shown). Background responses (unstimulated TT.tox and TPPD) were subtracted from T.tox and PPD-
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of TPPD or TT.tox. The proliferative responses of T.tox-activated TT.tox cell lines (Figure 2A) 
and PPD-activated TPPD cell lines (Figure 2B) were suppressed (P < 0.01) by the addition 
of THCgp-39 by up to 67%. In contrast, addition of T.tox-directed T cells to PPD-directed 
T cells and vice versa did not result in inhibition of proliferation, indicating that the 
suppression observed after adding THCgp-39 was not because of competition for space 
or nutrients at high cell concentrations. Moreover, inhibition required the presence of 
THCgp-39 cells because APCs pulsed with the HC gp-39 protein were not able to mediate 
suppression (data not shown). HC gp-39-directed T cell lines did not display detectable 
proliferative responses toward HC gp-39 (data not shown), which is in line with their 
regulatory phenotype. Together, these findings indicate that HC gp-39 by itself is not 
able to polarize the APCs into a “regulatory” APC and, more importantly, indicate that HC 
gp-39-directed T cell lines display regulatory functions.
The suppressive capacity of HC gp-39-directed T cell lines was confirmed in a read-
out system where CFSE-labeled T.tox or PPD-directed T cell lines were cocultured with 
autologous HC gp-39-directed T cells. In this manner, the inhibition of proliferation of 
antigen-specific T cell lines can be monitored directly in a quantitative manner. Figure 
2C shows that addition of THCgp-39 results in the inhibition of TT.tox cell division by 62% (from 
28 × 103 to 10 × 103 divided cells), whereas no such inhibition was observed by adding 
the “crowding” control TPPD. In Figure 2D, the results of three independent experiments 
are shown employing T cell lines obtained from three different donors. Although we also 
observed inhibition of the proliferative response after addition of an irrelevant control 
cell line in one of three cases, the addition of THCgp-39 resulted in a considerably stronger 
inhibition.
The observation that THCgp-39 displays a regulatory phenotype led us to investigate 
whether cell–cell contact was required for HC gp-39-directed T cell lines to inhibit other 
CD4+ effector T cells. The suppressive action of THCgp-39 on CFSE-labeled cell division was 
abrogated when cell–cell contact between THCgp-39 and CFSE-labeled TT.tox or TPPD was pre-
vented in transwell assays (Figure 3 A–D). As the control, a simultaneously performed 
coculture assay was performed in which strong suppression of the proliferative activity 
of CSFE-labeled T.tox- or PPD-directed T cell lines was observed (Figure 3 E and F), indi-
cating that the THCgp-39 cells were viable and immunosuppressive. Together these results 
indicate that THCgp-39 cells are able to mediate suppression in a cell–cell contact-dependent 
fashion.
Ex Vivo HC gp-39-Directed Immune Responses Can Suppress Recall Responses 
and CD8+ T Cell Activity
As described above, our in vitro assays indicate that THCgp-39, once activated, down-
regulate other immune responses in a cell–cell contact-dependent manner. To address 









































taken from the donors is efficient enough to suppress other immune responses, donors 
that displayed IL-10 responses after stimulation with HC gp-39 were selected for further 
study. PBMCs from these donors were stimulated with a 10× diluted mixture of recall 
antigens to induce intermediate recall antigen-specific IFN-γ responses as measured 
by elispot analyses. To study whether stimulation by HC gp-39 can suppress this IFN-γ 
production, we triggered the PBMCs simultaneously with HC gp-39 to activate regula-
tory cells and the recall antigen mixture to activate recall antigen-specific memory cells. 
HC gp-39 could stimulate regulatory circuits as observed by a marked inhibition of the 
recall response (Figure 4A).
Next, we determined whether HC gp-39 stimulation could also inhibit CD8+ T cell 
responsiveness. Therefore, an HLA-A2-restricted CTL clone directed against a peptide 
derived from the tumor antigen PRAME was used. PBMCs from HLA-A2+ donors were 
stimulated with HC gp-39 and, after 48 h, loaded with the PRAME peptide. Subsequently, 
the PRAME-specific CTL clone was added, and IFN-γ production was measured by elispot 
analyses. HC gp-39-stimulated HLA-A2+ PBMCs were able to suppress IFN-γ production 
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Figure 3. Cell– cell contact is required for the immunosuppressive activity of CD4+T cell lines directed 
against HC gp-39. The absolute number of dividing CFSE-labeled TT.tox cells is indicated in each histogram. 
(A) Unstimulated TT.tox in outer wells (B) TT.tox stimulated with T.tox-pulsed APCs in outer wells. (C) TT.tox 
stimulated with T.tox-pulsed APCs in outer wells and TPPD in inner wells. (D) TT.tox stimulated with T.tox-
pulsed APCs in outer wells and THCgp-39 in inner wells. (E) TT.tox stimulated with T.tox-pulsed APCs and TPPD 
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of activated PRAME-specific CTL as shown in Figure 4B. Together these data indicate 
that the “naturally” occurring HC gp-39-reactive immune response is highly effective in 
suppressing other immune responses.
The HC gp-39-Directed Immune Response in RA Patients Is Biased Toward a 
Proinflammatory Response
Intrigued by the antiinflammatory properties of HC gp-39-directed immune responses 
in healthy donors, we postulated that the immune response in RA patients might have 
shifted toward a proinflammatory response. Therefore, the immune response in RA 
patients was evaluated by employing IFN-γ and IL-10 elispots. In contrast to healthy 
donors, which produce primarily IL-10 (Figs. 1 A and 5 A and B), RA patients produce 
considerable amounts of IFN-γ (P < 0.05; i.e., 17 of 34 patients analyzed produced IFN-γ). 
These findings could not be attributed to a generalized increase in IFN-γ production in 
RA patients because the recall antigen-specific immune reactivity is diminished in RA 
patients compared with controls (Figure 5 C and D). Next we compared PBMC cultures 
Figure 4. Ex vivo HC gp-39-directed immune responses can suppress other immune responses. (A) HC 
gp-39-activated PBMCs are able to suppress IFN-γ responses to recall antigens in three different healthy 
donors. (B) HC gp-39- stimulated HLA-A2+ PBMCs from three different healthy donors are capable of 









































from RA patients (n = 40) with the ability of PBMC cultures from healthy donors (n = 21) 
to reduce recall antigen responses after costimulation with HC gp-39. It was found that 
HC gp-39 was less effective in stimulating regulatory response in PBMC cultures from RA 
patients compared with cultures from healthy controls (Figure 5E) because the majority 
of PBMC cultures from RA patients gave rise to more IFN-γ spots after costimulation 
with HC gp-39. In some patients, this increase was even 4-fold or higher. Together these 
data imply that a disease-associated bias is displayed by the HC gp-39-directed immune 
response.
Figure 5. IFN-γ and IL-10 responses to HC gp-39 and recall antigens by PBMCs from healthy donors (n = 
31) and RA patients (n = 34) as determined by elispot. (A and B) Healthy donors produce primarily IL-10 
but not IFN-γ, whereas RA patients produce both IL-10 and considerable amounts of IFN-γ in response to 
HC gp-39 (*, P < 0.05). (C and D) Recall antigen-directed reactivity is characterized by IFN-γ production 
but not IL-10 production in both RA patients and healthy donors. Moreover, PBMCs from healthy donors 
produce more IFN-γ after exposure to recall antigens as compared with RA patients (***, P < 0.001). (E) HC 
gp-39-stimulated PBMCs from healthy donors (n = 21; unbiased for HC gp-39-induced IL-10 production) 
are better suppressors of recall antigen-induced IFN-γ production than HC gp-39-stimulated PBMCs from 
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These findings indicate that HC gp-39 serves as an autoantigen in both healthy donors 
and RA patients. However, despite a reduced Th1 response against recall antigens, the 
HC gp-39-directed immune responsiveness in RA patients is shifted toward a proinflam-
matory phenotype in a substantial number of RA patients as more IFN-γ is produced and 
is paralleled by a reduced suppression of recall responses.
Discussion
In the present study, we demonstrated a clear discrepancy in immune reactivity 
between healthy donors and RA patients against the naturally occurring autoantigen 
HC gp-39. IFN-γ production by PBMC cultures from the majority of healthy donors that 
were stimulated by recall antigens could be inhibited by costimulation by HC gp-39. In 
contrast, the majority of such cultures from RA patients displayed an increase in IFN-γ-
producing cells. Moreover, in contrast to HC gp-39-activated cells from RA patients that 
also produced IFN-γ, the HC gp-39-directed immune response of healthy individuals was 
hallmarked by the production of IL-10. IL-10 production depended on CD3-expressing 
cells, and CD4+ T cell lines against HC gp-39 displayed regulatory capacities.
These findings clearly indicate that healthy individuals, rather than being nonrespon-
sive, frequently react to HC gp-39 with the production of IL-10. Our data can best be 
explained by the presence of HC gp-39-directed Treg cells in healthy subjects because 
these cells have the potential to effectively suppress various proliferative and inflamma-
tory responses.
The observations that the immune response of a considerable number of RA pa-
tients displays a proinflammatory polarization toward HC gp-39 and is less capable of 
inhibiting other immune responses are intriguing. Although some caution is required 
in interpreting these results because the lack of detecting suppression does not neces-
sarily indicate the absence of suppressive responses, these data suggest that the inflam-
matory processes accompanying RA development/progression favor the induction of 
HC gp-39-directed Th1 cells. To become activated, naïve T cells have to encounter their 
specific antigens presented by HLA molecules on DCs. Although this event alone causes 
naïve T cell division, it does not necessarily establish a productive immune response 
because full mobilization to effector cells crucially depends on proper maturation of 
DCs (25). It is plausible that the inflammatory environment observed in the joints of 
RA patients meets the requirements for proper maturation of local DCs, enabling the 
induction of Th1 cell responses. Moreover, it has been reported that DCs present in the 
synovial tissue are able to present HC gp-39-derived peptides in the context of HLA 
class II molecules (11, 12). Therefore, we hypothesize that the emergence of IFN-γ-









































by maturated DCs that have the capacity to activate Th1 cells as a consequence of the 
maturation signals present in the inflamed synovium. In this way, the HC gp-39-specific 
Th1 cells are a result, rather than a cause, of the disease and could also be present in 
other (rheumatic) diseases.
The observation that a disease-associated bias is present with respect to the class of 
HC gp-39-directed immune response might point toward a more generalized phenom-
enon because it has recently been shown also that in diabetes and multiple sclerosis 
the autoreactive T cell response is polarized toward a proinflammatory Th1 phenotype, 
whereas a regulatory response is observed in health (26, 27). Although these observa-
tions have been made in different diseases, together these findings clearly indicate that 
induction of autoimmunity not only requires the emergence of pathogenic T cells (Th1 
and/or Th2 cells) but also is associated with the loss of Treg cell function that normally 
protects against autoimmunity. These findings are highly relevant for the development 
of antigen-specific intervention protocols because they suggest an approach for con-
trolling immune responses. Particularly, RA might represent an autoimmune disease 
that is especially suited for targeting Treg cells because, due to its systemic nature, a 
systemic approach is required to dampen the inflammatory reaction. It is likely that Treg 
cells will focus on areas of inflammation, such as the inflamed joint, because they carry 
several receptors for inflammatory chemokines (5, 28–30). Indeed, the presence of Treg 
cells in the inflamed joint, in addition to activated potentially pathogenic T cells, was 
recently demonstrated in synovial fluid of RA patients (31). Moreover, we have shown 
that CD4+ CD25+ Treg cells are also involved in collagen-induced arthritis because deple-
tion of CD4+ CD25+ T cells significantly increased severity and incidence of the disease, 
whereas reconstitution studies showed that infusion of CD4+ CD25+ Treg cells conferred 
disease protection (32). The challenge for the future will be to induce and/or expand 
residual antigen-specific Treg cell activity to treat autoimmune diseases in an antigen-
specific manner.
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Summary and discussion
Results in short
In this thesis several studies are described that include both clinical- and biological as-
pects in the field of undifferentiated (part I) and rheumatoid arthritis (part II). Chapter 
2 describes the incidence and progression of undifferentiated arthritis to reumatoid 
artritis as monitored in different early arthritis clinics. Depending on the study popu-
lation 6-55% of the patients who present with undifferentiated arthritis actually fulfill 
the criteria for rheumatoid arthritis as defined by the ACR in 1987 over time. For the 
prognosis of the first 4 years, it does not make a difference whether patients present 
with the clinical syndrome of an evident rheumatoid arthritis or with undifferentiated 
arthritis progressing to rheumatoid arthritis within one year (chapter 3). Radiographic 
joint damage, disease activity and HAQ had a comparable course as measured over four 
years. The difference was not explicable by the duration of symptoms and thus time of 
the clinical phase, as median symptom duration was the same for both groups. Unfor-
tunately, part of the window of opportunity might have been missed in the group of 
patients that presented with undifferentiated arthritis. In the PROMPT study, patients 
with undifferentiated arthritis were treated with either methotrexate or placebo. In the 
MTX group, the progression to rheumatoid arthritis was postponed, and radiographic 
damage was retarded. In patients with ACPAs the results were even more pronounced 
(chapter 4 and 7). In PROMPT patients who had low and intermediate pretreatment 
ACPA-levels and were treated with MTX, the incidence of rheumatoid arthritis was lower 
than in patients with high levels. In a total group of DMARD-naive patients with undif-
ferentiated arthritis or recently diagnosed rheumatoid arthritis, low and intermediate 
pretreatment ACPA-levels were associated with a more favorable response to MTX 
compared to patients with high levels of ACPA (chapter 7). The treatment in patients 
with undifferentiated arthritis in PROMPT was aimed at a DAS <2.4, a scoring system that 
had been developed for patients with rheumatoid arthritis. Further analysis revealed 
that the use of DAS is justified in patients with undifferentiated arthritis (Chapter 5). 
To identify which patient with undifferentiated arthritis has actually or will progress to 
rheumatoid arthritis and will thus benefit from early DMARD treatment, a prediction rule 
was developed. Based on sex, age, localization of symptoms, tender- and swollen joint 
count, C-reactive protein level, the severity of morning stiffness, and the presence of 
rheumatoid factor and ACPA, a prediction score with a cutoff level between 6 and 8 re-
vealed a positive predictive value of 84% and a negative predictive value of 91% (chap-
ter 6). Treatment with DMARDs and biologicals are used to modulate immune responses 
in RA. Among other effects, it was shown that a TNF-alpha antagonist depleted activated 
CD4+CD25+ T cells by binding to membrane-bound TNF-alpha, resulting in recovery of 









































importance of the presence of functional regulatory T cells was emphasized in chapter 
9. Whereas patients with rheumatoid arthritis reacted with a pro-inflammatory response 
to the human cartilage glycoprotein 39, healthy individuals had an anti-inflammatory 
response. The strength of the anti-inflammatory response was to such a degree that it 
even suppressed other pro-inflammatory responses.
Arthritis
It is unknown whether every patient with undifferentiated arthritis has the potential 
to develop rheumatoid arthritis. In this thesis, the assumption was made that some 
patients with undifferentiated arthritis actually had rheumatoid arthritis, which was 
not recognized as such yet. However, the clinical syndrome rheumatoid arthritis that 
fulfills the ACR criteria for rheumatoid arthritis can be seen as an end stage rheumatoid 
arthritis. Although the end product is destruction of the joint, the etiology may differ in 
this heterogeneous group. This heterogeneity is emphasized by the different onset of 
disease (chapter 3).
Recently it has become clear that patients with ACPAs represent a distinct disease sub-
set within the clinical syndrome rheumatoid arthritis (1;2). Having a shared epitope in 
the HLA class II molecules predisposes to the development of ACPAs (3;4). Most patients 
with ACPAs eventually show clinical characteristics of rheumatoid arthritis. However, it 
takes up to 13 years to progress to the clinical syndrome of rheumatoid arthritis (5;6). 
Somehow it requires an unidentified second hit to progress to clinical symptoms.
For patients without the presence of ACPA who have developed rheumatoid arthritis 
it is unclear which factors play a role. So far, no obvious genetic factor has been found. 
Like the danger model (7), one could propose that an undifferentiated arthritis for any 
reason could predispose to persisting arthritis if the danger signal persists, or even 
after a second hit may progress to a destructive rheumatoid arthritis. In that case, all 
patients with undifferentiated arthritis have the potential to progress to a higher level, 
rheumatoid arthritis, when the second event is provided. This is in contrast to the idea 
that undifferentiated arthritis at presentation is actually already rheumatoid arthritis. 
Because the biomarkers that make the difference have not been identified yet and the 
percentage of patients with undifferentiated arthritis that progresses to rheumatoid 
arthritis depends on the inclusion criteria of the study population, the prediction rule 
(chapter 6) is based on clinical symptoms and laboratory findings.
Monitoring undifferentiated arthritis
There are different ways to monitor rheumatoid arthritis, but most of them have not 
been validated in patients with undifferentiated arthritis. With the initiation of DMARDs 
early in the disease process, the outcome variables may be less pronounced, possibly 
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disease activity, the difference in improvement criteria and remission criteria is clear, 
in undifferentiated arthritis the improvement criteria partially resemble the remission 
criteria. Therefore, treatment goals should not be improvement, but remission in the 
most strict way.
In chapter 5 it was shown that the use of the original DAS, which was used in the 
PROMPT study, was valid in patients with undifferentiated arthritis. The DAS28, however, 
may lead to an underestimation of disease activity if only few joints are involved that are 
not among the 28 counted, such as the feet. In undifferentiated arthritis, disease activity 
is generally low, and by using extended joint counts including the feet an underestima-
tion of the number of joints involved may be prevented.
Although the DAS mirrors the disease activity in undifferentiated arthritis adequately, 
the translation to clinical practice should be defined. A DAS of more than 2.4 in patients 
with rheumatoid arthritis means an active disease state for most rheumatologists that 
is high enough to intensify medication (8). A DAS of 1.6 is used as a cut off for remission 
(9). However, accepting that a patient with initially undifferentiated arthritis who has a 
DAS less than 1.6 with still arthritis in at least 1 joint would be considered to be in remis-
sion is contradictory, as 1 swollen joint was enough to enter the PROMPT study. In 1981 
the ARA remission criteria for rheumatoid arthritis were published. For remission, five 
or more of the following criteria must be fulfilled for at least two consecutive months: 
duration of morning stiffness not exceeding 15 minutes, no fatigue, no joint pain (by his-
tory), no joint tenderness or pain on motion, no soft tissue swelling in joints or tendon 
sheets, ESR less than 20 mm/h (male) or less than 30 mm/h (female) (10). Only 40% of 
the PROMPT patients with a DAS less than 1.6 fulfilled the ARA remission criteria. This is 
in contrast to patients with rheumatoid arthritis, where the DAS less than 1.6 correlates 
well with the ARA criteria for remission (9). This emphasizes that the definitions used for 
rheumatoid arthritis are not equally useful in undifferentiated arthritis. In the PROMPT 
study, remission was therefore defined as no clinical symptoms of arthritis and further-
more no DMARD use. The role of imaging in the definition of remission is up for debate. 
As ultrasound reveals more subclinical arthritis (11;12), one could argue that for remis-
sion and the treatment decision to stop DMARD therapy, even this subclinical arthritis 
should be absent. The predictive value on the long term is unclear and the advantages 
of continuing medication should be very carefully outweighed by the side-effects.
As erosive disease is very disabling, retarding bone erosions as quantified by radio-
graphic damage is a very important outcome measurement. Studies in clinical rheu-
matoid arthritis show that the best effect of DMARDs on radiographic progression is 
when they are given in the first two years after rheumatoid arthritis is diagnosed (13-15). 
However, the majority of the patients in the PROMPT study had no radiographic joint 
progression in 18 months. If DMARD treatment is initiated in the window of opportunity 









































of radiographic damage alone is inconclusive. Repair of erosions was not scored in the 
PROMPT study, as it requires more patients with radiographic damage. Furthermore, it 
was reported that repair of erosions was observed in patients with absence of clinical 
synovitis for a longer period than the study time (16;17). As the radiographic damage 
was clearly seen in ACPA positive patients in the PROMPT study, radiographic monitor-
ing should not be omitted, but for monitoring in early undifferentiated arthritis it is not 
the best measurement. 
Treatment strategies in the window of opportunity
Once clinical symptoms of arthritis do occur, starting a treatment is justified. For patients 
who present with rheumatoid arthritis, DMARDs can be started immediately without 
discussion. However, in patients with undifferentiated arthritis, from which 6-55% actu-
ally has rheumatoid arthritis (chapter 2), and thus 45-96% does not have rheumatoid 
arthritis, it is very important to withhold a potential toxic treatment with DMARDs for 
those who do not need it. To narrow down this very wide range a prediction rule was 
designed (chapter 6). The ACR criteria for rheumatoid arthritis are not suitable for this 
purpose, as these criteria were designed for describing the population of patients with 
an established rheumatoid arthritis. Nor are the criteria for probable rheumatoid arthri-
tis, as all the patients in the PROMPT study fulfilled the criteria for probable rheumatoid 
arthritis, and only 53% of the patients in the placebo group had reumatoid arthritis after 
18 months. In 2002 a prediction model to discriminate between self-limiting, persistent 
non-erosive and persistent erosive arthritis was developed (18). In the present prediction 
rule, the aim was not to predict persistent arthritis, but to predict rheumatoid arthritis 
and the consequent justification for DMARD treatment. Depending on the cohort, no 
adequate prediction could be made in 6 to 25% of the patients. These results have been 
replicated in other cohorts (19-22). Although the prediction rule is a useful tool, there is 
still some space for improvement by adding other factors, like genetic or environmental, 
to simplify treatment decisions in the grey area in which no adequate prediction can be 
made.
In an ideal situation, DMARD treatment will induce remission before permanent 
damage has occurred. In the PROMPT study, the disease process could not be reversed, 
although the intervention was done in the presumed window of opportunity (chapter 
4). Maybe the duration of symptoms might have been too long for MTX to reverse the 
process or MTX monotherapy is just not enough. It is tempting to extrapolate the data 
from patients with early diagnosed rheumatoid arthritis to patients with undifferentiated 
arthritis who actually have rheumatoid arthritis. The BeSt- en COBRA-study showed that 
combination therapy is superior to monotherapy or step-up therapy (23;24). However, 
there is little evidence-based information on the choice of treatment of undifferenti-
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sulphasalazine in case of persistent or progressive disease resulted in more absence of 
synovitis at 1 year when compared with NSAIDs followed by the same delayed interven-
tion if necessary (25). In patients with poor prognosis undifferentiated arthritis, which is 
recurrence of synovitis after a single dose of corticosteroids with symptom duration of 
less than 1 year, a randomized, placebo-controlled trial with infliximab provided mod-
est short-term relief, but did not prevent the development of rheumatoid arthritis (26). 
Other double-blind randomized placebo-controlled studies in undifferentiated arthritis 
comprise treatment with antibiotics in mixed populations of undifferentiated arthritis 
and reactive arthritis and have had so far no effect on the disease course (27;28). Other 
open label studies with DMARDs in patients with undifferentiated arthritis were per-
formed, but in mixed populations without a matched control group, and DMARDs were 
also initiated further in the disease process (29;30). So far the best treatment strategy for 
undifferentiated arthritis has not been found, though early intervention with DMARDs 
shows beneficial effects with regard to symptom reduction and postponing the clinical 
syndrome of rheumatoid arthritis.
ACPA-positive disease and ACPA-negative disease differ in histology, etiology and 
genetic background (1;2). Although the number of patients in the PROMPT study who 
were ACPA positive was small and it was a post-hoc analysis, the difference in the efficacy 
of methotrexate was striking. Moreover, in ACPA-positive patients, patients with low and 
intermediate levels of ACPA showed a more favorable response to MTX compared to pa-
tients with high levels of ACPA (chapter 7). If this corresponds to an earlier phase in the 
development to the clinical syndrome rheumatoid arthritis, than a different treatment 
strategy for patients with low and intermediate levels might be more appropriate. There 
are no results of clinical trials with treatment strategies that distinguish between ACPA-
positive and -negative disease. This will provide an extra dimension towards tailor-made 
treatment. 
Immunomodulation
In autoimmune diseases the challenge is to stop the effect of the autoimmune 
processes. To achieve this goal most treatment strategies aim at suppressing the im-
mune system by using agents that interfere with general processes like DNA synthesis, 
cytokinesignalling or receptorsignalling. Irrespective of the origin of the autoimmune 
disease or the affected organ these agents are successfully used. The counterpart of 
these agents is the incidence of infections due to the lack in a pro-inflammatory immune 
system. Biologicals, like anti-TNF-alpha, have had a major impact on the outcome of 
rheumatoid arthritis. It was shown that the suppressive capability of CD4+ CD25+ T cells 
was compromised in patients with active rheumatoid arthritis and was reversed after 
anti-TNF-alpha therapy (31;32). The CD4+CD25+ membrane-bound TNF-alpha-negative 









































TNF-alpha resulted in depletion of activated CD4+CD25+ T cells and restoration of the 
suppressive capacity of the remaining functional CD4+CD25+ membrane-bound TNF-
alpha-negative T cells. The presence of membrane-bound TNF-alpha on CD4+CD25+ T 
cells was correlated to disease activity in rheumatoid arthritis patients (chapter 8). This 
emphasizes the imbalance between the pro-inflammatory response and the regulatory 
T cell response in patients with rheumatoid arthritis. This imbalance was also found in 
the immunologic response to HC-gp39. T cells from rheumatoid arthritis patients pro-
duced anti-inflammatory cytokines like IFN-gamma in response to stimulation with HC-
gp39, whereas T cells from healthy individuals reacted with producing IL-10. T cell lines 
against HC-gp39 from healthy individuals were able to suppress a pro-inflammatory 
response from a T cell line against a peptide from mycobacterium, suggesting that the 
response with IL-10 production was a regulatory response. Furthermore, the T cell lines 
against HC-gp39 from healthy individuals were CD4+ and expressed high levels of CD25 
(chapter 9).
Understanding the mechanisms in autoimmunity will provide tools in developing 
more specific treatment strategies. Autoimmune diseases occur in up to 3-5% of the gen-
eral population. Both genetic and environmental factors contribute to the susceptibility 
to autoimmunity (33). In this thesis, T cell mediated immunoregulation is addressed. It 
is postulated that the immune system distinguishes between the absence and presence 
of danger signals in combination with either self or non-self peptides. In the presence 
of a danger signal, like pathogen-associated molecular patterns (PAMPs) binding to pat-
tern recognition receptors and non-programmed cell death, the immune response is 
directed towards a pro-inflammatory response. In combination with a self peptide this 
will result in autoimmunity (7;34). The described imbalance between pro-inflammatory 
and regulatory immune responses implies that skewing the immune response from pro-
inflammatory to anti-inflammatory or restoring the suppressor function at specific sites 
might invert the autoimmune process. As DMARDs and biologicals are broad spectrum 
agents that potentially react on every inflammation in the body, the ultimate challenge 
in autoimmunity will be to interfere within the immune processes more specifically. HC-
gp39 might be a candidate auto antigen to target for redirecting the immune response 
as it is one of the major constituents of human cartilage, the mRNA and protein are 
upregulated in synovium of rheumatoid arthritis patients and T cell-epitopes from HC 
gp-39 are presented by antigen presenting cells in synovium of rheumatoid arthritis 
patients (35-39). In a mouse model, intranasal treatment with HC-gp39 suppressed 
HC-gp39-induced and collagen-induced arthritis (40;41). However, tolerance induction 
in rodents is possible via specialised superficial cervical and internal jugular draining 
lymphnodes of the nose. Other lymfnodes do not have this capacity (42). It is difficult to 
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humans. Here, it was shown that the response to HC-gp39 differs between healty donors 
and rheumatoid arthritis patients.
In an attempt to influence the immunological response to HC gp-39 in order to influ-
ence disease outcome, a phase I trial was performed. Briefly, rheumatoid arthritis pa-
tients with moderate disease activity were treated with once weekly 25 μg, 125 μg, 625 
μg or 3125 μg HC gp-39 intranasally during 4 weeks, and followed for another 8 weeks. 
In every treatment group, eight patients received HC gp-39 and two patients received 
placebo. No severe adverse events were reported, however, a clinical significant effect 
on the disease activity of the rheumatoid arthritis patients was not seen either (43). To 
determine the underlying immunological reaction, peripheral blood mononuclear cells 
(PBMCs) were isolated and cryopreserved from patients with RA who participated in 
the phase I clinical trial. Blood samples were taken before entering the trial, after ap-
proximately 4 weeks of treatment and after an 8-week HC gp-39 free interval being 
approximately 12 weeks after entering the trial. The HC gp-39 response was not tested 
before entering the trial. PBMCs of only 23 patients were available for analysis. Differ-
ence at the level of cytokine production as measured by cytometric bead arrays and in 
enzyme linked immuno sorbent culture did not distinguish the placebo group from the 
four treatment groups (H. van Dongen, unpublished results). The obtained results were 
not elegible for publication for several reasons. Blood samples from only 23 out of 40 
patients were available for the analysis. As the remaining initial groups were too small 
for correct statistical testing, a proof of principle would be the only possibility. After 
selecting the patients based on clinical outcome, the groups were also too small, and 
the results differed per patient. Induction to tolerance against HC-gp39 in humans has 
not been performed yet. The fact that HC-gp39 is probably not the antigen that drives 
the expansion of T cells to an autoimmune process should be irrelevant as long as the 
response to HC-gp39 is strong enough to suppress the other immune responses in the 
joint. This might even be an advantage, as a reduced frequency of nickel hypersensitiv-
ity was reported after oral nickel contact at an early age by oral braces. The reduced 
frequency was only seen if the oral contact was prior to sensitization to nickel by i.e. 
earpearcing (44). Perhaps HC-gp39 should be administered to patients in rheumatoid 
arthritis who do not show a pro-inflammatory response to HC-gp39 (yet), to reinforce 
the existing anti-inflammatory response and will hopefully suppress other inflammatory 
responses as HC-gp39 is up regulated in the inflamed synovium. In mice, collagen type II 
induced arthritis is also best prevented when the feeding of collagen type II starts before 
the induction of arthritis. Studies concerning oral tolerance induction in rheumatoid 
arthritis patients have been performed, but clinical efficacy was poor and functional 
evidence of tolerance was not convincing, as cytokine profiles and markers like FoxP3 











































Undifferentiated arthritis remains a challenging state of disease. The outcome varies 
from self limiting to severe destructive arthritis. As the evidence for early treatment of 
rheumatoid arthritis is accumulating, the urge for selecting patients early in the disease 
course increases. As genetic susceptibility is already present at birth and ACPA can be 
detected up to 14 years before clinical symptoms of arthritis occur, there will be no 
support for starting a treatment in the preclinical phase (5;6). The choice of treatment 
should be crystallized in clinical trials in patients with undifferentiated arthritis. When 
patients with rheumatoid arthritis are distinguishable in a population of patients with 
undifferentiated arthritis, and the immunologic reaction is not widespread, perhaps oral 
tolerance induction will be possible. Many candidate auto antigens have been investi-
gated, but most of them do not make it from bench to bedside. For HC-gp39 the curtains 
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Het onderzoek dat beschreven wordt in dit proefschrift bestaat uit twee delen: Deel I 
gaat over ongedifferentiëerde artritis, de progressie daarvan naar reumatoïde artritis, 
het resultaat van agressieve behandeling in een vroeg stadium van reumatoïde artritis 
en hoe te voorspellen welke patiënten daarvoor in aanmerking komen. In deel II worden 
enige immunologische aspecten van reumatoïde artritis beschreven.
Deel I: Ongedifferentiëerde artritis
Artritis
Een gewrichtsontsteking of artritis wordt gekenmerkt door warmte, pijn en zwelling in 
een of meerdere gewrichten. Reumatoïde artritis is de meest voorkomende chronisch 
inflammatoire gewrichtsaandoening en komt bij 1% van de bevolking voor, waarbij 
meer vrouwen dan mannen zijn aangedaan. Het is belangrijk om reumatoïde artritis 
in een vroeg stadium te herkennen, omdat deze ziekte onbehandeld uiteindelijk leidt 
tot destructie van het gewricht. Door het starten van behandeling zodra de diagnose 
reumatoïde artritis duidelijk is, kan deze schade voorkomen worden. Om reumatoïde 
artritis in een vroeg stadium te onderzoeken, zijn zogenaamde ‘early artritis clinics’ 
opgezet. Vanaf de jaren 50 zijn er criteria ontworpen om de verschillende vormen van 
artritis in te delen. Hierbij worden o.a. het voorkomen van ochtendstijfheid, het soort en 
aantal aangedane gewrichten, de aanwezigheid van antilichamen zoals reumafactor, en 
al bestaande gewrichtsschade beoordeeld (zie ook tabel 1, hoofdstuk 1). Als een artritis 
niet valt te categorizeren in een van de ziekteëntiteiten die is gedefinieerd door de Ame-
rican College of Rheumatology (ACR), betreft het een ongedifferentiëerde artritis. Uit de 
Leidse ‘early artritis clinic’ bleek dat 37% van de patiënten die de polikliniek bezocht met 
een artritis een ongedifferentiëerde artritis had. Na een jaar had 30% van deze patiënten 
geen artritis meer. 28% bleek echter een reumatoïde artritis te hebben. In hoofdstuk 2 
is onderzocht hoe vaak patiënten met ongedifferentiëerde artritis in verschillende ‘early 
artritis clinics’ wereldwijd binnen 1 jaar reumatoïde artritis ontwikkelden. Afhankelijk 
van het soort en het aantal gewrichten dat is aangedaan bleek 6-55% van de patiënten 
met een ongedifferentiëerde artritis binnen 1 jaar reumatoïde artritis te hebben. Indien 
werd vereist dat patiënten bij een eerste beoordeling door een reumatoloog een artritis 
hadden en dat voor de diagnose reumatoïde artritis moest worden voldaan aan de clas-
sificatie criteria zoals opgesteld door de ACR, bleek 17-32% van de patiënten binnen 1 









































Beoordelen en vervolgen van artritis
Reumatoïde artritis wordt gekenmerkt door toenemende destructie van gewrichten, die 
uiteindelijk tot invaliditeit leiden. Er zijn verschillende methoden om de ernst van een 
artritis en de ziekte activiteit te beoordelen en te vervolgen. Deze methoden kunnen 
gebruikt worden om de effectiviteit van therapie te beoordelen, of als uitgangspunt om 
wel of geen medicatie te starten. 
De ‘disease activity score’, kortweg DAS, is een formule die is gebaseerd op een aantal 
pijnlijke gewrichten, een aantal gezwollen gewrichten, de hoogte van een onstekings-
parameter in het bloed (bezinking), en de beoordeling van algemeen welbevinden op 
een schaal van een tot tien door de patiënt. De DAS was gebaseerd op ziekteactiviteit in 
patiënten met reumatoïde artritis. In hoofdstuk 5 blijkt dat de DAS score ook toepasbaar 
is in patiënten met een ongedifferentiëerde artritis. In patiënten met reumatoïde artritis 
is een DAS van 2,4 reden om medicatie op te hogen, en een DAS van 1,6 wordt gebruikt 
als afkapwaarde voor remissie. Echter in patiënten met een ongedifferentiëerde artritis, 
die per definitie minder pijnlijke en gezwollen gewrichten hebben, kan de DAS 1,6 zijn 
terwijl er artritis is. Met de huidige behandelstrategieën en het toenemend bewijs voor 
het starten van agressieve therapieën vroeg in het ziekte proces zal de definitie van 
remissie, al dan niet op basis van de DAS, voor patiënten met ongedifferentiëerde artritis 
aangepast moeten worden.
Beeldvorming van het aangedane gewricht speelt ook een rol in de beoordeling van 
de ernst van de reumatoïde artritis. De Sharp-van der Heijde gemodificeerde scorings-
methode is een manier om röntgenfoto’s van handen en voeten te beoordelen op het 
optreden van gewrichtsspleetversmalling en erosies (zie figuur 1, hoofdstuk 1). Hoe 
hoger de score, des te meer schade aan het gewricht. Deze manier van beoordelen is 
ook gebruikt in de onderzoeken beschreven in dit proefschrift.
Andere manieren om de ernst van de ziekte te beoordelen zijn meer subjectieve 
methoden met vragenlijsten naar algemeen functioneren, zoals de ‘health assessment 
questionnaire’ (HAQ), de ‘arthritis impact measurement scales’ (AIMS), en de ‘rheumatoid 
arthritis disease activity index’ (RADAI).
Beargumentatie voor behandeling vroeg in het ziekteproces
De afgelopen twintig jaar is de behandeling van reumatoïde artritis sterk veranderd. 
Voor 1994 werd een patiënt met nieuw gediagnostiseerde reumatoïde artritis behandeld 
volgens de pyramide strategie. Er werd dan begonnen met een ontstekingsremmer, een 
zogenaamde ‘non-steroid anti-inflammatory drug’ (NSAID) en pas bij ernstige ziekte 
werd gestart met een ‘disease-modifying anti-rheumatic drug’ (DMARD). Met een NSAID 
werden wel de klachten verminderd, maar van NSAIDs wordt niet gedacht dat ze het 
onderliggende ziekteproces beïnvloeden zoals bij DMARDs. Later bleek dat patiënten 









































aan de gewrichten op rontgenfoto’s van handen en voeten en een lagere ziekteakti-
viteit hadden dan patiënten behandeld volgens de pyramide strategie. Het grootste 
effect werd daarbij in het eerste jaar van behandeling gezien. Na 10 jaar was dit effect 
nog steeds zichtbaar in het aantal operaties dat nodig was als gevolg van opgelopen 
gewrichtsschade. Het lijkt er dus op dat hoe eerder er in het ziekteproces ingegrepen 
wordt, des te beter de uitkomst op lange termijn is. In hoofdstuk 3 is onderzocht of 
patiënten die zich presenteren met een ongedifferentiëerde artritis en binnen een jaar 
reumatoïde artritis ontwikkelen een milder ziektebeeld hebben dan patiënten die zich 
presenteren met een duidelijke reumatoïde artritis. Het blijkt dat in een tijdsbestek 
van vier jaar de patiënten die in het begin een ongedifferentiëerde artritis hadden net 
zo veel gewrichstbeschadiging en ziekteactiviteit hadden ontwikkeld als diegenen 
die in het begin een duidelijke reumatoïde artritis hadden. Wanneer het grootste ef-
fect van behandeling in het eerste jaar wordt gezien, zou het starten van DMARDs al 
in het stadium van ongedifferentiëerde artritis gerechtvaardigd zijn. Deze aanname 
is onderzocht in de PRObable RA: Methotrexate versus Placebo Treatment (PROMPT) 
studie (hoofdstuk 4). In de PROMPT studie zijn patiënten met een ongedifferentiëerde 
artritis behandeld met methotrexaat of placebo. In de methotrexaat groep bleek dat 
progressie van het ziektebeeld naar een duidelijke reumatoïde artritis uitgesteld was en 
dat er minder schade op röntgenfoto’s te zien was dan in de placebo groep. In patiënten 
met antistoffen tegen gecitrullineerde peptiden (ACPAs) waren de resultaten nog meer 
uitgesproken (hoofdstuk 4 and 7). 
Recent is duidelijk geworden dat patiënten die ACPAs hebben een aparte groep 
vormen binnen de groep patiënten met een reumatoïde artritis. Het hebben van een 
bepaalde gezamelijke aminozuursequentie, de zogenaamde ‘shared epitope’, in human 
leucocyte antigen (HLA) klasse II moleculen is een aanleg voor het ontwikkelen van 
ACPAs. De meeste patiënten met ACPAs ontwikkelen uiteindelijk reumatoïde artritis. 
Het kan echter wel 13 jaar duren voor dit plaats vindt. Op een of andere manier is er een 
onbekende tweede factor nodig om klinische verschijnselen te ontwikkelen (zie figuur 
2, hoofdstuk 1). Voor patiënten die geen ACPAs hebben, maar wel reumatoïde artritis, is 
het nog onduidelijk welke andere factoren een rol spelen.
Binnen de PROMPT studie was de incidentie van reumatoïde artritis lager in patiënten 
die lage of intermediaire ACPA titers hadden en behandeld werden met methotrexaat 
dan in patiënten met een hoge antistoftiter. In een groep patiënten die nooit eerder was 
behandeld met een ‘disease-modifying anti-rheumatic drug’ (DMARD) en gediagnos-
tiseerd waren met ongedifferentiëerde artritis of een net ontstane reumatoïde artritis 
bleek dat lage en intermediaire ACPA titers geassocieerd waren met een betere reactie 
op methotrexaat behandeling dan patiënten met hoge antistoftiters (hoofdstuk 7). 
Om te bepalen welke patiënt met een ongedifferentiëerde artritis eigenlijk reumato-









































vroege behandeling met een DMARD, is een voorspelregel ontwikkeld. Op basis van 
geslacht, leeftijd, plaats van de klachten, het aantal pijnlijke en gezwollen gewrichten, 
de hoogte van het C-reactieve proteine, de mate van ochtendstijfheid, en de aanwe-
zigheid van reumafactor en ACPA leverde een voorspellende score met afkapwaarden 
tussen de 6 en 8 punten een positief voorspellende waarde van 84% en een negatief 
voorspellende waarde van 91% op (hoofdstuk 6). 
Deel II: Reumatoïde artritis
Reumatoïde artritis is een zogenaamde auto-immuunziekte waarbij het immuunsysteem 
zorgt voor een ontstekingsproces in de gewrichten met als eind resultaat destructie van 
het gewricht. De gedachte is dat door een combinatie van genetische factoren en uitlok-
kende omgevingsfactoren schadelijke T cellen worden geactiveerd die onder andere B 
cellen kunnen stimuleren en daarmee de antistofproductie op gang brengen (zie figuur 
2, hoofdstuk 1). Verschillende onderdelen van deze cascade van gebeurtenissen zijn 
onderzocht.
De invloed van genetisch factoren blijkt uit een drie tot vier keer zo vaak voorkomen 
van reumatoïde artritis in een-eïge in vergelijking tot twee-eïge tweelingen. De totale 
genetische bijdrage wordt geschat op 50 tot 60 %. De meest bekende risicofactor tot nu 
toe is de ‘shared epitope’ in het HLA klasse II gen.
T cellen
De betrokkenheid van HLA klasse II moleculen en de aanwezigheid van T cellen gericht 
tegen eiwitten afkomstig uit het gewricht suggereren een rol voor CD4+ T cellen. Nadat 
de T cellen zijn onstaan uit voorlopercellen in het beenmerg, verhuizen ze naar de thy-
mus om daar het onderscheid te leren maken tussen lichaamsvreemde en lichaamsei-
gen eiwitten, gepresenteerd in eigen HLA moleculen. Allereerst vindt positieve selectie 
plaats van die T cellen die peptiden herkennen in de context van eigen HLA moleculen. 
Daarna vindt een negatieve selectie procedure plaats waarbij T cellen die reageren op 
lichaamseigen eiwitten geëlimineerd worden. Grofweg bestaan er twee typen T cellen. 
Cytotoxische T cellen die gekenmerkt worden door CD8 expressie en die antigenen 
herkennen in de context van HLA klasse I moleculen. Deze moleculen zitten op vrijwel 
alle cellen met een celkern en presenteren intracellulaire eiwitten. Als de CD8+ T cel 
geaktiveerd wordt, doodt de T cel de antigeen presenterende cel door cellysis. Tijdens 
aktivatie van CD8+ T cellen komen pro-inflammatoire cytokinen als interferon-gamma, 
tumor necrosis factor- alfa en interleukine-2 vrij. T helper cellen brengen CD4 op hun 
celmembraan tot expressie en herkennen antigenen in de context van HLA klasse II. 









































en B cellen kunnen extracellulaire eiwitten opnemen, bewerken en presenteren in HLA 
klasse II moleculen. Wanneeer de T helper cel geactiveerd wordt, kan deze B cellen 
activeren die vervolgens van bepaalde antistoffen gaan produceren. Deze processen 
worden gekenmerkt door het vrij komen van interleukine-4 en interleukine-10.
Bovenstaande processen verklaren echter niet waarom regulatoire of suppressor 
T cellen bestaan en waarom er autoimmuunziekten kunnen ontstaan. Er bestaan ver-
schillende hypothesen over de origine van autoimmuniteit, variërend van genetische 
defecten die het selectie proces in de thymus beinvloeden tot ‘danger models’ waarin 
beschadigde weefsels een waarschuwingssignaal afgeven, waarbij dit waarschuwings-
signaal fungeert als co-stimulerende factor voor activatie van een autoimmuunproces. 
Het bestaan van regulatoire T cellen is functioneel voor het eerst aangetoond in 
naakte muizen waarbij infusie van CD25+CD4+ T cellen na infusie van CD25-CD4+ T 
cellen voorkwam dat er een autoimmuunziekte ontstond. CD25 is de alfa keten van de 
interleukine-2 receptor. Bij analyse met behulp van flowcytometrie komt CD25 hoog tot 
expressie op geactiveerde T cellen vroeg in de activatiefase, terwijl er een intermediair 
expressie patroon op regulatoire T cellen wordt beschreven. Ander celmarkers, zoals 
‘cytotoxic T lymphocyte antigen-4’ (CTLA-4), ‘glucocorticoid induced TNF receptor (GITR) 
en FoxP3 worden ook wel gebruikt om regulatoire T cellen te beschrijven, maar deze 
markers zijn ook niet specifiek. De regulatoire T cel reactie wordt gekenmerkt door 
het vrijkomen van anti-inflammatoire cytokinen, zoals interleukine-10 en tumor groei 
factor-beta. T cel gemedieerde immunoregulatie speelt waarschijnlijk wel een rol in de 
tolerantie van lichaamseigen eiwitten, maar de exacte rol van regulatoire T cellen blijft 
onduidelijk, vooral in de mens.
De uitdaging in autoimmuunziekten is het beëindigen van het autoimmuunproces. 
Behandeling met DMARDs en zogenaamde ‘biologicals’, zoals TNF-alfa antagonisten, 
worden gebruikt om de immunologische processen in onder andere patiënten met 
reumatoïde artritis te beinvloeden. Het bleek dat de suppressieve capaciteit van 
CD4+CD25+ T cellen in patiënten met reumatoïde artritis was verminderd, en weer 
hersteld na anti-TNF-alfa therapie. In hoofdstuk 8 bleek dat de aanwezigheid van 
membraangebonden TNF-alfa op CD4+ CD25+ cellen samenhing met ziekteactiviteit in 
patiënten met reuamatoide artritis. Binding van een gehumaniseerde TNF-alfa antago-
nist, adalimumab, aan membraangebonden TNF-alfa resulteerde in het uitschakelen van 
geactiveerde CD4+CD25+ T cellen, waardoor de functie van CD4+CD25+ regulatoire T 
cellen hersteld werd. Dit benadrukt de onevenwichtigheid tussen de pro-inflammatoire 
reaktie en de regulatoire T cel reactie in patiënten met reumatoïde artritis.
Deze onevenwichtigheid wordt ook gevonden in de immunologische reactie op het 
humane kraakbeen glycoproteïne-39 (HC gp-39). In hoofdstuk 9 blijkt dat patiënten met 
reumatoïde artritis een pro-inflammatoire reactie hadden op HC gp-39, terwijl gezonde 









































reactie was zo groot dat deze andere pro-inflammatoire reacties kon onderdrukken. 
Bovendien maakt HC gp-39 een groot deel uit van het humane kraakbeen, het mRNA en 
het eiwit zelf komen verhoogd tot expressie in het synovium van patiënten met reuma-
toïde artritis en delen van HC gp-39 worden door antigeen presenterende cellen in het 
synovium van patiënten met reumatoïde artritis gepresenteerd aan T cellen. HC gp-39 
zou daarmee een potentiëel middel kunnen zijn om het autoimmuunproces in reuma-
toïde artritis te beïnvloeden. In een muismodel bleek dat intranasaal toedienen van HC 
gp-39 het ontstaan van artritis kon onderdrukken. Naar analogie hiervan werd een fase 
I studie in patiënten met reumatoïde artritis opgezet, waarbij HC gp-39 gedurende 4 
weken wekelijks werd toegediend. Daarna werden de patiënten nog 8 weken beoor-
deeld op ziekte activiteit. Helaas bleek er klinisch geen duidelijk effect waarneembaar. 
Om onderliggende immunologische reacties te analyseren, zijn tijdens deze fase I studie 
bloedmonsters afgenomen. In de Summary and discussion worden de resultaten van 
deze analyse besproken. Helaas was er voor deelname aan de fase I studie niet getest 
op de aanwezigheid van een pro-inflammatoire reactie op HC gp-39, waardoor de groep 
patiënten zeer heterogeen bleek. Daar niet van alle patiënten een monster beschikbaar 
was, en per type HC-gp-39 reactie te weinig patiënten per groep waren, was het niet 
mogelijk om hier een goede conclusie uit te trekken. Daarbij komt nog dat knaagdieren 
mogelijk een ander werkingsmechanisme van tolerantie inductie hebben dan mensen, 
er geen duidelijk klinisch effect waarneembaar was in de patiënten in de fase I studie, en 
het niet duidelijk is of in de fase I studie de best mogelijke doseringen zijn gebruikt. Der-
halve zijn de resultaten van dit laatste project niet gepubliceerd. Dat tolerantie inductie 
mogelijk is bij mensen blijkt uit het feit dat bij mensen die op jonge leeftijd een beugel 
of piercing gehad hebben, op latere leeftijd minder vaak nikkel allergieën voorkomen.
Toekomstperspectieven
Ongedifferentiëerde artritis blijft klinisch een enorme uitdaging. Er is steeds meer be-
wijs dat vroeg starten van een behandeling in patiënten met reumatoïde artritis zeer 
gunstige effecten heeft op het latere beloop van de ziekte. Des te belangrijker is het 
om de reumatoïde artritis patiënt al in een vroeg stadium te herkennen. De keuze van 
therapie lijkt vooralsnog verschillend te zijn in verschillende stadia van de ziekte. Waar 
het beste mee gestart kan worden in de fase van een ongedifferentiëerde artritis zal nog 
verder uitgezocht moeten worden. Tevens lijkt de aanwezigheid van ACPAs al in een 
vroeg stadium van belang. Het is nog niet uitgesloten dat orale tolerantie inductie een 
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